<![CDATA[Oncology Today with Dr Neil Love]]>b586d896-f728-585b-aa54-68b882dfd545Fri, 03 Apr 2026 19:58:59 +0000Captivate.fmDr. Neil Lovehttps://artwork.captivate.fm/464a03b3-1b7f-4b39-a2c6-e3de4b1e77b7/8YAjpM6wBeZeb3Gyb3zbR3bE.jpgOncology Today with Dr Neil LoveDr. Neil LoveDr. Neil LoveMedical oncologist Dr Neil Love interviews clinical investigators on new research and practical application to general medical oncology practice. https://www.researchtopractice.comfalseepisodichttps://feeds.captivate.fm/oncologytoday/nopodcastImmunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers SymposiumImmunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers SymposiumDr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Samuel Klempner from Massachusetts General Hospital in Boston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, and Dr John Strickler from Duke University in Durham, North Carolina, review relevant data supporting immunotherapy for patients with gastroesophageal cancers and recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium.

CME information and select publications here.

]]>Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Samuel Klempner from Massachusetts General Hospital in Boston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, and Dr John Strickler from Duke University in Durham, North Carolina, review relevant data supporting immunotherapy for patients with gastroesophageal cancers and recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium.

CME information and select publications here.

]]>c3342b1f-0926-4ce8-9774-55ba1c4f7493Fri, 03 Apr 2026 15:45:00 -040022:10falsefull2621821826Nonmelanoma Skin Cancers — A Roundtable Discussion on the Multidisciplinary Management of Cutaneous Squamous Cell and Basal Cell CarcinomasNonmelanoma Skin Cancers — A Roundtable Discussion on the Multidisciplinary Management of Cutaneous Squamous Cell and Basal Cell CarcinomasDr Nikhil I Khushalani from Moffitt Cancer Center in Tampa, Florida, Dr Soo J Park from the UC San Diego Moores Cancer Center in California, Dr Vishal Anil Patel from the GW Cancer Center in Washington, DC, and Dr Evan Wuthrick, also from Moffitt Cancer Center, discusses recent updates on available and novel treatment strategies for nonmelanoma skin cancers.

CME information and select publications here.

]]>Dr Nikhil I Khushalani from Moffitt Cancer Center in Tampa, Florida, Dr Soo J Park from the UC San Diego Moores Cancer Center in California, Dr Vishal Anil Patel from the GW Cancer Center in Washington, DC, and Dr Evan Wuthrick, also from Moffitt Cancer Center, discusses recent updates on available and novel treatment strategies for nonmelanoma skin cancers.

CME information and select publications here.

]]>2dfb26fc-b169-4a8c-bfaa-87543488c979Thu, 02 Apr 2026 15:00:00 -040002:13:32falsefull2621721726Immune Thrombocytopenia — Microlearning Activity 4 with Dr Hanny Al-Samkari: ASH 2025 ReviewImmune Thrombocytopenia — Microlearning Activity 4 with Dr Hanny Al-Samkari: ASH 2025 ReviewDr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.

CME information and select publications here.

]]>Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.

CME information and select publications here.

]]>2406bfe5-d330-4087-9155-49086a442594Wed, 01 Apr 2026 15:00:00 -040024:50falsefull2621621626AKT Inhibition in Prostate Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Genitourinary Cancers SymposiumAKT Inhibition in Prostate Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Genitourinary Cancers SymposiumProf Karim Fizazi from the Centre Oscar Lambret in Lille, France, Dr Daniel George from the Duke Cancer Institute in Durham, North Carolina, and moderator Dr Elisabeth I Heath from Mayo Clinic in Rochester, Minnesota, discuss the future role of AKT inhibition in prostate cancer.

CME information and select publications here.

]]>Prof Karim Fizazi from the Centre Oscar Lambret in Lille, France, Dr Daniel George from the Duke Cancer Institute in Durham, North Carolina, and moderator Dr Elisabeth I Heath from Mayo Clinic in Rochester, Minnesota, discuss the future role of AKT inhibition in prostate cancer.

CME information and select publications here.

]]>be991859-84dc-4081-a43a-3b6a0f802584Mon, 30 Mar 2026 14:00:00 -040001:29:22falsefull2621521526Diabetology in Breast Cancer — Managing Hyperglycemia in Patients with Breast Cancer Receiving Agents Targeting the PI3K/AKT/PTEN PathwayDiabetology in Breast Cancer — Managing Hyperglycemia in Patients with Breast Cancer Receiving Agents Targeting the PI3K/AKT/PTEN PathwayMs Jaime Carroll from Mayo Clinic in Rochester, Minnesota, Professor Giuseppe Curigliano from the European Institute of Oncology in Milan, Italy, Dr Marie E McDonnell from Brigham and Women’s Hospital in Boston, Massachusetts, and Dr Hope S Rugo from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss the incidence, prevention and management of hyperglycemia in breast cancer patients receiving PI3K/AKT/PTEN inhibitors.

CME information and select publications here.

]]>Ms Jaime Carroll from Mayo Clinic in Rochester, Minnesota, Professor Giuseppe Curigliano from the European Institute of Oncology in Milan, Italy, Dr Marie E McDonnell from Brigham and Women’s Hospital in Boston, Massachusetts, and Dr Hope S Rugo from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss the incidence, prevention and management of hyperglycemia in breast cancer patients receiving PI3K/AKT/PTEN inhibitors.

CME information and select publications here.

]]>33d539e9-d1e8-4907-889a-039d20f44af9Sat, 28 Mar 2026 09:00:00 -040001:15:32falsefull2621421426Metastatic Bladder Cancer — Rapid Case Review Issue 3Metastatic Bladder Cancer — Rapid Case Review Issue 3Dr Matthew Milowsky from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, comments on real patient cases of metastatic urothelial bladder cancer presented by Dr Jacqueline T Brown from the Emory University School of Medicine in Atlanta, Georgia and Dr Nazli Dizman from The University of Texas MD Anderson Cancer Center in Houston.

CME information and select publications here.

]]>Dr Matthew Milowsky from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, comments on real patient cases of metastatic urothelial bladder cancer presented by Dr Jacqueline T Brown from the Emory University School of Medicine in Atlanta, Georgia and Dr Nazli Dizman from The University of Texas MD Anderson Cancer Center in Houston.

CME information and select publications here.

]]>3babe137-490f-46fb-8c76-b2870a8c54e9Fri, 27 Mar 2026 11:00:00 -040032:43falsefull2621321326Localized Colorectal Cancer — Microlearning Activity 1: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers SymposiumLocalized Colorectal Cancer — Microlearning Activity 1: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers SymposiumDr Stacey A Cohen from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Jenny Seligmann from the University of Leeds in the United Kingdom and Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora review clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium relevant to the management of localized colorectal cancer.

CME information and select publications here.

]]>Dr Stacey A Cohen from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Jenny Seligmann from the University of Leeds in the United Kingdom and Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora review clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium relevant to the management of localized colorectal cancer.

CME information and select publications here.

]]>ed8cb852-6dfc-4048-82db-9c7c7932c5bbThu, 26 Mar 2026 15:00:00 -040017:11falsefull2621221226Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Genitourinary Cancers SymposiumNon-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Genitourinary Cancers SymposiumDr Matthew D Galsky from The Tisch Cancer Institute in New York, New York, Dr Shilpa Gupta from Cleveland Clinic’s Taussig Cancer Institute in Ohio, Prof Andrea Necchi from IRCCS San Raffaele Hospital in Milan, Italy, and moderator Dr Terence Friedlander from the University of California, San Francisco discuss recent data surrounding the management of non-muscle-invasive and muscle-invasive bladder cancer, alongside their perspectives on clinical application and disease management.

CME information and select publications here.

]]>Dr Matthew D Galsky from The Tisch Cancer Institute in New York, New York, Dr Shilpa Gupta from Cleveland Clinic’s Taussig Cancer Institute in Ohio, Prof Andrea Necchi from IRCCS San Raffaele Hospital in Milan, Italy, and moderator Dr Terence Friedlander from the University of California, San Francisco discuss recent data surrounding the management of non-muscle-invasive and muscle-invasive bladder cancer, alongside their perspectives on clinical application and disease management.

CME information and select publications here.

]]>a6212564-0982-4bd5-bb1b-2fd55e453df2Wed, 25 Mar 2026 14:30:00 -040001:58:06falsefull2621121126Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Microlearning Activity 1: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers SymposiumImmunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Microlearning Activity 1: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers SymposiumDr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, Dr John Strickler from Duke University in Durham, North Carolina, and moderator Dr Samuel Klempner from Massachusetts General Hospital in Boston review relevant data supporting immunotherapy for patients with gastroesophageal cancers and review recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium.

CME information and select publications here.

]]>Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, Dr John Strickler from Duke University in Durham, North Carolina, and moderator Dr Samuel Klempner from Massachusetts General Hospital in Boston review relevant data supporting immunotherapy for patients with gastroesophageal cancers and review recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium.

CME information and select publications here.

]]>0d2d27b3-0112-42d2-8a77-92fc1d21bf3bTue, 24 Mar 2026 15:00:00 -040024:55falsefull2621021026CELMoDs for Multiple Myeloma — Microlearning Activity 1 with Dr Paul G RichardsonCELMoDs for Multiple Myeloma — Microlearning Activity 1 with Dr Paul G RichardsonDr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma.

CME information and select publications here.

]]>Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma.

CME information and select publications here.

]]>ffd117a5-37aa-4a43-a2a9-f7db907e5d01Mon, 23 Mar 2026 14:00:00 -040024:29falsefull2620920926Immune Thrombocytopenia — Microlearning Activity 3 with Dr Hanny Al-Samkari: ASH 2025 ReviewImmune Thrombocytopenia — Microlearning Activity 3 with Dr Hanny Al-Samkari: ASH 2025 ReviewDr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.

CME information and select publications here.

]]>Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.

CME information and select publications here.

]]>49693b28-6aa2-4f4a-9083-bd05f3d05203Sat, 21 Mar 2026 08:00:00 -040029:16falsefull2620820826HER2-Positive Gastrointestinal Cancers — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers SymposiumHER2-Positive Gastrointestinal Cancers — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers SymposiumDr Haley Ellis from Harvard Medical School in Boston, Massachusetts, Prof Eric Van Cutsem from University Hospitals Leuven in Belgium, Dr Zev Wainberg from UCLA School of Medicine in Los Angeles, California, and moderator Dr Lionel A Kankeu Fonkoua from Mayo Clinic in Rochester, Minnesota, discuss recent data surrounding the management of HER2-positive GI cancers, alongside their perspectives on its clinical application and management.

CME information and select publications here.

]]>Dr Haley Ellis from Harvard Medical School in Boston, Massachusetts, Prof Eric Van Cutsem from University Hospitals Leuven in Belgium, Dr Zev Wainberg from UCLA School of Medicine in Los Angeles, California, and moderator Dr Lionel A Kankeu Fonkoua from Mayo Clinic in Rochester, Minnesota, discuss recent data surrounding the management of HER2-positive GI cancers, alongside their perspectives on its clinical application and management.

CME information and select publications here.

]]>672382f2-7711-4faf-95df-02ce92ba8a18Thu, 19 Mar 2026 12:00:00 -040021:38falsefull2620720726Breast Cancer — 5-Minute Journal Club Issue 2 with Dr Lajos Pusztai: Current and Future Role of Tumor-Informed Circulating Tumor DNA AssaysBreast Cancer — 5-Minute Journal Club Issue 2 with Dr Lajos Pusztai: Current and Future Role of Tumor-Informed Circulating Tumor DNA AssaysDr Lajos Pusztai from Yale Cancer Center in New Haven, Connecticut, discusses recent developments with circulating tumor DNA assays in the management of breast cancer.

CME information and select publications here.

]]>Dr Lajos Pusztai from Yale Cancer Center in New Haven, Connecticut, discusses recent developments with circulating tumor DNA assays in the management of breast cancer.

CME information and select publications here.

]]>3f516a01-1b5c-4c72-b285-253165eb29abWed, 18 Mar 2026 11:00:00 -040030:21falsefull2620620626Desmoid Tumors — Microlearning Activity 1 with Dr Ravin RatanDesmoid Tumors — Microlearning Activity 1 with Dr Ravin RatanDr Ravin Ratan from The University of Texas MD Anderson Cancer Center in Houston discusses available clinical data with treatment approaches for desmoid tumors, alongside clinical cases illustrating real-world application.

CME information and select publications here.

]]>Dr Ravin Ratan from The University of Texas MD Anderson Cancer Center in Houston discusses available clinical data with treatment approaches for desmoid tumors, alongside clinical cases illustrating real-world application.

CME information and select publications here.

]]>9801eff7-84d0-4d68-8cc4-af6a27809100Mon, 16 Mar 2026 14:30:00 -040016:43falsefull2620520526HER2-Positive Gastrointestinal Cancers — Microlearning Activity 1: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers SymposiumHER2-Positive Gastrointestinal Cancers — Microlearning Activity 1: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers SymposiumDr Haley Ellis from Mass General Brigham Cancer Institute in Boston, Massachusetts, Prof Eric Van Cutsem from University Hospitals Leuven in Belgium, Dr Zev Wainberg from UCLA Jonsson Comprehensive Cancer Center in Los Angeles, California, and moderator Dr Lionel A Kankeu Fonkoua from Mayo Clinic in Rochester, Minnesota, discuss recent data and provide their perspectives on the management of HER2-positive GI cancers.

CME information and select publications here.

]]>Dr Haley Ellis from Mass General Brigham Cancer Institute in Boston, Massachusetts, Prof Eric Van Cutsem from University Hospitals Leuven in Belgium, Dr Zev Wainberg from UCLA Jonsson Comprehensive Cancer Center in Los Angeles, California, and moderator Dr Lionel A Kankeu Fonkoua from Mayo Clinic in Rochester, Minnesota, discuss recent data and provide their perspectives on the management of HER2-positive GI cancers.

CME information and select publications here.

]]>69c5bfcd-ffdf-4b50-9d6e-6cc21936aa9cSat, 14 Mar 2026 09:00:00 -040012:53falsefull2620420426CD19 x CD3 BiTEs for Acute Lymphoblastic Leukemia — An Interview with Dr Bijal ShahCD19 x CD3 BiTEs for Acute Lymphoblastic Leukemia — An Interview with Dr Bijal ShahDr Bijal Shah from Moffitt Cancer Center in Tampa, Florida, discusses the role of BiTEs in the management of ALL.

CME information and select publications here.

]]>Dr Bijal Shah from Moffitt Cancer Center in Tampa, Florida, discusses the role of BiTEs in the management of ALL.

CME information and select publications here.

]]>44dde3e4-ba3f-4b43-8013-54bf8d73d96eThu, 12 Mar 2026 14:00:00 -040001:03:21falsefull2620320326Chronic Lymphocytic Leukemia — An Interview with Prof Constantine Tam on Key Presentations from the 2025 ASH Annual MeetingChronic Lymphocytic Leukemia — An Interview with Prof Constantine Tam on Key Presentations from the 2025 ASH Annual MeetingProf Constantine Tam from Monash University in Melbourne, Australia, reviews recent datasets and discusses their implications for current and future management of chronic lymphocytic leukemia.

CME information and select publications here.

]]>Prof Constantine Tam from Monash University in Melbourne, Australia, reviews recent datasets and discusses their implications for current and future management of chronic lymphocytic leukemia.

CME information and select publications here.

]]>fb99ce60-c6bb-4711-9864-1f5dc0fc1f3bTue, 10 Mar 2026 14:00:00 -040047:10falsefull2620220226Immune Thrombocytopenia — Microlearning Activity 2 with Dr Hanny Al-Samkari: ASH 2025 ReviewImmune Thrombocytopenia — Microlearning Activity 2 with Dr Hanny Al-Samkari: ASH 2025 ReviewDr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.

CME information and select publications here.

]]>Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.

CME information and select publications here.

]]>8b9b7d98-653b-4424-b1fc-c17a7e039ec4Mon, 09 Mar 2026 15:00:00 -040019:21falsefull2620120126Ovarian Cancer — Year in Review Series on Relevant New Datasets and AdvancesOvarian Cancer — Year in Review Series on Relevant New Datasets and AdvancesProf Nicoletta Colombo and Dr Kathleen N Moore discuss the selection and sequencing of therapy for patients with ovarian cancer and summarize major advances in the treatment landscape over the past year.

CME information and select publications here.

]]>Prof Nicoletta Colombo and Dr Kathleen N Moore discuss the selection and sequencing of therapy for patients with ovarian cancer and summarize major advances in the treatment landscape over the past year.

CME information and select publications here.

]]>11454038-db04-411c-84df-48579b430073Sat, 07 Mar 2026 09:00:00 -040055:39falsefull2620020026Oncology Nursing Update: Colorectal Cancer — An Interview with Dr Christopher Lieu on Molecular Residual Disease AnalysisOncology Nursing Update: Colorectal Cancer — An Interview with Dr Christopher Lieu on Molecular Residual Disease AnalysisDr Christopher Lieu from the University of Colorado Cancer Center in Aurora, Colorado, discusses circulating tumor DNA-based molecular residual disease assessment and its current role in the management of colorectal cancer.

NCPD information and select publications here.

]]>Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora, Colorado, discusses circulating tumor DNA-based molecular residual disease assessment and its current role in the management of colorectal cancer.

NCPD information and select publications here.

]]>f0209fd4-8704-4865-bcf2-248663227934Fri, 06 Mar 2026 14:00:00 -040058:59falsefull2619919926Immune Thrombocytopenia — Microlearning Activity 1 with Dr Hanny Al-Samkari: ASH 2025 ReviewImmune Thrombocytopenia — Microlearning Activity 1 with Dr Hanny Al-Samkari: ASH 2025 ReviewDr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.

CME information and select publications here.

]]>Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.

CME information and select publications here.

]]>969fccf0-0dc5-4071-a248-680540287b94Tue, 03 Mar 2026 15:00:00 -040024:25falsefull2619819826Antibody-Drug Conjugates for Breast Cancer — Year in Review Series on Relevant New Datasets and AdvancesAntibody-Drug Conjugates for Breast Cancer — Year in Review Series on Relevant New Datasets and AdvancesDr Hope S Rugo from City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Sara M Tolaney from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss key clinical trial data with antibody-drug conjugates in the management of breast cancer.

CME information and select publications here.

]]>Dr Hope S Rugo from City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Sara M Tolaney from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss key clinical trial data with antibody-drug conjugates in the management of breast cancer.

CME information and select publications here.

]]>aa2aa6d6-270c-433e-8219-a9aac81309b0Sat, 28 Feb 2026 10:00:00 -040058:40falsefull2619719726Extensive-Stage Small Cell Lung Cancer — Current Patterns of Care with First-Line and Maintenance TherapyExtensive-Stage Small Cell Lung Cancer — Current Patterns of Care with First-Line and Maintenance TherapyDr Hossein Borghaei from Fox Chase Cancer Center in Philadelphia, Pennsylvania, and Dr Anne Chiang from Yale Cancer Center in New Haven, Connecticut, discuss key clinical trial data in the first-line management of ES-SCLC, real-world case studies and current patterns of care among oncologists.

CME information and select publications here.

]]>Dr Hossein Borghaei from Fox Chase Cancer Center in Philadelphia, Pennsylvania, and Dr Anne Chiang from Yale Cancer Center in New Haven, Connecticut, discuss key clinical trial data in the first-line management of ES-SCLC, real-world case studies and current patterns of care among oncologists.

CME information and select publications here.

]]>4bd94391-cddb-4013-a9a2-934397dc393dFri, 27 Feb 2026 15:00:00 -040059:42falsefull2619619626Colorectal Cancer — A Roundtable Discussion on the Use of Molecular Residual Disease AnalysisColorectal Cancer — A Roundtable Discussion on the Use of Molecular Residual Disease AnalysisDr Stacey A Cohen from the University of Washington in Seattle, Dr Arvind Dasari from The University of Texas MD Anderson Cancer Center in Houston, and Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora discuss the role of molecular residual disease assessment using circulating tumor DNA-based tools in the management of colorectal cancer.

CME information and select publications here.

]]>Dr Stacey A Cohen from the University of Washington in Seattle, Dr Arvind Dasari from The University of Texas MD Anderson Cancer Center in Houston, and Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora discuss the role of molecular residual disease assessment using circulating tumor DNA-based tools in the management of colorectal cancer.

CME information and select publications here.

]]>36362da5-de3e-4ada-be50-b552363b76c4Thu, 26 Feb 2026 14:20:00 -040002:00:23falsefull2619519526Urothelial Bladder Cancer — Microlearning Activity 2 with Dr Terence Friedlander: ESMO Congress 2025 ReviewUrothelial Bladder Cancer — Microlearning Activity 2 with Dr Terence Friedlander: ESMO Congress 2025 ReviewDr Terence Friedlander discusses the selection and sequencing of therapy for patients with bladder cancer and reviews clinical findings recently presented at the 2025 ESMO Congress.

CME information and select publications here.

]]>Dr Terence Friedlander discusses the selection and sequencing of therapy for patients with bladder cancer and reviews clinical findings recently presented at the 2025 ESMO Congress.

CME information and select publications here.

]]>37b27857-f5f8-4da2-ace8-20c99a1b9117Mon, 23 Feb 2026 14:00:00 -040023:29falsefull2619419426Multiple Myeloma: Inside the Issue of Cereblon E3 Ligase ModulatorsMultiple Myeloma: Inside the Issue of Cereblon E3 Ligase ModulatorsDr Natalie S Callander from the University of Wisconsin Carbone Cancer Center in Madison and Dr Paul G Richardson from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss the potential role of CELMoDs in the management of multiple myeloma, supporting clinical data and ongoing investigations.

CME information and select publications here.

]]>Dr Natalie S Callander from the University of Wisconsin Carbone Cancer Center in Madison and Dr Paul G Richardson from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss the potential role of CELMoDs in the management of multiple myeloma, supporting clinical data and ongoing investigations.

CME information and select publications here.

]]>4e435fbd-c69f-4b25-96f5-68100acc69fcWed, 18 Feb 2026 14:00:00 -040057:58falsefull2619319326Metastatic Bladder Cancer — Rapid Case Review Issue 2Metastatic Bladder Cancer — Rapid Case Review Issue 2Dr Fern Anari from the Fox Chase Cancer Center in Philadelphia, Pennsylvania, and Dr Catherine Fahey from the Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, present real patient cases on metastatic bladder cancer, with additional commentary from Dr Matthew Galsky from The Tisch Cancer Institute in New York, New York.

CME information and select publications here.

]]>Dr Fern Anari from the Fox Chase Cancer Center in Philadelphia, Pennsylvania, and Dr Catherine Fahey from the Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, present real patient cases on metastatic bladder cancer, with additional commentary from Dr Matthew Galsky from The Tisch Cancer Institute in New York, New York.

CME information and select publications here.

]]>24636fb0-7894-49a8-9dfa-7bc569e07c45Tue, 17 Feb 2026 14:00:00 -040029:11falsefull2619219226Gynecologic Cancers — Highlights from the 2025 ESMO Annual MeetingGynecologic Cancers — Highlights from the 2025 ESMO Annual MeetingDr Ritu Salani from the David Geffen School of Medicine at UCLA in Los Angeles, California, reviews datasets from ESMO Congress 2025 relevant to the care of patients with gynecologic cancers.

CME information and select publications here.

]]>Dr Ritu Salani from the David Geffen School of Medicine at UCLA in Los Angeles, California, reviews datasets from ESMO Congress 2025 relevant to the care of patients with gynecologic cancers.

CME information and select publications here.

]]>c2e723cb-9aa8-46bf-8e1a-0c9ea5e453cfMon, 16 Feb 2026 08:00:00 -040057:09falsefull2619119126Relapsed/Refractory Multiple Myeloma — Microlearning Activity 2 with Dr Sagar Lonial: ASH 2025 ReviewRelapsed/Refractory Multiple Myeloma — Microlearning Activity 2 with Dr Sagar Lonial: ASH 2025 ReviewDr Sagar Lonial from Winship Cancer Institute in Atlanta, Georgia, discusses recent clinical developments with BCMA-targeted therapy and investigational agents for relapsed/refractory multiple myeloma presented at ASH 2025.

CME information and select publications here.

]]>Dr Sagar Lonial from Winship Cancer Institute in Atlanta, Georgia, discusses recent clinical developments with BCMA-targeted therapy and investigational agents for relapsed/refractory multiple myeloma presented at ASH 2025.

CME information and select publications here.

]]>a265548f-a477-495d-b5e4-2d93ebf6a2eeFri, 13 Feb 2026 15:00:00 -040017:18falsefull2619019026Squamous Cell Carcinoma of the Anal Canal — An Interview with Dr Marwan FakihSquamous Cell Carcinoma of the Anal Canal — An Interview with Dr Marwan FakihDr Marwah Fakih from the City of Hope Comprehensive Cancer Center in Duarte, California, discusses current and potential therapeutic strategies for the treatment of squamous cell carcinoma of the anal canal.

CME information and select publications here.

]]>Dr Marwah Fakih from the City of Hope Comprehensive Cancer Center in Duarte, California, discusses current and potential therapeutic strategies for the treatment of squamous cell carcinoma of the anal canal.

CME information and select publications here.

]]>6f1c0e42-4b81-42ea-8050-910544181729Wed, 11 Feb 2026 15:00:00 -040037:15falsefull2618918926Prostate Cancer — Microlearning Activity 2 with Dr Rana R McKay: ESMO Congress 2025 ReviewProstate Cancer — Microlearning Activity 2 with Dr Rana R McKay: ESMO Congress 2025 ReviewDr McKay discusses the selection of and efficacy data with androgen pathway-targeting agents for patients with prostate cancer and reviews recently presented clinical findings from the ESMO Congress 2025.

CME information and select publications here.

]]>Dr McKay discusses the selection of and efficacy data with androgen pathway-targeting agents for patients with prostate cancer and reviews recently presented clinical findings from the ESMO Congress 2025.

CME information and select publications here.

]]>993c9a14-cf72-4c47-935f-7fb684926124Tue, 10 Feb 2026 16:00:00 -040018:06falsefull2618818826Antibody-Drug Conjugates for Ovarian Cancer — An Interview with Dr Kathleen N MooreAntibody-Drug Conjugates for Ovarian Cancer — An Interview with Dr Kathleen N MooreDr Kathleen N Moore from the Fred and Pamela Buffett Cancer Center in Omaha, Nebraska, discusses recent updates on available and novel treatment strategies with antibody-drug conjugates for ovarian cancer.

CME information and select publications here.

]]>Dr Kathleen N Moore from the Fred and Pamela Buffett Cancer Center in Omaha, Nebraska, discusses recent updates on available and novel treatment strategies with antibody-drug conjugates for ovarian cancer.

CME information and select publications here.

]]>7736e3b0-61d0-4eaf-a930-fd567750fb73Mon, 09 Feb 2026 15:00:00 -040054:56falsefull2618718726Localized Colorectal Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Gastrointestinal Cancers SymposiumLocalized Colorectal Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Gastrointestinal Cancers SymposiumDr Stacey A Cohen from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Jenny Seligmann from the University of Leeds in the United Kingdom and Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora review clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium relevant to the management of localized colorectal cancer.

CME information and select publications here.

]]>Dr Stacey A Cohen from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Jenny Seligmann from the University of Leeds in the United Kingdom and Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora review clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium relevant to the management of localized colorectal cancer.

CME information and select publications here.

]]>f5118b63-d7f3-4726-aaee-65affd110b83Sat, 07 Feb 2026 08:00:00 -040001:31:15falsefull2518618625Immune Thrombocytopenia — ASH 2025 ReviewImmune Thrombocytopenia — ASH 2025 ReviewDr Hanny Al-Samkari from Massachusetts General Hospital in Boston, Dr Cindy Neunert from Columbia University Irving Medical Center in New York and Prof Francesco Zaja from ASUGI in Trieste, Italy discuss cases of immune thrombocytopenia and recent findings from the 2025 ASH Annual Meeting.

CME information and select publications here.

]]>Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston, Dr Cindy Neunert from Columbia University Irving Medical Center in New York and Prof Francesco Zaja from ASUGI in Trieste, Italy discuss cases of immune thrombocytopenia and recent findings from the 2025 ASH Annual Meeting.

CME information and select publications here.

]]>199fee12-989c-4cb6-bd4c-7f68075b391bFri, 06 Feb 2026 14:00:00 -040001:30:07falsefull2518518525Urothelial Bladder Cancer — Microlearning Activity 1 with Dr Terence Friedlander: ESMO Congress 2025 ReviewUrothelial Bladder Cancer — Microlearning Activity 1 with Dr Terence Friedlander: ESMO Congress 2025 ReviewDr Terence Friedlander discusses the selection and sequencing of therapy for patients with bladder cancer and reviews clinical findings recently presented at the 2025 ESMO Congress.

CME information and select publications here.

]]>Dr Terence Friedlander discusses the selection and sequencing of therapy for patients with bladder cancer and reviews clinical findings recently presented at the 2025 ESMO Congress.

CME information and select publications here.

]]>6926ba73-db35-47f1-b32f-eaf22d819106Wed, 04 Feb 2026 16:00:00 -040031:09falsefull2518418425Relapsed/Refractory Multiple Myeloma — Microlearning Activity 1 with Dr Sagar Lonial: ASH 2025 ReviewRelapsed/Refractory Multiple Myeloma — Microlearning Activity 1 with Dr Sagar Lonial: ASH 2025 ReviewDr Sagar Lonial from Winship Cancer Institute in Atlanta, Georgia, discusses recent clinical developments with BCMA-targeted therapy and investigational agents for relapsed/refractory multiple myeloma presented at ASH 2025.

CME information and select publications here.

]]>Dr Sagar Lonial from Winship Cancer Institute in Atlanta, Georgia, discusses recent clinical developments with BCMA-targeted therapy and investigational agents for relapsed/refractory multiple myeloma presented at ASH 2025.

CME information and select publications here.

]]>f8729c60-d056-4984-985f-78115083720eTue, 03 Feb 2026 15:00:00 -040023:23falsefull2518318325Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Proceedings from a Session Held Adjunct to the 2026 ASCO Gastrointestinal Cancers SymposiumImmunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Proceedings from a Session Held Adjunct to the 2026 ASCO Gastrointestinal Cancers SymposiumDr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, Dr John Strickler from Duke University in Durham, North Carolina, and Dr Samuel Klempner from Massachusetts General Hospital in Boston review relevant data supporting immunotherapy for patients with gastroesophageal cancers and review recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium.

CME information and select publications here.

]]>Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, Dr John Strickler from Duke University in Durham, North Carolina, and Dr Samuel Klempner from Massachusetts General Hospital in Boston review relevant data supporting immunotherapy for patients with gastroesophageal cancers and review recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium.

CME information and select publications here.

]]>50dcb41e-7b22-480f-b9b4-0fdb926401e8Mon, 02 Feb 2026 15:00:00 -040001:57:08falsefull2518218225Prostate Cancer — Microlearning Activity 1 with Dr Rana R McKay: ESMO Congress 2025 ReviewProstate Cancer — Microlearning Activity 1 with Dr Rana R McKay: ESMO Congress 2025 ReviewDr Rana R McKay discusses the selection and sequencing of therapy for patients with prostate cancer in a review of recently presented clinical findings from ESMO Congress 2025.

CME information and select publications here.

]]>Dr Rana R McKay discusses the selection and sequencing of therapy for patients with prostate cancer in a review of recently presented clinical findings from ESMO Congress 2025.

CME information and select publications here.

]]>d9761aa6-cb7f-4746-8841-bcf4fc1d7118Thu, 29 Jan 2026 15:00:00 -040018:08falsefull2518118125HER2-Positive Gastrointestinal Cancers — Proceedings from a Session Held Adjunct to the 2026 ASCO Gastrointestinal Cancers SymposiumHER2-Positive Gastrointestinal Cancers — Proceedings from a Session Held Adjunct to the 2026 ASCO Gastrointestinal Cancers SymposiumDr Haley Ellis from Harvard Medical School in Boston, Massachusetts, Prof Eric Van Cutsem from University Hospitals Leuven in Belgium, Dr Zev Wainberg from UCLA School of Medicine in Los Angeles, California, and moderator Dr Lionel KankeuFonkoua from Mayo Clinic in Rochester, Minnesota, discuss recent data surrounding the management of HER2-positive GI cancers, alongside their perspectives on its clinical application and management.

CME information and select publications here.

]]>Dr Haley Ellis from Harvard Medical School in Boston, Massachusetts, Prof Eric Van Cutsem from University Hospitals Leuven in Belgium, Dr Zev Wainberg from UCLA School of Medicine in Los Angeles, California, and moderator Dr Lionel KankeuFonkoua from Mayo Clinic in Rochester, Minnesota, discuss recent data surrounding the management of HER2-positive GI cancers, alongside their perspectives on its clinical application and management.

CME information and select publications here.

]]>e67c3372-1824-46b0-9a1d-d126233bcecbWed, 28 Jan 2026 14:00:00 -040001:28:40falsefull2518018025Endocrine-Based Therapy for HR-Positive Breast Cancer — Proceedings from a San Antonio 2025 Symposium SeriesEndocrine-Based Therapy for HR-Positive Breast Cancer — Proceedings from a San Antonio 2025 Symposium SeriesDr Angela DeMichele from the Abramson Cancer Center in Philadelphia, Pennsylvania, Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, Dr Erica Mayer from Dana-Farber Cancer Institute in Boston, Massachusetts, Dr Hope S Rugo from City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Seth Wander from Massachusetts General Hospital in Boston discuss real-world cases and recent clinical data surrounding the management of HR-positive breast cancer.

CME information and select publications here.

]]>Dr Angela DeMichele from the Abramson Cancer Center in Philadelphia, Pennsylvania, Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, Dr Erica Mayer from Dana-Farber Cancer Institute in Boston, Massachusetts, Dr Hope S Rugo from City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Seth Wander from Massachusetts General Hospital in Boston discuss real-world cases and recent clinical data surrounding the management of HR-positive breast cancer.

CME information and select publications here.

]]>d75e6685-f88f-42a8-8d79-b8b7477a1dfdTue, 27 Jan 2026 14:40:00 -040002:01:07falsefull2517917925Metastatic Bladder Cancer — Rapid Case Review Issue 1Metastatic Bladder Cancer — Rapid Case Review Issue 1Dr Catherine Fahey from the Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, and Dr Fern Anari from the Fox Chase Cancer Center in Philadelphia, Pennsylvania, present real patient cases on metastatic bladder cancer, with additional commentary from Dr Matthew Galsky from The Tisch Cancer Institute in New York, New York.

CME information and select publications here.

]]>Dr Catherine Fahey from the Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, and Dr Fern Anari from the Fox Chase Cancer Center in Philadelphia, Pennsylvania, present real patient cases on metastatic bladder cancer, with additional commentary from Dr Matthew Galsky from The Tisch Cancer Institute in New York, New York.

CME information and select publications here.

]]>673f516d-8b14-42f7-8469-4f1f9b57371cFri, 23 Jan 2026 12:46:00 -040027:27falsefull2517817825Bispecific Antibodies in the Management of Lymphoma — ASH 2025 ReviewBispecific Antibodies in the Management of Lymphoma — ASH 2025 ReviewProf Michael Dickinson from Peter MacCallum Cancer Centre in Melbourne, Australia, and Dr Laurie H Sehn from the University of British Columbia in Vancouver, Canada, discuss clinical cases and recent findings from the 2025 ASH Annual Meeting relating to the use of bispecific antibodies in the management of lymphoma.

CME information and select publications here.

]]>Prof Michael Dickinson from Peter MacCallum Cancer Centre in Melbourne, Australia, and Dr Laurie H Sehn from the University of British Columbia in Vancouver, Canada, discuss clinical cases and recent findings from the 2025 ASH Annual Meeting relating to the use of bispecific antibodies in the management of lymphoma.

CME information and select publications here.

]]>19a4e5c9-8c41-4712-bd7d-292cc43bf13aWed, 21 Jan 2026 15:00:00 -040001:01:12falsefull2517717725Relapsed/Refractory Multiple Myeloma — ASH 2025 ReviewRelapsed/Refractory Multiple Myeloma — ASH 2025 ReviewDr Sagar Lonial from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr María-Victoria Mateos from the University Hospital of Salamanca in Salamanca, Spain, discuss cases of relapsed/refractory multiple myeloma and recentresearch findings from the 2025 ASH Annual Meeting.

CME information and select publications here.

]]>Dr Sagar Lonial from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr María-Victoria Mateos from the University Hospital of Salamanca in Salamanca, Spain, discuss cases of relapsed/refractory multiple myeloma and recentresearch findings from the 2025 ASH Annual Meeting.

CME information and select publications here.

]]>92ccd7a8-58de-4589-9669-d7ad7812b1c6Fri, 16 Jan 2026 16:59:00 -040001:01:06falsefull2517617625HER2-Positive Breast Cancer — Proceedings from a San Antonio 2025 Symposium SeriesHER2-Positive Breast Cancer — Proceedings from a San Antonio 2025 Symposium SeriesProf Giuseppe Curigliano from the University of Milan in Italy, Prof Nadia Harbeck from LMU University Hospital in Munich, Germany, Dr Ian E Krop from Yale Cancer Center, Dr Nancy U Lin from Dana-Farber Cancer Institute and Dr Joyce O’Shaughnessy from Baylor University Medical Center discuss real-world cases and recent clinical data pertinent to the management of HER2-positive breast cancer.

CME information and select publications here.

]]>Prof Giuseppe Curigliano from the University of Milan in Italy, Prof Nadia Harbeck from LMU University Hospital in Munich, Germany, Dr Ian E Krop from Yale Cancer Center, Dr Nancy U Lin from Dana-Farber Cancer Institute and Dr Joyce O’Shaughnessy from Baylor University Medical Center discuss real-world cases and recent clinical data pertinent to the management of HER2-positive breast cancer.

CME information and select publications here.

]]>030de743-eade-4990-a055-1c80ca2429e2Wed, 14 Jan 2026 15:52:00 -040001:58:18falsefull2517517525Follicular Lymphoma and Diffuse Large B-Cell Lymphoma — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and ExpositionFollicular Lymphoma and Diffuse Large B-Cell Lymphoma — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and ExpositionDr Nancy L Bartlett from the Washington University School of Medicine, Dr John P Leonard from the Perlmutter Cancer Center, Dr Matthew Matasar from Rutgers Cancer Institute, Dr Loretta J Nastoupil from Southwest Oncology and Prof Pier Luigi Zinzani from the University of Bologna in Italy discuss recent updates on available and novel treatment strategies for follicular lymphoma and diffuse large B-cell lymphoma.

CME information and select publications here.

]]>Dr Nancy L Bartlett from the Washington University School of Medicine, Dr John P Leonard from the Perlmutter Cancer Center, Dr Matthew Matasar from Rutgers Cancer Institute, Dr Loretta J Nastoupil from Southwest Oncology and Prof Pier Luigi Zinzani from the University of Bologna in Italy discuss recent updates on available and novel treatment strategies for follicular lymphoma and diffuse large B-cell lymphoma.

CME information and select publications here.

]]>881a3e82-c4fa-4ace-9a9f-4c223b761e90Tue, 13 Jan 2026 16:09:00 -040001:56:55falsefull2517417425Colorectal Cancer — 5-Minute Journal Club Issue 2 with Dr Scott Kopetz: Current and Future Role of Tumor-Informed Circulating Tumor DNA AssaysColorectal Cancer — 5-Minute Journal Club Issue 2 with Dr Scott Kopetz: Current and Future Role of Tumor-Informed Circulating Tumor DNA AssaysDr Scott Kopetz from The University of Texas MD Anderson Cancer Center in Houston discusses recent developments with circulating tumor DNA assays in the management of colorectal cancer.

CME information and select publications here.

]]>Dr Scott Kopetz from The University of Texas MD Anderson Cancer Center in Houston discusses recent developments with circulating tumor DNA assays in the management of colorectal cancer.

CME information and select publications here.

]]>c3f950e6-8345-463a-b821-a6d8a5232097Mon, 12 Jan 2026 18:33:00 -040025:18falsefull2517317325Myelofibrosis and Systemic Mastocytosis — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and ExpositionMyelofibrosis and Systemic Mastocytosis — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and ExpositionProf Claire Harrison from Guy’s and St Thomas’ NHS Foundation Trust in London, Dr Andrew T Kuykendall from Moffitt Cancer Center, Dr Stephen T Oh from the Washington University School of Medicine, Dr Jeanne Palmer from the Mayo Clinic School of Medicine and Dr Raajit K Rampal from Memorial Sloan Kettering Cancer Center discuss recent updates on available and novel treatment strategies for myelofibrosis and systemic mastocytosis.

CME information and select publications here.

]]>Prof Claire Harrison from Guy’s and St Thomas’ NHS Foundation Trust in London, Dr Andrew T Kuykendall from Moffitt Cancer Center, Dr Stephen T Oh from the Washington University School of Medicine, Dr Jeanne Palmer from the Mayo Clinic School of Medicine and Dr Raajit K Rampal from Memorial Sloan Kettering Cancer Center discuss recent updates on available and novel treatment strategies for myelofibrosis and systemic mastocytosis.

CME information and select publications here.

]]>64157c06-731e-43dd-919f-36022789045fFri, 09 Jan 2026 09:00:00 -040001:57:30falsefull2517217225Antibody-Drug Conjugates for Breast Cancer — Proceedings from a San Antonio 2025 Symposium SeriesAntibody-Drug Conjugates for Breast Cancer — Proceedings from a San Antonio 2025 Symposium SeriesDr Javier Cortés from the International Breast Cancer Center in Barcelona, Spain, Dr Rita Nanda from the University of Chicago, Prof Peter Schmid from Barts Cancer Institute in London, United Kingdom, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood discuss key clinical data with antibody-drug conjugates for metastatic breast cancer and their expert perspectives surrounding its clinical applications.

CME information and select publications here.

]]>Dr Javier Cortés from the International Breast Cancer Center in Barcelona, Spain, Dr Rita Nanda from the University of Chicago, Prof Peter Schmid from Barts Cancer Institute in London, United Kingdom, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood discuss key clinical data with antibody-drug conjugates for metastatic breast cancer and their expert perspectives surrounding its clinical applications.

CME information and select publications here.

]]>0114498f-33ec-4685-959f-37b2e28c8d0fThu, 08 Jan 2026 15:00:00 -040001:30:21falsefull2517117125Chronic Lymphocytic Leukemia — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and ExpositionChronic Lymphocytic Leukemia — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and ExpositionDr Matthew S Davids from Dana-Farber Cancer Institute, Dr Bita Fakhri from Stanford University School of Medicine, Prof Constantine Tam from Alfred Health in Melbourne, Australia, and Dr Jennifer Woyach from The Ohio State University Comprehensive Cancer Center review the treatment landscape for patients with chronic lymphocytic leukemia and discuss current research immediately before the 67th ASH Annual Meeting.

CME information and select publications here.

]]>Dr Matthew S Davids from Dana-Farber Cancer Institute, Dr Bita Fakhri from Stanford University School of Medicine, Prof Constantine Tam from Alfred Health in Melbourne, Australia, and Dr Jennifer Woyach from The Ohio State University Comprehensive Cancer Center review the treatment landscape for patients with chronic lymphocytic leukemia and discuss current research immediately before the 67th ASH Annual Meeting.

CME information and select publications here.

]]>2e83f093-eab1-4317-bd9c-1542ac4006cdWed, 07 Jan 2026 15:00:00 -040001:55:47falsefull2517017025Colorectal Cancer — 5-Minute Journal Club Issue 1 with Dr Scott Kopetz: Current and Future Role of Tumor-Informed Circulating Tumor DNA AssaysColorectal Cancer — 5-Minute Journal Club Issue 1 with Dr Scott Kopetz: Current and Future Role of Tumor-Informed Circulating Tumor DNA AssaysDr Scott Kopetz from The University of Texas MD Anderson Cancer Center in Houston discusses recent developments with circulating tumor DNA assays in the management of colorectal cancer.

CME information and select publications here.

]]>Dr Scott Kopetz from The University of Texas MD Anderson Cancer Center in Houston discusses recent developments with circulating tumor DNA assays in the management of colorectal cancer.

CME information and select publications here.

]]>2c464fb3-098e-4615-a5bc-7249e779472fTue, 06 Jan 2026 15:00:00 -040022:33falsefull2516916925Acute Myeloid Leukemia — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and ExpositionAcute Myeloid Leukemia — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and ExpositionDr Harry Paul Erba from the Duke Cancer Institute, Dr Amir Fathi from Massachusetts General Hospital, Dr Tara L Lin from The University of Kansas Medical Center, Dr Alexander Perl from the University of Pennsylvania’s Abramson Cancer Center and Dr Eytan M Stein from Memorial Sloan Kettering Cancer Center discuss recent data surrounding the management of AML and their perspectives on clinical application.

CME information and select publications here.

]]>Dr Harry Paul Erba from the Duke Cancer Institute, Dr Amir Fathi from Massachusetts General Hospital, Dr Tara L Lin from The University of Kansas Medical Center, Dr Alexander Perl from the University of Pennsylvania’s Abramson Cancer Center and Dr Eytan M Stein from Memorial Sloan Kettering Cancer Center discuss recent data surrounding the management of AML and their perspectives on clinical application.

CME information and select publications here.

]]>51a8455f-dc34-427f-9784-496c2cefe7c8Sat, 03 Jan 2026 09:00:00 -040001:57:33falsefull2516816825Toxicities Associated with Antibody-Drug Conjugates for Metastatic Breast Cancer — Clinical Investigator Perspectives on Actual Patient CasesToxicities Associated with Antibody-Drug Conjugates for Metastatic Breast Cancer — Clinical Investigator Perspectives on Actual Patient CasesDr Lisa A Carey from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, and Dr Rita Nanda from The University of Chicago in Illinois engage in an evidence-based discussion around real-world cases involving common toxicities associated with antibody-drug conjugates in the management of breast cancer.

CME information and select publications here.

]]>Dr Lisa A Carey from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, and Dr Rita Nanda from The University of Chicago in Illinois engage in an evidence-based discussion around real-world cases involving common toxicities associated with antibody-drug conjugates in the management of breast cancer.

CME information and select publications here.

]]>625cd584-12f4-419f-b4a7-2e6d6dd02f9cTue, 23 Dec 2025 14:00:00 -040001:00:14falsefull2516716725Advanced Gastroesophageal Cancers — Expert Perspectives on Actual Patient Cases: Part 2 of 2Advanced Gastroesophageal Cancers — Expert Perspectives on Actual Patient Cases: Part 2 of 2Dr Yelena Janjigian from Memorial Sloan Kettering Cancer Center in New York, New York, discusses updates across the treatment landscape for gastroesophageal cancers, as well as real-world clinical case examples.

CME information and select publications here.

]]>Dr Yelena Janjigian from Memorial Sloan Kettering Cancer Center in New York, New York, discusses updates across the treatment landscape for gastroesophageal cancers, as well as real-world clinical case examples.

CME information and select publications here.

]]>337a81a1-6179-45f3-b252-75c0946a453cMon, 22 Dec 2025 08:00:00 -040001:00:36falsefull2516616625Urothelial Bladder Cancer and Prostate Cancer — Highlights from the 2025 ESMO Annual MeetingUrothelial Bladder Cancer and Prostate Cancer — Highlights from the 2025 ESMO Annual MeetingDr Terence Friedlander from the UCSF Helen Diller Family Comprehensive Cancer Center and Dr Rana R McKay from the UC San Diego Moores Cancer Center summarize the treatment landscape for prostate and urothelial bladder cancer and discuss the implications of clinical findings recently presented at the ESMO Congress 2025.

CME information and select publications here.

]]>Dr Terence Friedlander from the UCSF Helen Diller Family Comprehensive Cancer Center and Dr Rana R McKay from the UC San Diego Moores Cancer Center summarize the treatment landscape for prostate and urothelial bladder cancer and discuss the implications of clinical findings recently presented at the ESMO Congress 2025.

CME information and select publications here.

]]>0a3bba98-df8b-4cb3-8565-8f841438d07eFri, 19 Dec 2025 14:00:00 -040001:01:32falsefull2516516525Extensive-Stage Small Cell Lung Cancer — What Clinicians Want to Know About First-Line and Maintenance TherapyExtensive-Stage Small Cell Lung Cancer — What Clinicians Want to Know About First-Line and Maintenance TherapyDr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid and Dr Shields from Indiana University School of Medicine in Indianapolis discuss key datasets surrounding first-line and maintenance therapy for patients with extensive-stage small cell lung cancer and their clinical implications. 

CME information and select publications here.

]]>Dr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid and Dr Shields from Indiana University School of Medicine in Indianapolis discuss key datasets surrounding first-line and maintenance therapy for patients with extensive-stage small cell lung cancer and their clinical implications. 

CME information and select publications here.

]]>acf201bb-2e4d-450b-a9d6-676e414e23daWed, 17 Dec 2025 09:00:00 -040057:46falsefull2516416425Gastroesophageal Cancers — Proceedings from a Symposium Held in Partnership with the American Oncology NetworkGastroesophageal Cancers — Proceedings from a Symposium Held in Partnership with the American Oncology NetworkDr Manish A Shah from Weill Cornell Medicine in New York, New York, summarizes the treatment landscape and reviews relevant clinical datasets for patients with gastroesophageal cancers.     

CME information and select publications here.

]]>Dr Manish A Shah from Weill Cornell Medicine in New York, New York, summarizes the treatment landscape and reviews relevant clinical datasets for patients with gastroesophageal cancers.     

CME information and select publications here.

]]>7e715bab-e1e3-45f7-8932-bc3c510cece1Sat, 13 Dec 2025 10:00:00 -040050:25falsefull2516316325Ovarian Cancer — Proceedings from a Symposium Held in Partnership with the American Oncology NetworkOvarian Cancer — Proceedings from a Symposium Held in Partnership with the American Oncology NetworkDr Gottfried E Konecny from the University of California, Los Angeles, summarizes the treatment landscape and reviews relevant clinical datasets for patients with ovarian cancer. 

CME information and select publications here.

]]>Dr Gottfried E Konecny from the University of California, Los Angeles, summarizes the treatment landscape and reviews relevant clinical datasets for patients with ovarian cancer. 

CME information and select publications here.

]]>c825e821-a973-4434-ba08-225d8a7841beSat, 13 Dec 2025 09:00:00 -040048:48falsefull2516216225Chronic Lymphocytic Leukemia — Proceedings from a Symposium Held in Partnership with the American Oncology NetworkChronic Lymphocytic Leukemia — Proceedings from a Symposium Held in Partnership with the American Oncology NetworkDr Kerry A Rogers from The Ohio State University in Columbus summarizes the treatment landscape and reviews relevant clinical datasets for patients with chronic lymphocytic leukemia. 

CME information and select publications here.

]]>Dr Kerry A Rogers from The Ohio State University in Columbus summarizes the treatment landscape and reviews relevant clinical datasets for patients with chronic lymphocytic leukemia. 

CME information and select publications here.

]]>1596d757-c1ea-420e-88cc-0e6574f723f5Fri, 12 Dec 2025 14:00:00 -040051:19falsefull2516116125Lung Cancer — Proceedings from a Symposium Held in Partnership with the American Oncology NetworkLung Cancer — Proceedings from a Symposium Held in Partnership with the American Oncology NetworkDr Justin F Gainor, Dr Corey J Langer and Dr Misty Dawn Shields summarize the treatment landscape and review relevant clinical datasets for patients with lung cancer.

CME information and select publications here.

]]>Dr Justin F Gainor, Dr Corey J Langer and Dr Misty Dawn Shields summarize the treatment landscape and review relevant clinical datasets for patients with lung cancer.

CME information and select publications here.

]]>df199c17-adad-424b-b99f-1e437ed5e598Fri, 12 Dec 2025 13:00:00 -040001:43:11falsefull2516016025CAR T-Cell Therapy for Non-Hodgkin Lymphoma | Cancer Q&A — Discussing Common Questions Posed by PatientsCAR T-Cell Therapy for Non-Hodgkin Lymphoma | Cancer Q&A — Discussing Common Questions Posed by PatientsDr Jeremy S Abramson from Massachusetts General Hospital in Boston and Dr Loretta J Nastoupil from CommonSpirit Mercy Hospital in Durango, Colorado, discuss the clinical applications of chimeric antigen receptor T-cell therapy for patients with non-Hodgkin lymphoma.   

CME information and select publications here.

]]>Dr Jeremy S Abramson from Massachusetts General Hospital in Boston and Dr Loretta J Nastoupil from CommonSpirit Mercy Hospital in Durango, Colorado, discuss the clinical applications of chimeric antigen receptor T-cell therapy for patients with non-Hodgkin lymphoma.   

CME information and select publications here.

]]>f9fdf674-3910-4ea8-ac61-69e7bf2d9c93Thu, 11 Dec 2025 15:00:00 -040058:30falsefull2515915925HER2-Altered Non-Small Cell Lung Cancer — An Interview with Dr John V HeymachHER2-Altered Non-Small Cell Lung Cancer — An Interview with Dr John V HeymachDr John Heymach from The University of Texas MD Anderson Cancer Center in Houston discusses recent updates on available and novel treatment strategies for HER2-altered non-small cell lung cancer.   

CME information and select publications here.

]]>Dr John Heymach from The University of Texas MD Anderson Cancer Center in Houston discusses recent updates on available and novel treatment strategies for HER2-altered non-small cell lung cancer.   

CME information and select publications here.

]]>8f9a1b68-b20e-4a29-9b74-d6bc4b6eb319Tue, 09 Dec 2025 13:30:00 -040001:05:13falsefull2515815825Breast Cancer — Highlights from the 2025 ESMO Annual MeetingBreast Cancer — Highlights from the 2025 ESMO Annual MeetingProf Giuseppe Curigliano from the European Institute of Oncology in Milan, Italy, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood, Kansas, discuss the implications of clinical findings in breast cancer recently presented at the 2025 ESMO Annual Meeting. 

CME information and select publications here.

]]>Prof Giuseppe Curigliano from the European Institute of Oncology in Milan, Italy, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood, Kansas, discuss the implications of clinical findings in breast cancer recently presented at the 2025 ESMO Annual Meeting. 

CME information and select publications here.

]]>ecf4c25a-d1fe-4a7a-9251-057031464eddMon, 08 Dec 2025 16:00:00 -040001:27:39falsefull2515715725Breast Cancer — Microlearning Activity Issue 3 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting UpdatesBreast Cancer — Microlearning Activity Issue 3 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting UpdatesDr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer and discusses the implications of recently presented clinical findings from the ESMO Congress 2025. 

CME information and select publications here.

]]>Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer and discusses the implications of recently presented clinical findings from the ESMO Congress 2025. 

CME information and select publications here.

]]>38ba1330-ec07-4eaa-ba7b-13931ed7223cFri, 05 Dec 2025 15:00:00 -040015:27falsefull2515615625Toxicities Associated with CAR T-Cell Therapy — An Interview with Dr Matthew LunningToxicities Associated with CAR T-Cell Therapy — An Interview with Dr Matthew LunningDr Matthew Lunning from the Fred and Pamela Buffett Cancer Center in Omaha, Nebraska, discusses recent updates on the management of toxicities associated with CAR T-cell therapy.   

CME information and select publications here.

]]>Dr Matthew Lunning from the Fred and Pamela Buffett Cancer Center in Omaha, Nebraska, discusses recent updates on the management of toxicities associated with CAR T-cell therapy.   

CME information and select publications here.

]]>959e64fd-cec8-498e-8d2c-31d6cb3bfb98Wed, 03 Dec 2025 15:30:00 -040052:03falsefull2515515525Breast Cancer — Microlearning Activity 2 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting UpdatesBreast Cancer — Microlearning Activity 2 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting UpdatesDr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer and discusses the implications of recently presented clinical findings from the ESMO Congress 2025. 

CME information and select publications here.

]]>Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer and discusses the implications of recently presented clinical findings from the ESMO Congress 2025. 

CME information and select publications here.

]]>8352f8dc-e2d4-48f4-bb43-8bb37292632aTue, 02 Dec 2025 15:00:00 -040016:55falsefull2515415425Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 2Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 2Dr Rinath M Jeselsohn and Dr Joyce O’Shaughnessy review current literature and datasets exploring the use of oral selective estrogen receptor degraders for the management of metastatic breast cancer. 

CME information and select publications here.

]]>Dr Rinath M Jeselsohn and Dr Joyce O’Shaughnessy review current literature and datasets exploring the use of oral selective estrogen receptor degraders for the management of metastatic breast cancer. 

CME information and select publications here.

]]>71617f37-4255-4089-a467-62f3c4b10485Sat, 29 Nov 2025 09:00:00 -040058:54falsefull2515315325Breast Cancer — Microlearning Activity 1 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting UpdatesBreast Cancer — Microlearning Activity 1 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting UpdatesDr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer and discusses the implications of recently presented clinical findings from the ESMO Congress 2025. 

CME information and select publications here.

]]>Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer and discusses the implications of recently presented clinical findings from the ESMO Congress 2025. 

CME information and select publications here.

]]>9a4a702f-8f85-4a4e-bbc0-3c1ac266a30dWed, 26 Nov 2025 09:30:00 -040012:49falsefull2515215225HER2-Positive Gastrointestinal Cancers — Clinical Investigator Perspectives on Actual Patient CasesHER2-Positive Gastrointestinal Cancers — Clinical Investigator Perspectives on Actual Patient CasesDr Tanios Bekaii-Saab and Dr Kristen K Ciombor summarize the treatment landscape and review key datasets in consideration of HER2-directed therapies for patients with HER2-positive gastrointestinal cancers. 

CME information and select publications here.

]]>Dr Tanios Bekaii-Saab and Dr Kristen K Ciombor summarize the treatment landscape and review key datasets in consideration of HER2-directed therapies for patients with HER2-positive gastrointestinal cancers. 

CME information and select publications here.

]]>bb1d00e3-5adb-4f3c-bebe-7e326df7cfdfFri, 21 Nov 2025 08:30:00 -040057:31falsefull2515115125HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor DegradersHR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor DegradersDr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, reviews available clinical data with PROTAC estrogen receptor degraders and their potential role in the management of HR-positive metastatic breast cancer. 

CME information and select publications here.

]]>Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, reviews available clinical data with PROTAC estrogen receptor degraders and their potential role in the management of HR-positive metastatic breast cancer. 

CME information and select publications here.

]]>3d0db272-3490-474c-bdeb-19d313909b49Wed, 19 Nov 2025 15:30:00 -040058:36falsefull2515015025Patient Education Resource: Non-Hodgkin Lymphoma — Clinical Experts Address Common Questions Posed by Patients About CAR T-Cell TherapyPatient Education Resource: Non-Hodgkin Lymphoma — Clinical Experts Address Common Questions Posed by Patients About CAR T-Cell TherapyDr Jeremy S Abramson from Massachusetts General Hospital in Boston and Dr Manali Kamdar from the University of Colorado Cancer Center in Aurora discuss patient questions and experiences with CAR T-cell therapy for non-Hodgkin lymphoma. 

Educational information and select publications here.

]]>Dr Jeremy S Abramson from Massachusetts General Hospital in Boston and Dr Manali Kamdar from the University of Colorado Cancer Center in Aurora discuss patient questions and experiences with CAR T-cell therapy for non-Hodgkin lymphoma. 

Educational information and select publications here.

]]>ae8c939f-2153-4779-a323-a5ae7c60c7c2Sat, 15 Nov 2025 08:00:00 -040059:42falsefull2514914925ER-Positive Metastatic Breast Cancer — A Roundtable Discussion on the Current and Future Role of Oral SERDsER-Positive Metastatic Breast Cancer — A Roundtable Discussion on the Current and Future Role of Oral SERDsProf Francois-Clement Bidard from the Institut Curie in Paris, France, Dr Hope S Rugo from the City of Hope Comprehensive Cancer Center in Duarte, California, Dr Rebecca Shatsky from the University of California San Diego Moores Cancer Center and Dr Seth Wander from Massachusetts General Hospital in Boston discuss recent updates on available and emerging treatment strategies involving oral SERDs for ER-positive metastatic breast cancer.  

CME information and select publications here.

]]>Prof Francois-Clement Bidard from the Institut Curie in Paris, France, Dr Hope S Rugo from the City of Hope Comprehensive Cancer Center in Duarte, California, Dr Rebecca Shatsky from the University of California San Diego Moores Cancer Center and Dr Seth Wander from Massachusetts General Hospital in Boston discuss recent updates on available and emerging treatment strategies involving oral SERDs for ER-positive metastatic breast cancer.  

CME information and select publications here.

]]>9760e003-9d6c-43c5-a567-9b498925bf74Fri, 14 Nov 2025 15:30:00 -040002:30:36falsefull2514814825Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research InstituteDiffuse Large B-Cell Lymphoma and Follicular Lymphoma — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research InstituteDr Matthew Lunning and Dr Sonali M Smith share their perspectives on the evolving therapeutic landscape for patients with diffuse large B-cell lymphoma and follicular lymphoma. 

CME information and select publications here.

]]>Dr Matthew Lunning and Dr Sonali M Smith share their perspectives on the evolving therapeutic landscape for patients with diffuse large B-cell lymphoma and follicular lymphoma. 

CME information and select publications here.

]]>17af156a-8eec-4e8b-a6e8-7e2f63836a43Thu, 13 Nov 2025 14:00:00 -040001:00:13falsefull2514714725Colorectal Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research InstituteColorectal Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research InstituteDr Christopher Lieu and Dr John Strickler share their perspectives on the evolving therapeutic landscape for patients with colorectal cancer. 

CME information and select publications here.

]]>Dr Christopher Lieu and Dr John Strickler share their perspectives on the evolving therapeutic landscape for patients with colorectal cancer. 

CME information and select publications here.

]]>f4be39ea-5c7c-49e8-80d7-33ad98ab8afeWed, 12 Nov 2025 16:00:00 -040001:04:25falsefull2514614625Prostate Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research InstituteProstate Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research InstituteDr Emmanuel S Antonarakis and Dr Matthew R Smith share their perspectives on the evolving therapeutic landscape for patients with prostate cancer. 

CME information and select publications here.

]]>Dr Emmanuel S Antonarakis and Dr Matthew R Smith share their perspectives on the evolving therapeutic landscape for patients with prostate cancer. 

CME information and select publications here.

]]>02656f1f-9f0b-47f9-bd28-d624c18aeb36Tue, 11 Nov 2025 14:30:00 -040054:28falsefull2514514525Breast Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research InstituteBreast Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research InstituteDr Harold J Burstein, Dr Matthew P Goetz, Dr Heather McArthur and Dr Rita Nanda share their perspectives on the evolving therapeutic landscape for patients with breast cancer. 

CME information and select publications here.

]]>Dr Harold J Burstein, Dr Matthew P Goetz, Dr Heather McArthur and Dr Rita Nanda share their perspectives on the evolving therapeutic landscape for patients with breast cancer. 

CME information and select publications here.

]]>9aeccd90-f07f-4f5c-bf7c-197aa2185ef7Mon, 10 Nov 2025 14:30:00 -040001:57:51falsefull2514414425Lung Cancer — 5-Minute Journal Club Issue 4 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug ConjugatesLung Cancer — 5-Minute Journal Club Issue 4 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug ConjugatesDr Aaron Lisberg from the University of California, Los Angeles, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. 

CME information and select publications here.

]]>Dr Aaron Lisberg from the University of California, Los Angeles, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. 

CME information and select publications here.

]]>f5e8aa7e-e935-431e-9a20-ff08d8d7bec4Fri, 07 Nov 2025 16:00:00 -040021:21falsefull2514314325Endometrial Cancer — Clinical Investigator Perspectives on Actual Patient CasesEndometrial Cancer — Clinical Investigator Perspectives on Actual Patient CasesDr Kathleen N Moore from OU Health Stephenson Cancer Center in Oklahoma City, Oklahoma, and Dr Matthew A Powell from the Washington University School of Medicine in St Louis, Missouri, discuss recent updates on available and novel treatment strategies for endometrial cancer. 

CME information and select publications here.

]]>Dr Kathleen N Moore from OU Health Stephenson Cancer Center in Oklahoma City, Oklahoma, and Dr Matthew A Powell from the Washington University School of Medicine in St Louis, Missouri, discuss recent updates on available and novel treatment strategies for endometrial cancer. 

CME information and select publications here.

]]>4b8dd9db-7e72-4ee5-be80-843041800cd6Thu, 06 Nov 2025 15:00:00 -040001:00:17falsefull2514214225ER-Positive Metastatic Breast Cancer — An Interview with Prof Patrick Neven on the Role of Oral Selective Estrogen Receptor DegradersER-Positive Metastatic Breast Cancer — An Interview with Prof Patrick Neven on the Role of Oral Selective Estrogen Receptor DegradersProf Patrick Neven from University Hospitals Leuven in Leuven, Belgium, discusses recent updates on available and novel treatment strategies with oral SERDs for ER-positive metastatic breast cancer.   

CME information and select publications here.

]]>Prof Patrick Neven from University Hospitals Leuven in Leuven, Belgium, discusses recent updates on available and novel treatment strategies with oral SERDs for ER-positive metastatic breast cancer.   

CME information and select publications here.

]]>962ccf6f-89c8-44b2-bc7c-c43b28e07626Mon, 03 Nov 2025 15:30:00 -040041:17falsefull2514114125Colorectal Cancer — An Interview with Dr John Strickler on Molecular Residual Disease AnalysisColorectal Cancer — An Interview with Dr John Strickler on Molecular Residual Disease AnalysisDr John Strickler from Duke University in Durham, North Carolina, discusses the measurement of molecular residual disease and its current and potential role in colorectal cancer risk assessment, surveillance and treatment decision-making. 

CME information and select publications here.

]]>Dr John Strickler from Duke University in Durham, North Carolina, discusses the measurement of molecular residual disease and its current and potential role in colorectal cancer risk assessment, surveillance and treatment decision-making. 

CME information and select publications here.

]]>0b821f39-f3be-4bb5-befd-42026f3f38c0Wed, 29 Oct 2025 14:00:00 -040050:39falsefull2514014025Breast Cancer — 5-Minute Journal Club Issue 4 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug ConjugatesBreast Cancer — 5-Minute Journal Club Issue 4 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug ConjugatesKevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of breast cancer. 

CME information and select publications here.

]]>Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of breast cancer. 

CME information and select publications here.

]]>6377169a-e5e2-486d-b95a-d74ef541e1d7Fri, 24 Oct 2025 16:00:00 -040015:40falsefull2513913925Acute Myeloid Leukemia — An Interview with Dr Eunice S Wang to Review Key Presentations from ASCO and EHAAcute Myeloid Leukemia — An Interview with Dr Eunice S Wang to Review Key Presentations from ASCO and EHADr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, discusses recent datasets and their implications for the current and future management of acute myeloid leukemia.  

CME information and select publications here.

]]>Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, discusses recent datasets and their implications for the current and future management of acute myeloid leukemia.  

CME information and select publications here.

]]>f4cf62c7-0fa7-4eff-a1f1-77be53c6dc1bWed, 22 Oct 2025 15:30:00 -040054:59falsefull2513813825Metastatic Breast Cancer — Current and Future Integration of Antibody-Drug ConjugatesMetastatic Breast Cancer — Current and Future Integration of Antibody-Drug ConjugatesDr Aditya Bardia and Dr Adam M Brufsky discuss published and emerging datasets investigating the incorporation of antibody-drug conjugates into the treatment of metastatic breast cancer.

CME information and select publications here.

]]>Dr Aditya Bardia and Dr Adam M Brufsky discuss published and emerging datasets investigating the incorporation of antibody-drug conjugates into the treatment of metastatic breast cancer.

CME information and select publications here.

]]>0a757b7a-008b-4ade-8251-3cc38987725fMon, 20 Oct 2025 15:00:00 -040056:46falsefull2513713725Lung Cancer — 5-Minute Journal Club Issue 3 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug ConjugatesLung Cancer — 5-Minute Journal Club Issue 3 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug ConjugatesDr Aaron Lisberg from the University of California, Los Angeles discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. 

CME information and select publications here.

]]>Dr Aaron Lisberg from the University of California, Los Angeles discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. 

CME information and select publications here.

]]>fb80e931-c1aa-4a17-a766-fd11d1afcb20Sat, 18 Oct 2025 09:00:00 -040024:47falsefull2513613625Non-Hodgkin Lymphoma — The Implications of Recent Datasets for Current and Future Disease ManagementNon-Hodgkin Lymphoma — The Implications of Recent Datasets for Current and Future Disease ManagementDr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, and Dr Brad S Kahl from Siteman Cancer Center in St Louis, Missouri, review recent datasets and their significance for the management of various forms of non-Hodgkin lymphoma. 

CME information and select publications here.

]]>Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, and Dr Brad S Kahl from Siteman Cancer Center in St Louis, Missouri, review recent datasets and their significance for the management of various forms of non-Hodgkin lymphoma. 

CME information and select publications here.

]]>26f410be-34ea-4e2e-8765-cb9d912fbe35Fri, 17 Oct 2025 16:22:00 -040057:59falsefull2513513525HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into TreatmentHR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into TreatmentDr Laura Huppert from the University of California, San Francisco, discusses approved and investigational antibody-drug conjugates in the current and future management of HR-positive and triple-negative metastatic breast cancer. 

CME information and select publications here.

]]>Dr Laura Huppert from the University of California, San Francisco, discusses approved and investigational antibody-drug conjugates in the current and future management of HR-positive and triple-negative metastatic breast cancer. 

CME information and select publications here.

]]>1870a65c-652f-459b-9f80-c90c8b3d6851Mon, 13 Oct 2025 13:00:00 -040043:40falsefull2513413425Follicular Lymphoma — Proceedings from a Session Held During the Society of Hematologic Oncology 2025 Annual MeetingFollicular Lymphoma — Proceedings from a Session Held During the Society of Hematologic Oncology 2025 Annual MeetingDr Jeremy S Abramson from Massachusetts General Hospital in Boston, Dr Jennifer Crombie from Dana-Farber Cancer Institute also in Boston and Dr Laurie H Sehn from the BC Cancer Centre for Lymphoid Cancer in Vancouver, British Columbia, Canada, discuss recent updates on available and novel treatment strategies for follicular lymphoma.  

CE information and select publications here.

]]>Dr Jeremy S Abramson from Massachusetts General Hospital in Boston, Dr Jennifer Crombie from Dana-Farber Cancer Institute also in Boston and Dr Laurie H Sehn from the BC Cancer Centre for Lymphoid Cancer in Vancouver, British Columbia, Canada, discuss recent updates on available and novel treatment strategies for follicular lymphoma.  

CE information and select publications here.

]]>3ad43493-ee76-4b76-ae5a-055cb031799fFri, 10 Oct 2025 18:34:00 -040059:34falsefull2513313325Acute Myeloid Leukemia — An Interview with Dr Ghayas Issa on the Role of Menin InhibitorsAcute Myeloid Leukemia — An Interview with Dr Ghayas Issa on the Role of Menin InhibitorsDr Ghayas Issa from The University of Texas MD Anderson Cancer Center in Houston discusses data guiding the use of menin inhibitors for patients with acute myeloid leukemia and select alterations. 

CME information and select publications here.

]]>Dr Ghayas Issa from The University of Texas MD Anderson Cancer Center in Houston discusses data guiding the use of menin inhibitors for patients with acute myeloid leukemia and select alterations. 

CME information and select publications here.

]]>7ccc654b-69f5-476a-880b-d9be81785744Wed, 08 Oct 2025 14:00:00 -040058:47falsefull2513213225Breast Cancer — An ASCO 2025 ReviewBreast Cancer — An ASCO 2025 ReviewDr Sara A Hurvitz and Dr Sara M Tolaney summarize the treatment landscape for breast cancer and discuss the implications of clinical findings recently presented at the 2025 ASCO Annual Meeting. 

CME information and select publications here.

]]>Dr Sara A Hurvitz and Dr Sara M Tolaney summarize the treatment landscape for breast cancer and discuss the implications of clinical findings recently presented at the 2025 ASCO Annual Meeting. 

CME information and select publications here.

]]>804088a7-1fb3-47a9-ba15-3dcb3e31f49eMon, 06 Oct 2025 14:00:00 -040001:02:01falsefull2513113125Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2025 Annual MeetingRelapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2025 Annual MeetingProf Meletios-Athanasios (Thanos) C Dimopoulos from Alexandra Hospital in Athens, Greece, Dr Hans Lee from Sarah Cannon Research Institute in Nashville, Tennessee, Dr Joseph Mikhael from City of Hope Cancer Center in Phoenix, Arizona, and Dr Noopur Raje from Massachusetts General Hospital in Boston discuss recent updates on available and novel treatment strategies for relapsed/refractory multiple myeloma.  

CE information and select publications here.

]]>Prof Meletios-Athanasios (Thanos) C Dimopoulos from Alexandra Hospital in Athens, Greece, Dr Hans Lee from Sarah Cannon Research Institute in Nashville, Tennessee, Dr Joseph Mikhael from City of Hope Cancer Center in Phoenix, Arizona, and Dr Noopur Raje from Massachusetts General Hospital in Boston discuss recent updates on available and novel treatment strategies for relapsed/refractory multiple myeloma.  

CE information and select publications here.

]]>87870f6b-26b0-4b55-b81a-5bb6406dea91Thu, 02 Oct 2025 09:00:00 -040058:29falsefull2513013025Breast Cancer — 5-Minute Journal Club Issue 3 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug ConjugatesBreast Cancer — 5-Minute Journal Club Issue 3 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug ConjugatesDr Kevin Kalinsky from the Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of breast cancer. 

CME information and select publications here.

]]>Dr Kevin Kalinsky from the Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of breast cancer. 

CME information and select publications here.

]]>6f3cb3da-5bcc-4b16-9552-8a7f1d7d4345Fri, 26 Sep 2025 16:00:00 -040021:51falsefull2512912925Metastatic BRCA-Negative, Triple-Negative Breast Cancer — An Interview with Prof Peter Schmid on Optimal ManagementMetastatic BRCA-Negative, Triple-Negative Breast Cancer — An Interview with Prof Peter Schmid on Optimal ManagementProf Peter Schmid from Barts Cancer Institute in London reviews available efficacy and safety data guiding the optimal management of metastatic triple-negative breast cancer. 

CME information and select publications here.

]]>Prof Peter Schmid from Barts Cancer Institute in London reviews available efficacy and safety data guiding the optimal management of metastatic triple-negative breast cancer. 

CME information and select publications here.

]]>39597225-3e28-4fb2-921a-e26f0ef75429Mon, 22 Sep 2025 15:00:00 -040040:53falsefull2512812825Extrapulmonary Neuroendocrine Carcinoma — An Interview with Dr Jonathan Strosberg on Current and Future ManagementExtrapulmonary Neuroendocrine Carcinoma — An Interview with Dr Jonathan Strosberg on Current and Future ManagementDr Jonathan Strosberg from Moffitt Cancer Center in Tampa, Florida, discusses recent updates on available and novel treatment strategies for extrapulmonary neuroendocrine carcinoma. 

CME information and select publications here.

]]>Dr Jonathan Strosberg from Moffitt Cancer Center in Tampa, Florida, discusses recent updates on available and novel treatment strategies for extrapulmonary neuroendocrine carcinoma. 

CME information and select publications here.

]]>3fb7f438-96c1-4bee-a73e-53d361e116b9Sat, 20 Sep 2025 09:00:00 -040044:34falsefull2512712725Oncology Nursing Update: Multiple Myeloma — An Interview with Dr Beth Faiman on CAR T-Cell TherapyOncology Nursing Update: Multiple Myeloma — An Interview with Dr Beth Faiman on CAR T-Cell TherapyDr Beth Faiman from Case Comprehensive Cancer Center in Cleveland, Ohio, discusses nursing considerations with CAR T-cell therapy for patients with multiple myeloma. 

NCPD information and select publications here.

]]>Dr Beth Faiman from Case Comprehensive Cancer Center in Cleveland, Ohio, discusses nursing considerations with CAR T-cell therapy for patients with multiple myeloma. 

NCPD information and select publications here.

]]>5c09bd27-e8ab-4de5-a821-5bcd8aa6b224Fri, 19 Sep 2025 16:00:00 -040053:08falsefull2512612625Metastatic Triple-Negative Breast Cancer — The Selection and Sequencing of TherapyMetastatic Triple-Negative Breast Cancer — The Selection and Sequencing of TherapyDr Ana C Garrido-Castro and Prof Peter Schmid review patient cases and provide insights regarding the treatment of metastatic triple-negative breast cancer.  

CME information and select publications here.

]]>Dr Ana C Garrido-Castro and Prof Peter Schmid review patient cases and provide insights regarding the treatment of metastatic triple-negative breast cancer.  

CME information and select publications here.

]]>fa56a94f-52ef-4fac-b0f5-776feb3cb33bWed, 17 Sep 2025 15:00:00 -040058:41falsefull2512512525Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 2 — An Interview with Dr Neel Pasricha on Adverse Event ManagementOcular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 2 — An Interview with Dr Neel Pasricha on Adverse Event ManagementDr Neel Pasricha from the University of California, San Franciso, reviews corneal and other ophthalmic toxicities associated with antibody-drug conjugates and other cancer therapies and strategies for their prevention and management.   

CME information and select publications here.

]]>Dr Neel Pasricha from the University of California, San Franciso, reviews corneal and other ophthalmic toxicities associated with antibody-drug conjugates and other cancer therapies and strategies for their prevention and management.   

CME information and select publications here.

]]>b792a4b4-188d-4f5c-9ddd-9cb9e4816742Tue, 16 Sep 2025 09:30:00 -040054:23falsefull2512412425Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 1 — Inside the Issue of Adverse Event ManagementOcular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 1 — Inside the Issue of Adverse Event ManagementProf Rebecca A Dent from National Cancer Centre Singapore, Dr Hans Lee from Sara Cannon Research Institute in Nashville, Tennessee, Dr Neel Pasricha from the University of California, San Francisco, and Dr Tiffany A Richards from The University of Texas MD Anderson Cancer Center in Houston, discuss strategies to manage ocular toxicities associated with antibody-drug conjugates and other cancer therapies. 

CME information and select publications here.

]]>Prof Rebecca A Dent from National Cancer Centre Singapore, Dr Hans Lee from Sara Cannon Research Institute in Nashville, Tennessee, Dr Neel Pasricha from the University of California, San Francisco, and Dr Tiffany A Richards from The University of Texas MD Anderson Cancer Center in Houston, discuss strategies to manage ocular toxicities associated with antibody-drug conjugates and other cancer therapies. 

CME information and select publications here.

]]>17f2b477-d90d-4fb3-a6e1-cdb710a67d22Mon, 15 Sep 2025 15:00:00 -040057:47falsefull2512312325Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 2 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug ConjugatesNon-Small Cell Lung Cancer — 5-Minute Journal Club Issue 2 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug ConjugatesDr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of lung cancer. 

CME information and select publications here.

]]>Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of lung cancer. 

CME information and select publications here.

]]>fb32ca96-b546-4133-9ef1-4482dddf66d7Fri, 12 Sep 2025 15:00:00 -040023:19falsefull2512212225Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 1Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 1Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas review available efficacy and safety data guiding the optimal integration of oral SERDs into clinical practice. 

CME information and select publications here.

]]>Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas review available efficacy and safety data guiding the optimal integration of oral SERDs into clinical practice. 

CME information and select publications here.

]]>e01829a9-3b02-4267-b8f7-156435e34760Mon, 08 Sep 2025 15:00:00 -040058:36falsefull2512112125Oncology Nursing Update: Newly Diagnosed Multiple Myeloma — An Interview with Ms Charise GleasonOncology Nursing Update: Newly Diagnosed Multiple Myeloma — An Interview with Ms Charise GleasonMs Charise Gleason from Emory Healthcare in Atlanta, Georgia, discusses the evolution of first-line therapy for patients with multiple myeloma. 

NCPD information and select publications here.

]]>Ms Charise Gleason from Emory Healthcare in Atlanta, Georgia, discusses the evolution of first-line therapy for patients with multiple myeloma. 

NCPD information and select publications here.

]]>b44aa14a-8efc-4017-82d4-10be3fea8e3bSat, 06 Sep 2025 09:00:00 -040054:17falsefull2512012025Oncology Nursing Update: Newly Diagnosed Multiple Myeloma — An Interview with Prof Xavier LeleuOncology Nursing Update: Newly Diagnosed Multiple Myeloma — An Interview with Prof Xavier LeleuProf Xavier Leleu from Poitiers University Hospital in Poitiers, France, discusses nursing considerations in the treatment of newly diagnosed multiple myeloma. 

NCPD information and select publications here.

]]>Prof Xavier Leleu from Poitiers University Hospital in Poitiers, France, discusses nursing considerations in the treatment of newly diagnosed multiple myeloma. 

NCPD information and select publications here.

]]>c3c341da-8130-4bff-850f-a8a570c26738Fri, 05 Sep 2025 10:00:00 -040053:08falsefull2511911925Breast Cancer — 5-Minute Journal Club Issue 2 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug ConjugatesBreast Cancer — 5-Minute Journal Club Issue 2 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug ConjugatesDr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discusses the monitoring, mitigation and management of adverse events with available antibody-drug conjugates and novel strategies incorporating ADCs into the breast cancer treatment paradigm.  

CME information and select publications here.

]]>Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discusses the monitoring, mitigation and management of adverse events with available antibody-drug conjugates and novel strategies incorporating ADCs into the breast cancer treatment paradigm.  

CME information and select publications here.

]]>179d163d-e3d2-4e77-868e-5adbc9128c38Mon, 01 Sep 2025 09:00:00 -040015:43falsefull2511811825Relapsed/Refractory Multiple Myeloma — Oncology Q&A: Discussing Common Questions Posed by PatientsRelapsed/Refractory Multiple Myeloma — Oncology Q&A: Discussing Common Questions Posed by PatientsDr Natalie S Callander and Dr Sagar Lonial provide clinical perspectives on the treatment and disease-management course for patients with relapsed/refractory multiple myeloma. 

CME information and select publications here.

]]>Dr Natalie S Callander and Dr Sagar Lonial provide clinical perspectives on the treatment and disease-management course for patients with relapsed/refractory multiple myeloma. 

CME information and select publications here.

]]>bcdea350-9cb7-4feb-9f1b-34f5f4462ee0Fri, 29 Aug 2025 09:00:00 -040059:21falsefull2511711725Biliary Tract Cancers — Expert Perspectives on Actual Patient Cases: Part 2 of 2Biliary Tract Cancers — Expert Perspectives on Actual Patient Cases: Part 2 of 2Dr Haley Ellis and Dr James J Harding review actual patient cases and summarize clinical trial findings regarding the treatment of biliary tract cancers. 

CME information and select publications here.

]]>Dr Haley Ellis and Dr James J Harding review actual patient cases and summarize clinical trial findings regarding the treatment of biliary tract cancers. 

CME information and select publications here.

]]>0cbb0c04-276e-4359-b9c9-df75f27363c3Thu, 28 Aug 2025 14:30:00 -040059:15falsefull2511611625Brain Metastases with HER2-Positive Breast Cancer — An Interview with Dr Sarah Sammons on Optimal Management ApproachesBrain Metastases with HER2-Positive Breast Cancer — An Interview with Dr Sarah Sammons on Optimal Management ApproachesDr Sarah Sammons from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses cases and reviews the current management of brain metastases in patients with HER2-positive breast cancer. 

CME information and select publications here.

]]>Dr Sarah Sammons from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses cases and reviews the current management of brain metastases in patients with HER2-positive breast cancer. 

CME information and select publications here.

]]>ace0a4bd-7a73-40f0-9ee0-085ea6add6abMon, 25 Aug 2025 15:00:00 -040045:42falsefull2511511525Small Cell Lung Cancer — Expert Perspectives on Actual Patient CasesSmall Cell Lung Cancer — Expert Perspectives on Actual Patient CasesDr Stephen V Liu from Georgetown University Hospital in Washington, DC and Dr Charles Rudin from Memorial Sloan Kettering Cancer Center in New York discuss the role of approved and novel investigational therapies for patients with limited-stage and extensive-stage small cell lung cancer. 

CME information and select publications here.

]]>Dr Stephen V Liu from Georgetown University Hospital in Washington, DC and Dr Charles Rudin from Memorial Sloan Kettering Cancer Center in New York discuss the role of approved and novel investigational therapies for patients with limited-stage and extensive-stage small cell lung cancer. 

CME information and select publications here.

]]>b7dc8a67-5aff-4cbd-a009-893fabcd7946Fri, 22 Aug 2025 15:00:00 -040058:18falsefull2511411425Ovarian and Endometrial Cancer — An Interview with Dr Shannon Westin on the Current Management ParadigmOvarian and Endometrial Cancer — An Interview with Dr Shannon Westin on the Current Management ParadigmDr Shannon Westin from the University of Texas MD Anderson Cancer Center in Houston discusses recent updates on available and novel treatment strategies for ovarian and endometrial cancer.  

CME information and select publications here.

]]>Dr Shannon Westin from the University of Texas MD Anderson Cancer Center in Houston discusses recent updates on available and novel treatment strategies for ovarian and endometrial cancer.  

CME information and select publications here.

]]>b592240d-4579-4a84-95de-c05f1cef7078Wed, 20 Aug 2025 15:30:00 -040052:35falsefull2511311325Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 1 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug ConjugatesNon-Small Cell Lung Cancer — 5-Minute Journal Club Issue 1 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug ConjugatesDr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. 

CME information and select publications here.

]]>Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. 

CME information and select publications here.

]]>35d46284-71c0-48e4-8a8f-a6a7aa4eb1d1Fri, 15 Aug 2025 15:00:00 -040017:44falsefull2511211225Multiple Myeloma | Oncology Q&A — Patient Education Resource: Clinical Experts Address Common Questions Posed by Patients with Relapsed/Refractory Multiple MyelomaMultiple Myeloma | Oncology Q&A — Patient Education Resource: Clinical Experts Address Common Questions Posed by Patients with Relapsed/Refractory Multiple MyelomaFor this patient-focused webinar, medical oncologist Dr Neil Love is joined by Dr Natalie S Callander from the University of Wisconsin Carbone Cancer Center in Madison and Dr Sagar Lonial from the Winship Cancer Institute of Emory University in Atlanta, Georgia, to discuss the patient experience associated with the diagnosis and treatment of relapsed/refractory multiple myeloma. 

Educational and faculty information here.

]]>For this patient-focused webinar, medical oncologist Dr Neil Love is joined by Dr Natalie S Callander from the University of Wisconsin Carbone Cancer Center in Madison and Dr Sagar Lonial from the Winship Cancer Institute of Emory University in Atlanta, Georgia, to discuss the patient experience associated with the diagnosis and treatment of relapsed/refractory multiple myeloma. 

Educational and faculty information here.

]]>6312d7df-14a5-44f8-bc11-9d0caf6faa8dThu, 14 Aug 2025 13:00:00 -040001:02:11falsefull2511111125Acute Myeloid Leukemia — An Interview with Dr Jorge Cortes on Optimal Management of FLT3 and IDH1/2 MutationsAcute Myeloid Leukemia — An Interview with Dr Jorge Cortes on Optimal Management of FLT3 and IDH1/2 MutationsDr Jorge Cortes from Georgia Cancer Center at Augusta University discusses patient cases and summarizes current treatment approaches for FLT3- and IDH1/2-mutant acute myeloid leukemia. 

CME information and select publications here.

]]>Dr Jorge Cortes from Georgia Cancer Center at Augusta University discusses patient cases and summarizes current treatment approaches for FLT3- and IDH1/2-mutant acute myeloid leukemia. 

CME information and select publications here.

]]>66d2c1c8-662f-42b4-a2c0-9778fc9e1a0cMon, 11 Aug 2025 15:00:00 -040043:01falsefull2511011025Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and AdvancesNon-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and AdvancesDr Benjamin Levy from Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial in Washington, DC, discusses important efficacy and safety data from 2024 related to the use of approved and investigational therapies for localized and advanced non-small cell lung cancer without a targetable mutation. 

CME information and select publications here.

]]>Dr Benjamin Levy from Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial in Washington, DC, discusses important efficacy and safety data from 2024 related to the use of approved and investigational therapies for localized and advanced non-small cell lung cancer without a targetable mutation. 

CME information and select publications here.

]]>633dd658-9f68-4ea8-b670-1b43dcc7df0dThu, 07 Aug 2025 13:00:00 -040059:02falsefull2510910925Multiple Myeloma — Optimizing the Selection of First-Line TherapyMultiple Myeloma — Optimizing the Selection of First-Line TherapyProf Xavier Leleu and Dr Peter Voorhees review relevant clinical data regarding first-line treatment decisions for patients with multiple myeloma. 

CME information and select publications here.

]]>Prof Xavier Leleu and Dr Peter Voorhees review relevant clinical data regarding first-line treatment decisions for patients with multiple myeloma. 

CME information and select publications here.

]]>88316f35-266f-45a3-95e4-95ca3160b02fWed, 06 Aug 2025 15:00:00 -040057:11falsefull2510810825Breast Cancer — 5-Minute Journal Club Issue 1 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug ConjugatesBreast Cancer — 5-Minute Journal Club Issue 1 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug ConjugatesDr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discusses available data and shares clinical investigator perspectives on the role of TROP2-directed antibody-drug conjugates in the management of HR-positive and triple-negative breast cancers. 

CME information and select publications here.

]]>Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discusses available data and shares clinical investigator perspectives on the role of TROP2-directed antibody-drug conjugates in the management of HR-positive and triple-negative breast cancers. 

CME information and select publications here.

]]>4b3133c8-4dc3-49ab-961a-5090054eae68Fri, 01 Aug 2025 09:00:00 -040020:18falsefull2510710725Gynecologic Cancers — Year in Review Series on Relevant New Datasets and AdvancesGynecologic Cancers — Year in Review Series on Relevant New Datasets and AdvancesProf Susana Banerjee from The Institute of Cancer Research in London and Dr Ursula Matulonis from Dana-Farber Cancer Institute in Boston discuss important efficacy and safety data from the past year related to the management of ovarian, endometrial and cervical cancers.

CME information and select publications here.

]]>Prof Susana Banerjee from The Institute of Cancer Research in London and Dr Ursula Matulonis from Dana-Farber Cancer Institute in Boston discuss important efficacy and safety data from the past year related to the management of ovarian, endometrial and cervical cancers.

CME information and select publications here.

]]>24e12418-e784-4f41-b567-da90ea02580dThu, 31 Jul 2025 16:00:00 -040059:34falsefull2510610625Oncology Nursing Update: Prostate Cancer — An Interview with Ms Kathleen D Burns on the Current Treatment Paradigm and New Approaches to Patient CareOncology Nursing Update: Prostate Cancer — An Interview with Ms Kathleen D Burns on the Current Treatment Paradigm and New Approaches to Patient CareMs Kathleen D Burns from City of Hope Comprehensive Cancer Center in Duarte, California, discusses nursing considerations in the care of patients with prostate cancer. 

NCPD information and select publications here.

]]>Ms Kathleen D Burns from City of Hope Comprehensive Cancer Center in Duarte, California, discusses nursing considerations in the care of patients with prostate cancer. 

NCPD information and select publications here.

]]>6a33f6ca-1cf0-45d2-9604-87f7b8d595a2Wed, 30 Jul 2025 15:00:00 -040044:11falsefull2510510525Endocrine-Resistant HR-Positive Metastatic Breast Cancer — An Interview with Dr Hope S Rugo on Optimal ManagementEndocrine-Resistant HR-Positive Metastatic Breast Cancer — An Interview with Dr Hope S Rugo on Optimal ManagementDr Hope S Rugo from City of Hope Comprehensive Cancer Center in Duarte, California, discusses the efficacy and safety of approved and investigational antibody-drug conjugates for endocrine-resistant HR-positive and triple-negative metastatic breast cancer. 

CME information and select publications here.

]]>Dr Hope S Rugo from City of Hope Comprehensive Cancer Center in Duarte, California, discusses the efficacy and safety of approved and investigational antibody-drug conjugates for endocrine-resistant HR-positive and triple-negative metastatic breast cancer. 

CME information and select publications here.

]]>d2fc1b98-acfc-49ea-92d2-021f6f03be4dMon, 28 Jul 2025 14:00:00 -040027:45falsefull2510410425Soft Tissue Sarcoma and Other Connective Tissue Neoplasms — Proceedings from a Webinar Held in Conjunction with the 2025 ASCO Annual MeetingSoft Tissue Sarcoma and Other Connective Tissue Neoplasms — Proceedings from a Webinar Held in Conjunction with the 2025 ASCO Annual MeetingDr Rashmi Chugh from Rogel Comprehensive Cancer Center in Ann Arbor, Michigan, and Dr Mrinal Gounder from Memorial Sloan Kettering Cancer Center in New York, New York, summarize major clinical findings presented at the 2025 ASCO Annual Meeting for patients with soft tissue sarcoma and other connective tissue neoplasms. 

CME information and select publications here.

]]>Dr Rashmi Chugh from Rogel Comprehensive Cancer Center in Ann Arbor, Michigan, and Dr Mrinal Gounder from Memorial Sloan Kettering Cancer Center in New York, New York, summarize major clinical findings presented at the 2025 ASCO Annual Meeting for patients with soft tissue sarcoma and other connective tissue neoplasms. 

CME information and select publications here.

]]>26674995-10cb-41e9-8006-d0adf64849d3Thu, 24 Jul 2025 14:30:00 -040001:00:57falsefull2510310325Renal Cell Carcinoma — Proceedings from a Webinar Held in Conjunction with the 2025 ASCO Annual MeetingRenal Cell Carcinoma — Proceedings from a Webinar Held in Conjunction with the 2025 ASCO Annual MeetingProf Laurence Albiges and Dr Tian Zhang summarize major findings presented at the 2025 ASCO Annual Meeting and review relevant ongoing clinical trials for patients with renal cell carcinoma. 

CME information and select publications here.

]]>Prof Laurence Albiges and Dr Tian Zhang summarize major findings presented at the 2025 ASCO Annual Meeting and review relevant ongoing clinical trials for patients with renal cell carcinoma. 

CME information and select publications here.

]]>8c3cf779-9e14-4318-88c6-afd2c19a7c67Wed, 23 Jul 2025 16:00:00 -040058:54falsefull2510210225Chronic Lymphocytic Leukemia — Proceedings from a Session Held During the 2025 ASCO Annual MeetingChronic Lymphocytic Leukemia — Proceedings from a Session Held During the 2025 ASCO Annual MeetingDr Catherine Coombs and Dr William Wierda summarize major treatment advances in chronic lymphocytic leukemia presented at the 2025 American Society of Clinical Oncology Annual Meeting and review ongoing clinical trials. 

CME information and select publications here.

]]>Dr Catherine Coombs and Dr William Wierda summarize major treatment advances in chronic lymphocytic leukemia presented at the 2025 American Society of Clinical Oncology Annual Meeting and review ongoing clinical trials. 

CME information and select publications here.

]]>c247c214-e13c-49e8-a87d-50e2f8ca909eMon, 21 Jul 2025 15:00:00 -040001:00:43falsefull2510110125Oncology Nursing Update: Ovarian Cancer — An Interview with Ms Jennifer Filipi on the Current Treatment Paradigm and New ApproachesOncology Nursing Update: Ovarian Cancer — An Interview with Ms Jennifer Filipi on the Current Treatment Paradigm and New ApproachesMs Jennifer Filipi from the Massachusetts General Hospital Cancer Center in Boston discusses nursing considerations for the treatment of ovarian cancer. 

NCPD information and select publications here.

]]>Ms Jennifer Filipi from the Massachusetts General Hospital Cancer Center in Boston discusses nursing considerations for the treatment of ovarian cancer. 

NCPD information and select publications here.

]]>0a100b56-1408-42c2-8f41-cba764d22c54Fri, 18 Jul 2025 15:00:00 -040053:51falsefull2510010025Multiple Myeloma — Proceedings from a Webinar Held in Conjunction with the 2025 ASCO Annual MeetingMultiple Myeloma — Proceedings from a Webinar Held in Conjunction with the 2025 ASCO Annual MeetingDr Ajay K Nooka from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Paul G Richardson from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss recent updates on available and novel treatment strategies for multiple myeloma. 

CME information and select publications here.

]]>Dr Ajay K Nooka from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Paul G Richardson from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss recent updates on available and novel treatment strategies for multiple myeloma. 

CME information and select publications here.

]]>9c55deed-4ca8-401a-921d-168320f16502Thu, 17 Jul 2025 14:00:00 -040058:41falsefull25999925Lung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting on the Current and Future Role of Immunotherapy and Antibody-Drug ConjugatesLung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting on the Current and Future Role of Immunotherapy and Antibody-Drug ConjugatesProf Marina Garassino, Dr John Heymach, Prof Solange Peters and moderator Dr Jacob Sands present key data from the ASCO 2025 Annual Meeting on the management of metastatic NSCLC without targetable mutations, as well as emerging evidence on the role of antibody-drug conjugates for patients with select actionable genomic alterations. 

CME information and select publications here.

]]>Prof Marina Garassino, Dr John Heymach, Prof Solange Peters and moderator Dr Jacob Sands present key data from the ASCO 2025 Annual Meeting on the management of metastatic NSCLC without targetable mutations, as well as emerging evidence on the role of antibody-drug conjugates for patients with select actionable genomic alterations. 

CME information and select publications here.

]]>3821a7f9-08c4-4b25-ba92-25d0b3d8bd4aWed, 16 Jul 2025 16:00:00 -040001:28:41falsefull25989825For Oncology Nurses: Prostate Cancer — Proceedings from the 2025 Annual ONS CongressFor Oncology Nurses: Prostate Cancer — Proceedings from the 2025 Annual ONS CongressDr Rahul Aggarwal and Dr William K Oh and nurse practitioners Ms Monica Averia and Ms Kathleen D Burns discuss the current treatment landscape for prostate cancer and protocols to mitigate and manage treatment-emergent adverse events. 

NCPD information and select publications here.

]]>Dr Rahul Aggarwal and Dr William K Oh and nurse practitioners Ms Monica Averia and Ms Kathleen D Burns discuss the current treatment landscape for prostate cancer and protocols to mitigate and manage treatment-emergent adverse events. 

NCPD information and select publications here.

]]>3b621be9-41f6-42de-ae63-dcb2430b4b7aTue, 15 Jul 2025 14:00:00 -040001:27:51falsefull25979725HER2-Positive Gastrointestinal Cancers — Proceedings from a Session Held During the 2025 ASCO Annual MeetingHER2-Positive Gastrointestinal Cancers — Proceedings from a Session Held During the 2025 ASCO Annual MeetingDr Haley Ellis from Massachusetts General Hospital in Boston, Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora, Dr Sara Lonardi from the Veneto Institute of Oncology IOV-IRCCS in Padua, Italy, and Dr Kanwal Raghav from The University of Texas MD Anderson Cancer Center in Houston discuss patient cases and provide their perspectives on clinical datasets informing the care of patients with HER2-positive gastrointestinal cancer.  

CME information and select publications here.

]]>Dr Haley Ellis from Massachusetts General Hospital in Boston, Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora, Dr Sara Lonardi from the Veneto Institute of Oncology IOV-IRCCS in Padua, Italy, and Dr Kanwal Raghav from The University of Texas MD Anderson Cancer Center in Houston discuss patient cases and provide their perspectives on clinical datasets informing the care of patients with HER2-positive gastrointestinal cancer.  

CME information and select publications here.

]]>9bd01b26-75b4-47ae-a59f-b86e3df0c66bMon, 14 Jul 2025 14:00:00 -040001:28:55falsefull25969625For Oncology Nurses: Chronic Lymphocytic Leukemia — Proceedings from the 2025 Annual ONS CongressFor Oncology Nurses: Chronic Lymphocytic Leukemia — Proceedings from the 2025 Annual ONS CongressDr Bita Fakhri, Dr Jeff Sharman, and nurse practitioners Dr Jacqueline Broadway-Duren and Ms Corinne Hoffman discuss the current treatment landscape for chronic lymphocytic leukemia and strategies to mitigate and manage treatment-emergent adverse events.   

NCPD information and select publications here.

]]>Dr Bita Fakhri, Dr Jeff Sharman, and nurse practitioners Dr Jacqueline Broadway-Duren and Ms Corinne Hoffman discuss the current treatment landscape for chronic lymphocytic leukemia and strategies to mitigate and manage treatment-emergent adverse events.   

NCPD information and select publications here.

]]>3cea51c5-18bc-4efa-a818-83ba50ddcc70Fri, 11 Jul 2025 08:00:00 -040001:30:22falsefull25959525Urothelial Bladder Cancer — Proceedings from a Session Held During the 2025 ASCO Annual MeetingUrothelial Bladder Cancer — Proceedings from a Session Held During the 2025 ASCO Annual MeetingDr Matthew D Galsky from The Tisch Cancer Institute in New York, New York, Prof Andrea Necchi from the IRCCS San Raffaele Hospital in Milan, Italy, and Prof Thomas Powles from the Barts Cancer Institute in London provide their perspectives on clinical scenarios and datasets informing the care of patients with urothelial bladder cancer. 

CME information and select publications here.

]]>Dr Matthew D Galsky from The Tisch Cancer Institute in New York, New York, Prof Andrea Necchi from the IRCCS San Raffaele Hospital in Milan, Italy, and Prof Thomas Powles from the Barts Cancer Institute in London provide their perspectives on clinical scenarios and datasets informing the care of patients with urothelial bladder cancer. 

CME information and select publications here.

]]>0268d9c7-5dcd-4c5f-9970-b2d79834c21eThu, 10 Jul 2025 14:00:00 -040001:00:11falsefull25949425Non-Hodgkin Lymphoma — Proceedings from a Session Held During the 2025 ASCO Annual MeetingNon-Hodgkin Lymphoma — Proceedings from a Session Held During the 2025 ASCO Annual MeetingDr Jeremy Abramson from Massachusetts General Hospital in Boston, Dr Joshua Brody from the Tisch Cancer Institute in New York, New York, Dr Christopher Flowers from The University of Texas MD Anderson Cancer Center in Houston, Dr Ann LaCasce from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Tycel Phillips from City of Hope Comprehensive Cancer Center in Duarte, California, discuss patient cases and provide their perspectives on clinical datasets informing the care of patients with non-Hodgkin lymphoma. 

CME information and select publications here.

]]>Dr Jeremy Abramson from Massachusetts General Hospital in Boston, Dr Joshua Brody from the Tisch Cancer Institute in New York, New York, Dr Christopher Flowers from The University of Texas MD Anderson Cancer Center in Houston, Dr Ann LaCasce from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Tycel Phillips from City of Hope Comprehensive Cancer Center in Duarte, California, discuss patient cases and provide their perspectives on clinical datasets informing the care of patients with non-Hodgkin lymphoma. 

CME information and select publications here.

]]>2e76c2ff-dfdb-4414-a368-cc1909a7eb8fWed, 09 Jul 2025 11:11:00 -040001:59:42falsefull25939325For Oncology Nurses: DLL3-Targeting Bispecific T-Cell Engagers for Small Cell Lung Cancer — Proceedings from the 2025 Annual ONS CongressFor Oncology Nurses: DLL3-Targeting Bispecific T-Cell Engagers for Small Cell Lung Cancer — Proceedings from the 2025 Annual ONS CongressDr Anne Chiang, Dr Erin Schenk, and nurse practitioners Ms Elizabeth Krueger and Ms Beth Sandy discuss the role of bispecific antibodies in the management of small cell lung cancer and strategies to mitigate and manage treatment-emergent adverse events. 

NCPD information and select publications here.

]]>Dr Anne Chiang, Dr Erin Schenk, and nurse practitioners Ms Elizabeth Krueger and Ms Beth Sandy discuss the role of bispecific antibodies in the management of small cell lung cancer and strategies to mitigate and manage treatment-emergent adverse events. 

NCPD information and select publications here.

]]>ecd54969-a3f3-4c10-b906-9035a690a990Mon, 07 Jul 2025 16:00:00 -040001:27:39falsefull25929225For Oncology Nurses: Non-Hodgkin Lymphoma — Proceedings from the 2025 Annual ONS CongressFor Oncology Nurses: Non-Hodgkin Lymphoma — Proceedings from the 2025 Annual ONS CongressDr Christopher Flowers and Dr Manali Kamdar summarize the clinical treatment landscape for patients with non-Hodgkin lymphoma, supported by clinical perspectives and management strategies from nurse practitioners Ms Robin Klebig and Ms Caitlin Murphy. 

NCPD information and select publications here.

]]>Dr Christopher Flowers and Dr Manali Kamdar summarize the clinical treatment landscape for patients with non-Hodgkin lymphoma, supported by clinical perspectives and management strategies from nurse practitioners Ms Robin Klebig and Ms Caitlin Murphy. 

NCPD information and select publications here.

]]>1571a1b9-bef3-48f8-a151-b855038e1a00Fri, 04 Jul 2025 09:00:00 -040001:26:53falsefull25919125Metastatic Breast Cancer — Proceedings from a Session Held During the 2025 ASCO Annual MeetingMetastatic Breast Cancer — Proceedings from a Session Held During the 2025 ASCO Annual MeetingDr Harold Burstein, Dr Javier Cortés, Prof Rebecca A Dent, Dr Kevin Kalinsky, Dr Joyce O’Shaughnessy and moderator Dr Hope S Rugo present data informing treatment decision-making for patients with metastatic breast cancer at the 2025 ASCO annual meeting. 

CME information and select publications here.

]]>Dr Harold Burstein, Dr Javier Cortés, Prof Rebecca A Dent, Dr Kevin Kalinsky, Dr Joyce O’Shaughnessy and moderator Dr Hope S Rugo present data informing treatment decision-making for patients with metastatic breast cancer at the 2025 ASCO annual meeting. 

CME information and select publications here.

]]>f80d8512-79f6-4559-84a1-b7da6a7fe1b5Thu, 03 Jul 2025 14:00:00 -040001:57:47falsefull25909025Colorectal Cancer — Proceedings from a Session Held During the 2025 ASCO Annual MeetingColorectal Cancer — Proceedings from a Session Held During the 2025 ASCO Annual MeetingDr Andrea Cercek from Memorial Sloan Kettering Cancer Center in New York, New York, Dr Arvind Dasari from The University of Texas MD Anderson Cancer Center in Houston, Dr Pashtoon Kasi from City of Hope Orange County in Irvine, California, Prof Eric Van Cutsem from University Hospitals Leuven in Belgium, and Dr J Randolph Hecht from the UCLA David Geffen School of Medicine in Santa Monica, California, discuss recent updates on available and novel treatment strategies for colorectal cancer. 

CME information and select publications here.

]]>Dr Andrea Cercek from Memorial Sloan Kettering Cancer Center in New York, New York, Dr Arvind Dasari from The University of Texas MD Anderson Cancer Center in Houston, Dr Pashtoon Kasi from City of Hope Orange County in Irvine, California, Prof Eric Van Cutsem from University Hospitals Leuven in Belgium, and Dr J Randolph Hecht from the UCLA David Geffen School of Medicine in Santa Monica, California, discuss recent updates on available and novel treatment strategies for colorectal cancer. 

CME information and select publications here.

]]>45eda3e2-9d84-4108-8b00-9341a11e0577Wed, 02 Jul 2025 14:00:00 -040002:02:10falsefull25898925Ovarian and Endometrial Cancer  — Proceedings from a Session Held During the 2025 ASCO Annual MeetingOvarian and Endometrial Cancer  — Proceedings from a Session Held During the 2025 ASCO Annual MeetingDrs Joyce F Liu, David M O’Malley, Ritu Salani, Alessandro D Santin and moderator Dr Shannon N Westin present data informing treatment decision-making for patients with advanced ovarian and endometrial cancers at the 2025 ASCO annual meeting. 

CME information and select publications here.

]]>Drs Joyce F Liu, David M O’Malley, Ritu Salani, Alessandro D Santin and moderator Dr Shannon N Westin present data informing treatment decision-making for patients with advanced ovarian and endometrial cancers at the 2025 ASCO annual meeting. 

CME information and select publications here.

]]>af87d0be-83f6-4bdf-8948-ddd123acc87cMon, 30 Jun 2025 15:00:00 -040001:59:45falsefull25888825For Oncology Nurses: Chronic Myeloid Leukemia — Proceedings from the 2025 Annual ONS CongressFor Oncology Nurses: Chronic Myeloid Leukemia — Proceedings from the 2025 Annual ONS CongressDr Michael Mauro, Dr Neil Shah, and nurse practitioners Ms Ilene Galinsky and Dr Sara Tinsley-Vance discuss important nursing considerations in the modern treatment of chronic myeloid leukemia. 

NCPD information and select publications here.

]]>Dr Michael Mauro, Dr Neil Shah, and nurse practitioners Ms Ilene Galinsky and Dr Sara Tinsley-Vance discuss important nursing considerations in the modern treatment of chronic myeloid leukemia. 

NCPD information and select publications here.

]]>334aa69a-a672-44b7-9708-f971e5b3bfe9Fri, 27 Jun 2025 13:00:00 -040001:26:22falsefull25878725Prostate Cancer  — Proceedings from a Session Held During the 2025 ASCO Annual MeetingProstate Cancer  — Proceedings from a Session Held During the 2025 ASCO Annual MeetingDr Neeraj Agarwal from the University of Utah Huntsman Cancer Institute in Salt Lake City, Dr Andrew J Armstrong from Duke Cancer Institute in Durham, North Carolina, Dr Himisha Beltran from Dana-Farber Cancer Institute in Boston, Massachusetts, Dr Fred Saad from the University of Montreal Hospital Center in Québec, Canada, and Dr Rana R McKay from the UC San Diego Moores Cancer Center discuss recent updates on available and novel treatment strategies for prostate cancer. 

CME information and select publications here.

]]>Dr Neeraj Agarwal from the University of Utah Huntsman Cancer Institute in Salt Lake City, Dr Andrew J Armstrong from Duke Cancer Institute in Durham, North Carolina, Dr Himisha Beltran from Dana-Farber Cancer Institute in Boston, Massachusetts, Dr Fred Saad from the University of Montreal Hospital Center in Québec, Canada, and Dr Rana R McKay from the UC San Diego Moores Cancer Center discuss recent updates on available and novel treatment strategies for prostate cancer. 

CME information and select publications here.

]]>d5f8a80f-53c7-4760-868c-05192594931bWed, 25 Jun 2025 15:00:00 -040001:56:26falsefull25868625For Oncology Nurses: Ovarian Cancer — Proceedings from the 2025 Annual ONS CongressFor Oncology Nurses: Ovarian Cancer — Proceedings from the 2025 Annual ONS CongressMs Jennifer Filipi from the Massachusetts General Hospital Cancer Center in Boston discusses nursing considerations for the treatment of ovarian cancer. 

NCPD information and select publications here.

]]>Ms Jennifer Filipi from the Massachusetts General Hospital Cancer Center in Boston discusses nursing considerations for the treatment of ovarian cancer. 

NCPD information and select publications here.

]]>d799b18b-a8eb-4cb8-a374-969a31a5a34cTue, 24 Jun 2025 14:00:00 -040001:29:57falsefull25858525IDH-Mutant Low-Grade Glioma — An Interview with Dr Patrick Y Wen on Current and Future Management StrategiesIDH-Mutant Low-Grade Glioma — An Interview with Dr Patrick Y Wen on Current and Future Management StrategiesDr Patrick Wen from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses the current and future management of IDH-mutant gliomas.  

CME information and select publications here.

]]>Dr Patrick Wen from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses the current and future management of IDH-mutant gliomas.  

CME information and select publications here.

]]>48636056-d623-4849-be3a-a8d53ebc0d6eMon, 23 Jun 2025 16:00:00 -040054:07falsefull25848425EGFR Mutation-Positive Non-Small Cell Lung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual MeetingEGFR Mutation-Positive Non-Small Cell Lung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual MeetingProf Nicolas Girard, Dr Jonathan Goldman, Dr Pasi Jänne, Dr Suresh Ramalingam, Dr Joshua Sabari and moderator Dr Helena Yu present data informing treatment decision-making for EGFR-mutated NSCLC at the 2025 ASCO annual meeting. 

CME information and select publications here.

]]>Prof Nicolas Girard, Dr Jonathan Goldman, Dr Pasi Jänne, Dr Suresh Ramalingam, Dr Joshua Sabari and moderator Dr Helena Yu present data informing treatment decision-making for EGFR-mutated NSCLC at the 2025 ASCO annual meeting. 

CME information and select publications here.

]]>ee7c707b-00b6-46e3-b197-d7b60ea251f1Fri, 20 Jun 2025 09:00:00 -040001:57:51falsefull25838325Advanced Gastroesophageal Cancers — Expert Perspectives on Actual Patient Cases: Part 1 of 2Advanced Gastroesophageal Cancers — Expert Perspectives on Actual Patient Cases: Part 1 of 2Dr Geoffrey Y Ku from the Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Zev Wainberg from the UCLA School of Medicine discuss patient cases and summarize current treatment approaches for gastroesophageal cancer. 

CME information and select publications here.

]]>Dr Geoffrey Y Ku from the Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Zev Wainberg from the UCLA School of Medicine discuss patient cases and summarize current treatment approaches for gastroesophageal cancer. 

CME information and select publications here.

]]>35106df3-4594-49a9-a0f4-abb46bc7ab79Wed, 18 Jun 2025 14:00:00 -040001:01:04falsefull25828225Multiple Myeloma — Year in Review Series on Relevant New Datasets and AdvancesMultiple Myeloma — Year in Review Series on Relevant New Datasets and AdvancesProf Meletios-Athanasios (Thanos) C Dimopoulos from the National and Kapodistrian University of Athens and Alexandra Hospital in Athens, Greece, and Dr Robert Z Orlowski from The University of Texas MD Anderson Cancer Center in Houston, Texas, provide their perspectives on relevant new clinical data in multiple myeloma and their application to disease treatment. 

CME information and select publications here.

]]>Prof Meletios-Athanasios (Thanos) C Dimopoulos from the National and Kapodistrian University of Athens and Alexandra Hospital in Athens, Greece, and Dr Robert Z Orlowski from The University of Texas MD Anderson Cancer Center in Houston, Texas, provide their perspectives on relevant new clinical data in multiple myeloma and their application to disease treatment. 

CME information and select publications here.

]]>65df5622-f4f2-454b-9c71-f604a70d7374Tue, 17 Jun 2025 15:00:00 -040059:09falsefull25818125For Oncology Nurses: Hormone Receptor-Positive Breast Cancer — Proceedings from the 2025 Annual ONS CongressFor Oncology Nurses: Hormone Receptor-Positive Breast Cancer — Proceedings from the 2025 Annual ONS CongressDrs Virginia F Borges and Seth Wander summarize the treatment landscape for patients with hormone receptor-positive breast cancer, supported with clinical perspectives and management strategies from nurse practitioners Ms Jamie Carroll and Mr Ronald Stein. 

NCPD information and select publications here.

]]>Drs Virginia F Borges and Seth Wander summarize the treatment landscape for patients with hormone receptor-positive breast cancer, supported with clinical perspectives and management strategies from nurse practitioners Ms Jamie Carroll and Mr Ronald Stein. 

NCPD information and select publications here.

]]>8a848c8a-aaf3-492f-ac95-9857bd68044bMon, 16 Jun 2025 15:33:00 -040001:54:49falsefull25808025For Oncology Nurses: Gastroesophageal Cancer — Proceedings from the 2025 Annual ONS CongressFor Oncology Nurses: Gastroesophageal Cancer — Proceedings from the 2025 Annual ONS CongressDr Sunnie Kim and Dr Manish Shah summarize the clinical treatment landscape for patients with gastroesophageal cancers, supported by clinical perspectives and management strategies from oncology nursing experts Ms Brooke Parker and Ms Michal Segal. 

NCPD information and select publications here.

]]>Dr Sunnie Kim and Dr Manish Shah summarize the clinical treatment landscape for patients with gastroesophageal cancers, supported by clinical perspectives and management strategies from oncology nursing experts Ms Brooke Parker and Ms Michal Segal. 

NCPD information and select publications here.

]]>27479761-068c-4f92-888c-157ef4a7a078Thu, 12 Jun 2025 14:00:00 -040001:29:49falsefull25797925Myelofibrosis — Year in Review Series on Relevant New Datasets and AdvancesMyelofibrosis — Year in Review Series on Relevant New Datasets and AdvancesProfessor Claire Harrison from the Guy’s and St Thomas’ NHS Foundation Trust in London, United Kingdom, and Dr John Mascarenas from The Tisch Cancer Institute in New York, New York, provide their perspectives on relevant new clinical data in myelofibrosis and discuss their application to treatment. 

CME information and select publications here.

]]>Professor Claire Harrison from the Guy’s and St Thomas’ NHS Foundation Trust in London, United Kingdom, and Dr John Mascarenas from The Tisch Cancer Institute in New York, New York, provide their perspectives on relevant new clinical data in myelofibrosis and discuss their application to treatment. 

CME information and select publications here.

]]>4d0afad9-33f5-43ba-8942-67b49f3fc442Wed, 11 Jun 2025 13:00:00 -040059:18falsefull25787825Non-Small Cell Lung Cancer and Therapeutic Targets Beyond EGFR — Year in Review Series on Relevant New Datasets and AdvancesNon-Small Cell Lung Cancer and Therapeutic Targets Beyond EGFR — Year in Review Series on Relevant New Datasets and AdvancesDr Jessica J Lin from Massachusetts General Hospital in Boston and Dr Joel W Neal from Stanford Cancer Institute in California summarize major treatment advances over the past year and review relevant ongoing clinical trials using targeted therapies for patients with non-small cell lung cancer. 

CME information and select publications here.

]]>Dr Jessica J Lin from Massachusetts General Hospital in Boston and Dr Joel W Neal from Stanford Cancer Institute in California summarize major treatment advances over the past year and review relevant ongoing clinical trials using targeted therapies for patients with non-small cell lung cancer. 

CME information and select publications here.

]]>36c888b8-f934-4d25-969a-4887f5e17e80Mon, 09 Jun 2025 09:00:00 -040058:22falsefull25777725For Oncology Nurses: Endometrial Cancer — Proceedings from the 2025 Annual ONS CongressFor Oncology Nurses: Endometrial Cancer — Proceedings from the 2025 Annual ONS CongressDr Ritu Salani and Dr Brian Slomovitz and nurse practitioners Ms Kathryn Lyle and Ms Jaclyn Shaver discuss datasets guiding treatment decision-making for patients with endometrial cancer and strategies to mitigate and manage treatment-emergent adverse events. 

NCPD information and select publications here.

]]>Dr Ritu Salani and Dr Brian Slomovitz and nurse practitioners Ms Kathryn Lyle and Ms Jaclyn Shaver discuss datasets guiding treatment decision-making for patients with endometrial cancer and strategies to mitigate and manage treatment-emergent adverse events. 

NCPD information and select publications here.

]]>728aebf1-422e-40a3-8413-91d480342430Fri, 06 Jun 2025 14:00:00 -040001:28:47falsefull25767625Non-Hodgkin Lymphoma — Year in Review Series on Relevant New Datasets and AdvancesNon-Hodgkin Lymphoma — Year in Review Series on Relevant New Datasets and AdvancesDr Stephen Ansell from Mayo Clinic in Rochester, Minnesota, and Dr Brian Hill from Cleveland Clinic Taussig Cancer Institute in Ohio summarize major treatment advances over the past year and review relevant ongoing clinical trials for patients with non-Hodgkin lymphoma. 

CME information and select publications here.

]]>Dr Stephen Ansell from Mayo Clinic in Rochester, Minnesota, and Dr Brian Hill from Cleveland Clinic Taussig Cancer Institute in Ohio summarize major treatment advances over the past year and review relevant ongoing clinical trials for patients with non-Hodgkin lymphoma. 

CME information and select publications here.

]]>539547a7-fdcd-4261-b7e0-9b977eb272b4Thu, 05 Jun 2025 14:00:00 -040059:08falsefull25757525Breast Cancer: Additional Perspectives — Year in Review Series on Relevant New Datasets and AdvancesBreast Cancer: Additional Perspectives — Year in Review Series on Relevant New Datasets and AdvancesDr Ian Krop from Yale Cancer Center in New Haven, Connecticut, and Dr Sara Tolaney from Dana-Farber Cancer Institute in Boston, Massachusetts, summarize major treatment advances over the past year and review relevant ongoing clinical trials for patients with breast cancer. 

CME information and select publications here.

]]>Dr Ian Krop from Yale Cancer Center in New Haven, Connecticut, and Dr Sara Tolaney from Dana-Farber Cancer Institute in Boston, Massachusetts, summarize major treatment advances over the past year and review relevant ongoing clinical trials for patients with breast cancer. 

CME information and select publications here.

]]>289c560a-c684-429f-8667-8f74a52e433aWed, 04 Jun 2025 15:00:00 -040001:01:12falsefull25747425Prostate Cancer and AKT Inhibitors — Proceedings from a Session Held During the American Urological Association Annual MeetingProstate Cancer and AKT Inhibitors — Proceedings from a Session Held During the American Urological Association Annual MeetingDr Leonard G Gomella from the Sidney Kimmel Cancer Center in Philadelphia, Pennsylvania, Dr Evan Y Yu from the Fred Hutchinson Cancer Center in Seattle, Washington, and Dr Daniel George from Duke Cancer Institute in Durham, North Carolina, discuss important clinical datasets and patient cases relevant to AKT inhibition in the care of patients with prostate cancer. 

CME information and select publications here.

]]>Dr Leonard G Gomella from the Sidney Kimmel Cancer Center in Philadelphia, Pennsylvania, Dr Evan Y Yu from the Fred Hutchinson Cancer Center in Seattle, Washington, and Dr Daniel George from Duke Cancer Institute in Durham, North Carolina, discuss important clinical datasets and patient cases relevant to AKT inhibition in the care of patients with prostate cancer. 

CME information and select publications here.

]]>a4abc1b4-55cd-4c94-8788-fabd19dea8a5Tue, 03 Jun 2025 15:00:00 -040001:22:55falsefull25737325Systemic Mastocytosis and Myelofibrosis — Fourth Annual National General Medical Oncology SummitSystemic Mastocytosis and Myelofibrosis — Fourth Annual National General Medical Oncology SummitClinical investigators discuss available data guiding the management of systemic mastocytosis and myelofibrosis.  

CME information and select publications here.

]]>Clinical investigators discuss available data guiding the management of systemic mastocytosis and myelofibrosis.  

CME information and select publications here.

]]>e1afeb45-f111-413a-a35c-3fd8ddef3a7fMon, 02 Jun 2025 09:00:00 -040047:55falsefull25727225Hepatocellular Carcinoma — Fourth Annual National General Medical Oncology SummitHepatocellular Carcinoma — Fourth Annual National General Medical Oncology SummitClinical investigators discuss available data guiding the management of hepatocellular carcinoma.  

CME information and select publications here.

]]>Clinical investigators discuss available data guiding the management of hepatocellular carcinoma.  

CME information and select publications here.

]]>6536974a-726f-43fe-9c85-95d8cdc4112aSun, 01 Jun 2025 16:08:00 -040051:04falsefull25717125Multiple Myeloma — Fourth Annual National General Medical Oncology SummitMultiple Myeloma — Fourth Annual National General Medical Oncology SummitClinical investigators discuss available data guiding the management of multiple myeloma.  

CME information and select publications here.

]]>Clinical investigators discuss available data guiding the management of multiple myeloma.  

CME information and select publications here.

]]>de0d88bf-4a5c-4a12-aca1-b7e667a9ae90Sat, 31 May 2025 09:00:00 -040050:41falsefull25707025For Oncology Nurses: Pancreatic Cancer — Proceedings from the 2025 Annual ONS CongressFor Oncology Nurses: Pancreatic Cancer — Proceedings from the 2025 Annual ONS CongressDrs Farshid Dayyani and Philip A Philip and oncology nursing professionals Caroline Kuhlman and Amanda K Wagner discuss datasets guiding treatment decision-making for patients with metastatic pancreatic cancer and strategies to mitigate and manage treatment-emergent adverse events.  

NCPD information and select publications here.

]]>Drs Farshid Dayyani and Philip A Philip and oncology nursing professionals Caroline Kuhlman and Amanda K Wagner discuss datasets guiding treatment decision-making for patients with metastatic pancreatic cancer and strategies to mitigate and manage treatment-emergent adverse events.  

NCPD information and select publications here.

]]>a35b155c-3754-4596-a94e-016ab79ceb47Fri, 30 May 2025 16:00:00 -040001:33:16falsefull25696925Multiple Myeloma — An Interview with Dr Rafael Fonseca on Key Presentations from the 66th American Society of Hematology (ASH) Annual MeetingMultiple Myeloma — An Interview with Dr Rafael Fonseca on Key Presentations from the 66th American Society of Hematology (ASH) Annual MeetingDr Rafael Fonseca from Mayo Clinic in Phoenix, Arizona, discusses datasets from the 2024 ASH meeting on the management of newly diagnosed and relapsed/refractory multiple myeloma. 

CME information and select publications here.

]]>Dr Rafael Fonseca from Mayo Clinic in Phoenix, Arizona, discusses datasets from the 2024 ASH meeting on the management of newly diagnosed and relapsed/refractory multiple myeloma. 

CME information and select publications here.

]]>73deb9d4-3b4c-475e-b9bb-a62dcc2579aeWed, 28 May 2025 17:10:00 -040050:50falsefull256868255-Minute Journal Club Issue 8 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer5-Minute Journal Club Issue 8 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast CancerDr Rinath Jeselsohn from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. 

CME information and select publications here.

]]>Dr Rinath Jeselsohn from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. 

CME information and select publications here.

]]>8bca76f2-91f8-4b80-9402-b06955c8e3f6Tue, 27 May 2025 16:00:00 -040013:48falsefull25676725Gastroesophageal Cancer — Fourth Annual National General Medical Oncology SummitGastroesophageal Cancer — Fourth Annual National General Medical Oncology SummitClinical investigators discuss available data guiding the management of gastroesophageal cancer.  

CME information and select publications here.

]]>Clinical investigators discuss available data guiding the management of gastroesophageal cancer.  

CME information and select publications here.

]]>144c7d20-cea9-42fc-9b00-d0fcc9c52f28Mon, 26 May 2025 09:00:00 -040052:32falsefull25666625Chronic Lymphocytic Leukemia — An Interview with Dr Lindsey Roeker on Key Presentations from the 66th American Society of Hematology (ASH) Annual MeetingChronic Lymphocytic Leukemia — An Interview with Dr Lindsey Roeker on Key Presentations from the 66th American Society of Hematology (ASH) Annual MeetingDr Lindsey Roeker from Mayo Clinic in Rochester, Minnesota, discusses recent updates on available and novel treatment strategies for chronic lymphocytic leukemia. 

CME information and select publications here.

]]>Dr Lindsey Roeker from Mayo Clinic in Rochester, Minnesota, discusses recent updates on available and novel treatment strategies for chronic lymphocytic leukemia. 

CME information and select publications here.

]]>d970d063-80a7-4bc9-8233-96720ebf7c90Sat, 24 May 2025 09:00:00 -040048:22falsefull25656525Relapsed/Refractory Follicular Lymphoma Part 3 — A Roundtable Discussion on the Selection and Sequencing of Other Novel TherapiesRelapsed/Refractory Follicular Lymphoma Part 3 — A Roundtable Discussion on the Selection and Sequencing of Other Novel TherapiesDr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. 

CME information and select publications here.

]]>Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. 

CME information and select publications here.

]]>220f395f-3148-46a6-8bb1-c89d019c52eaFri, 23 May 2025 12:00:00 -040042:34falsefull25646425Urothelial Bladder Cancer — Fourth Annual National General Medical Oncology SummitUrothelial Bladder Cancer — Fourth Annual National General Medical Oncology SummitClinical investigators discuss available data guiding the management of urothelial bladder cancer.  

CME information and select publications here.

]]>Clinical investigators discuss available data guiding the management of urothelial bladder cancer.  

CME information and select publications here.

]]>caa4d0de-7285-4f11-84b7-e3ec023636e7Thu, 22 May 2025 14:00:00 -040049:01falsefull25636325Pancreatic Cancer — Fourth Annual National General Medical Oncology SummitPancreatic Cancer — Fourth Annual National General Medical Oncology SummitClinical investigators discuss available data guiding the management of pancreatic cancer.  

CME information and select publications here.

]]>Clinical investigators discuss available data guiding the management of pancreatic cancer.  

CME information and select publications here.

]]>07c176c8-5c1a-4b2b-bcf8-ebc27834d9ddWed, 21 May 2025 14:00:00 -040049:14falsefull25626225Non-Hodgkin Lymphoma — An Interview with Dr Jennifer Crombie on the Use of Bispecific AntibodiesNon-Hodgkin Lymphoma — An Interview with Dr Jennifer Crombie on the Use of Bispecific AntibodiesDr Jennifer Crombie from the Dana-Farber Cancer Institute in Boston, Massachusetts, reviews available and investigational CD20 x CD3 targeted bispecific antibodies for the treatment of follicular and diffuse large B-cell lymphomas.   

CME information and select publications here.

]]>Dr Jennifer Crombie from the Dana-Farber Cancer Institute in Boston, Massachusetts, reviews available and investigational CD20 x CD3 targeted bispecific antibodies for the treatment of follicular and diffuse large B-cell lymphomas.   

CME information and select publications here.

]]>d69813cd-1833-465b-a9e5-14fbfea9300eTue, 20 May 2025 14:00:00 -040049:54falsefull256161255-Minute Journal Club Issue 7 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer5-Minute Journal Club Issue 7 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast CancerDr Rinath M Jeselsohn from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. 

CME information and select publications here.

]]>Dr Rinath M Jeselsohn from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. 

CME information and select publications here.

]]>fafacd23-cb62-492d-a6c5-2ed8b9e3ba16Mon, 19 May 2025 13:00:00 -040017:35falsefull25606025Immunotherapy and Nontargeted Approaches for NSCLC — Fourth Annual National General Medical Oncology SummitImmunotherapy and Nontargeted Approaches for NSCLC — Fourth Annual National General Medical Oncology SummitClinical investigators discuss available data guiding the management of non-small cell lung cancer with immunotherapy and other nontargeted approaches.  

CME information and select publications here.

]]>Clinical investigators discuss available data guiding the management of non-small cell lung cancer with immunotherapy and other nontargeted approaches.  

CME information and select publications here.

]]>de033d6f-201e-4d34-a512-8a420979dcceSun, 18 May 2025 12:00:00 -040050:15falsefull25595925Colorectal Cancer — Fourth Annual National General Medical Oncology SummitColorectal Cancer — Fourth Annual National General Medical Oncology SummitClinical investigators discuss available data guiding the management of colorectal cancer.  

CME information and select publications here.

]]>Clinical investigators discuss available data guiding the management of colorectal cancer.  

CME information and select publications here.

]]>f75e31c4-92f5-4068-8ef9-7f04f6c3e567Sat, 17 May 2025 12:00:00 -040050:09falsefull25585825Relapsed/Refractory Follicular Lymphoma Part 2 — A Roundtable Discussion on the Selection and Sequencing of CAR T-Cell TherapyRelapsed/Refractory Follicular Lymphoma Part 2 — A Roundtable Discussion on the Selection and Sequencing of CAR T-Cell TherapyDr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. 

CME information and select publications here.

]]>Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. 

CME information and select publications here.

]]>160224f1-cbda-4357-a312-8f416204d877Fri, 16 May 2025 16:00:00 -040037:08falsefull25575725Prostate Cancer — Year in Review Series on Relevant New Datasets and AdvancesProstate Cancer — Year in Review Series on Relevant New Datasets and AdvancesDr Emmanuel S Antonarakis from the University of Minnesota in Minneapolis and Professor Karim Fizazi from the Institut Gustave Roussy in Villejuif, France, provide their perspectives on relevant new clinical data in prostate cancer and discuss their application to the care of patients. 

CME information and select publications here.

]]>Dr Emmanuel S Antonarakis from the University of Minnesota in Minneapolis and Professor Karim Fizazi from the Institut Gustave Roussy in Villejuif, France, provide their perspectives on relevant new clinical data in prostate cancer and discuss their application to the care of patients. 

CME information and select publications here.

]]>e51e6ebe-fa2d-4237-9cbd-cc078a333de3Wed, 14 May 2025 16:00:00 -040001:00:00falsefull25565625Non-Hodgkin Lymphoma — Fourth Annual National General Medical Oncology SummitNon-Hodgkin Lymphoma — Fourth Annual National General Medical Oncology SummitClinical investigators discuss available data guiding the management of non-Hodgkin lymphoma.  

CME information and select publications here.

]]>Clinical investigators discuss available data guiding the management of non-Hodgkin lymphoma.  

CME information and select publications here.

]]>9d92de21-d802-46a5-9ba5-2719df0a87e6Mon, 12 May 2025 16:00:00 -040050:03falsefull25555525Gynecologic Cancers — Fourth Annual National General Medical Oncology SummitGynecologic Cancers — Fourth Annual National General Medical Oncology SummitClinical investigators discuss available data guiding the management of gynecologic cancers.  

CME information and select publications here.

]]>Clinical investigators discuss available data guiding the management of gynecologic cancers.  

CME information and select publications here.

]]>309fd8e5-4976-4946-8aec-6d3e24def5b8Sun, 11 May 2025 09:00:00 -040048:41falsefull25545425Non-Hodgkin Lymphoma — An Interview with Dr John P Leonard on Key Presentations from the 66th American Society of Hematology (ASH) Annual MeetingNon-Hodgkin Lymphoma — An Interview with Dr John P Leonard on Key Presentations from the 66th American Society of Hematology (ASH) Annual MeetingDr John P Leonard from Weill Cornell Medicine in New York, New York, reviews data presented at the 2024 ASH Annual Meeting and their implications for the treatment of non-Hodgkin lymphomas. 

CME information and select publications here.

]]>Dr John P Leonard from Weill Cornell Medicine in New York, New York, reviews data presented at the 2024 ASH Annual Meeting and their implications for the treatment of non-Hodgkin lymphomas. 

CME information and select publications here.

]]>19b6c427-1746-45ac-a830-46280836fc11Fri, 09 May 2025 15:30:00 -040052:36falsefull25535325Breast Cancer — Year in Review Series on Relevant New Datasets and AdvancesBreast Cancer — Year in Review Series on Relevant New Datasets and AdvancesDr Rebecca Dent from National Cancer Centre Singapore and Dr Nancy Lin from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss important efficacy and safety data from 2024 related to the management of localized and advanced breast cancers. 

CME information and select publications here.

]]>Dr Rebecca Dent from National Cancer Centre Singapore and Dr Nancy Lin from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss important efficacy and safety data from 2024 related to the management of localized and advanced breast cancers. 

CME information and select publications here.

]]>f011b040-94b8-41b1-bce5-85828ed179f1Mon, 05 May 2025 09:00:00 -040059:31falsefull25525225Chronic Lymphocytic Leukemia — Year in Review Series on Relevant New Datasets and AdvancesChronic Lymphocytic Leukemia — Year in Review Series on Relevant New Datasets and AdvancesDr Jennifer R Brown from Dana-Farber Cancer Institute in Boston and Prof Paolo Ghia from IRCCS Ospedale San Raffaele in Milano, Italy, summarize clinically relevant research findings and datasets over the past year regarding the treatment of chronic lymphocytic leukemia. 

CME information and select publications here.

]]>Dr Jennifer R Brown from Dana-Farber Cancer Institute in Boston and Prof Paolo Ghia from IRCCS Ospedale San Raffaele in Milano, Italy, summarize clinically relevant research findings and datasets over the past year regarding the treatment of chronic lymphocytic leukemia. 

CME information and select publications here.

]]>c65a2646-166b-4b8b-9cb7-5d504de5adc3Fri, 02 May 2025 09:00:00 -040059:14falsefull25515125EGFR Mutation-Positive NSCLC — Fourth Annual National General Medical Oncology SummitEGFR Mutation-Positive NSCLC — Fourth Annual National General Medical Oncology SummitClinical investigators discuss available data guiding the management of EGFR mutation-positive non-small cell lung cancer.  

CME information and select publications here.

]]>Clinical investigators discuss available data guiding the management of EGFR mutation-positive non-small cell lung cancer.  

CME information and select publications here.

]]>e1e7051c-328a-43b2-9d22-f42af60d160eWed, 30 Apr 2025 09:00:00 -040052:17falsefull25505025Prostate Cancer — Fourth Annual National General Medical Oncology SummitProstate Cancer — Fourth Annual National General Medical Oncology SummitClinical investigators discuss available data guiding the management of prostate cancers. 

CME information and select publications here.

]]>Clinical investigators discuss available data guiding the management of prostate cancers. 

CME information and select publications here.

]]>ae5ffeda-aa27-454b-a3d0-b738d702ca05Tue, 29 Apr 2025 10:00:00 -040047:33falsefull25494925Immune Thrombocytopenia — A Roundtable Discussion on Current and Future Management StrategiesImmune Thrombocytopenia — A Roundtable Discussion on Current and Future Management StrategiesDr Hanny Al-Samkari from Massachusetts General Hospital in Boston, Dr James B Bussel from Weill Cornell School of Medicine in New York, New York, and Prof Nichola Cooper from Hammersmith Hospital Campus in London, United Kingdom, share expert perspectives on the diagnosis of and optimal management strategies for immune thrombocytopenia. 

CME information and select publications here.

]]>Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston, Dr James B Bussel from Weill Cornell School of Medicine in New York, New York, and Prof Nichola Cooper from Hammersmith Hospital Campus in London, United Kingdom, share expert perspectives on the diagnosis of and optimal management strategies for immune thrombocytopenia. 

CME information and select publications here.

]]>c3349704-82be-4f26-b14e-011c0aa8de89Mon, 28 Apr 2025 16:32:00 -040001:56:57falsefull25484825Biliary Tract Cancers — Fourth Annual National General Medical Oncology SummitBiliary Tract Cancers — Fourth Annual National General Medical Oncology SummitClinical investigators discuss available data guiding the management of biliary tract cancers.  

CME information and select publications here.

]]>Clinical investigators discuss available data guiding the management of biliary tract cancers.  

CME information and select publications here.

]]>23a435d3-2774-4e73-8ac1-6bf970f9503eSun, 27 Apr 2025 09:00:00 -040048:54falsefull25474725For Oncology Nurses: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS CongressFor Oncology Nurses: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS CongressDr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events. 

NCPD information and select publications here.

]]>Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events. 

NCPD information and select publications here.

]]>cf31dc3d-84ae-4828-a654-8ffe4447db64Sat, 26 Apr 2025 09:00:00 -040001:33:02falsefull25464625Hormone Receptor-Positive Metastatic Breast Cancer — An Interview with Dr Adam M Brufsky on the Impact of Biomarkers and Existing Comorbidities on the Selection of First-Line TherapyHormone Receptor-Positive Metastatic Breast Cancer — An Interview with Dr Adam M Brufsky on the Impact of Biomarkers and Existing Comorbidities on the Selection of First-Line TherapyDr Adam M Brufsky from the University of Pittsburgh discusses first-line treatment selection for patients with HR-positive metastatic breast cancer and preexisting medical conditions. 

CME information and select publications here.

]]>Dr Adam M Brufsky from the University of Pittsburgh discusses first-line treatment selection for patients with HR-positive metastatic breast cancer and preexisting medical conditions. 

CME information and select publications here.

]]>52771add-7933-46dc-8f73-3c036c46924dWed, 23 Apr 2025 13:00:00 -040052:52falsefull25454525Genitourinary Cancers — An Interview with Dr William K Oh on Recent Trial UpdatesGenitourinary Cancers — An Interview with Dr William K Oh on Recent Trial UpdatesDr William Oh from the Yale Cancer Center in New Haven, Connecticut, discusses recent updates on available and novel treatment strategies for genitourinary cancers. 

CME information and select publications here.

]]>Dr William Oh from the Yale Cancer Center in New Haven, Connecticut, discusses recent updates on available and novel treatment strategies for genitourinary cancers. 

CME information and select publications here.

]]>66936cbe-e221-4aff-8d0d-9e93ce416d46Wed, 23 Apr 2025 08:00:00 -040044:21falsefull25444425Relapsed/Refractory Follicular Lymphoma Part 1 — A Roundtable Discussion on the Selection and Sequencing of Bispecific AntibodiesRelapsed/Refractory Follicular Lymphoma Part 1 — A Roundtable Discussion on the Selection and Sequencing of Bispecific AntibodiesDr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. 

CME information and select publications here.

]]>Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. 

CME information and select publications here.

]]>253c6d9f-5e10-44cb-9e2c-a15c82a44d0dTue, 22 Apr 2025 09:50:00 -040037:08falsefull25434325HER2-Positive and Triple-Negative Breast Cancer — Fourth Annual National General Medical Oncology SummitHER2-Positive and Triple-Negative Breast Cancer — Fourth Annual National General Medical Oncology SummitClinical investigators discuss available data guiding the management of HER2-positive, triple-negative and localized breast cancer.  

CME information and select publications here.

]]>Clinical investigators discuss available data guiding the management of HER2-positive, triple-negative and localized breast cancer.  

CME information and select publications here.

]]>a6812f85-12a8-48d3-8052-dbdb0e15f798Mon, 21 Apr 2025 15:00:00 -040001:39:35falsefull25424225Oncology Nursing Update Special 2-Part Edition: Bispecific Antibodies in Lymphoma — Part 2Oncology Nursing Update Special 2-Part Edition: Bispecific Antibodies in Lymphoma — Part 2Nurse practitioner Ms Amy Goodrich from The Sidney Kimmel Comprehensive Care Center in Baltimore, Maryland, presents cases from her practice illustrating the efficacy and safety of bispecific antibodies for non-Hodkin lymphoma. 

NCPD information and select publications here.

]]>Nurse practitioner Ms Amy Goodrich from The Sidney Kimmel Comprehensive Care Center in Baltimore, Maryland, presents cases from her practice illustrating the efficacy and safety of bispecific antibodies for non-Hodkin lymphoma. 

NCPD information and select publications here.

]]>363cf19f-7558-4532-b3cf-58be750a87bdFri, 18 Apr 2025 09:00:00 -040058:21falsefull25414125Ovarian Cancer — Proceedings from a Session Held During the 2025 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer®️Ovarian Cancer — Proceedings from a Session Held During the 2025 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer®️Dr Kathleen Moore, Dr Ritu Salani, Dr Shannon Westin and moderator Dr Angeles Alvarez Secord share their perspectives and summarize recently presented data from the SGO 2025 annual meeting guiding the management of ovarian cancer. 

CME information and select publications here.

]]>Dr Kathleen Moore, Dr Ritu Salani, Dr Shannon Westin and moderator Dr Angeles Alvarez Secord share their perspectives and summarize recently presented data from the SGO 2025 annual meeting guiding the management of ovarian cancer. 

CME information and select publications here.

]]>e1b49b4a-0f38-4b11-866a-2980d4390efaThu, 17 Apr 2025 16:00:00 -040001:29:33falsefull25404025Myelofibrosis — An Interview with Dr Raajit K Rampal on Key Presentations from the 66th American Society of Hematology (ASH) Annual MeetingMyelofibrosis — An Interview with Dr Raajit K Rampal on Key Presentations from the 66th American Society of Hematology (ASH) Annual MeetingDr Raajit K Rampal from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent updates on available and novel treatment strategies for myelofibrosis. 

CME information and select publications here.

]]>Dr Raajit K Rampal from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent updates on available and novel treatment strategies for myelofibrosis. 

CME information and select publications here.

]]>117ed02e-9805-4190-a60e-9a58e85dfa2aTue, 15 Apr 2025 08:00:00 -040043:18falsefull25393925Sarcoma and Other Connective Tissue Neoplasms — Fourth Annual National General Medical Oncology SummitSarcoma and Other Connective Tissue Neoplasms — Fourth Annual National General Medical Oncology SummitClinical investigators discuss available data guiding the management of sarcoma and other connective tissue neoplasms.  

CME information and select publications here.

]]>Clinical investigators discuss available data guiding the management of sarcoma and other connective tissue neoplasms.  

CME information and select publications here.

]]>07d4de02-3553-4cd5-8905-4d8a06bec4b2Mon, 14 Apr 2025 19:31:00 -040051:15falsefull25383825HR-Positive Breast Cancer — Fourth Annual National General Medical Oncology SummitHR-Positive Breast Cancer — Fourth Annual National General Medical Oncology SummitClinical investigators discuss available data guiding the management of hormone receptor-positive metastatic breast cancer. 

CME information and select publications here.

]]>Clinical investigators discuss available data guiding the management of hormone receptor-positive metastatic breast cancer. 

CME information and select publications here.

]]>01e44e60-7f1b-4b94-baf6-f8ad162ef527Sun, 13 Apr 2025 09:00:00 -040001:59:29falsefull25373725Chronic Lymphocytic Leukemia — Fourth Annual National General Medical Oncology SummitChronic Lymphocytic Leukemia — Fourth Annual National General Medical Oncology SummitClinical investigators discuss available data guiding the management of chronic lymphocytic leukemia.  

CME information and select publications here.

]]>Clinical investigators discuss available data guiding the management of chronic lymphocytic leukemia.  

CME information and select publications here.

]]>167adbc4-2fdc-477e-aa61-7fab2faff14eSat, 12 Apr 2025 09:00:00 -040050:12falsefull25363625Neuroendocrine Tumors — Fourth Annual National General Medical Oncology SummitNeuroendocrine Tumors — Fourth Annual National General Medical Oncology SummitClinical investigators discuss available data guiding the management of neuroendocrine tumors.  

CME information and select publications here.

]]>Clinical investigators discuss available data guiding the management of neuroendocrine tumors.  

CME information and select publications here.

]]>da7c0c95-8391-4069-abbb-b5823bba2c86Fri, 11 Apr 2025 17:15:00 -040050:16falsefull25353525First-Line Therapy for Metastatic Non-Small Cell Lung Cancer and an ALK Rearrangement — An Interview with Dr Justin F GainorFirst-Line Therapy for Metastatic Non-Small Cell Lung Cancer and an ALK Rearrangement — An Interview with Dr Justin F GainorDr Justin F Gainor from Massachusetts General Hospital in Boston reviews available clinical data on ALK inhibitors and first-line treatment strategies for ALK-positive metastatic non-small cell lung cancer. 

CME information and select publications here.

]]>Dr Justin F Gainor from Massachusetts General Hospital in Boston reviews available clinical data on ALK inhibitors and first-line treatment strategies for ALK-positive metastatic non-small cell lung cancer. 

CME information and select publications here.

]]>b287d69f-0bda-4373-ae21-92314fd2264eWed, 09 Apr 2025 16:00:00 -040057:28falsefull25343425Breast Cancer — An Interview with Dr Adrienne G Waks on Recent Trial UpdatesBreast Cancer — An Interview with Dr Adrienne G Waks on Recent Trial UpdatesDr Adrienne G Waks from Dana-Farber Cancer Institute in Boston, Massachusetts, reviews recent trial updates and their significance for the management of breast cancer. 

CME information and select publications here.

]]>Dr Adrienne G Waks from Dana-Farber Cancer Institute in Boston, Massachusetts, reviews recent trial updates and their significance for the management of breast cancer. 

CME information and select publications here.

]]>ca069ebf-67fe-4964-a29c-c4b92152f91bMon, 07 Apr 2025 15:00:00 -040054:56falsefull25333325Chronic Lymphocytic Leukemia — An Interview with Dr Catherine C Coombs on Real-World Cases and Current Questions and Controversies Presented at Recent ConferencesChronic Lymphocytic Leukemia — An Interview with Dr Catherine C Coombs on Real-World Cases and Current Questions and Controversies Presented at Recent ConferencesDr Catherine C Coombs from UCI Health in Orange County, California, discusses patient cases from her practice and provides an overview of existing and emerging treatment approaches for chronic lymphocytic leukemia. 

CME information and select publications here.

]]>Dr Catherine C Coombs from UCI Health in Orange County, California, discusses patient cases from her practice and provides an overview of existing and emerging treatment approaches for chronic lymphocytic leukemia. 

CME information and select publications here.

]]>3c258554-fbd9-4295-8142-83a0f52778f3Thu, 03 Apr 2025 15:00:00 -040058:13falsefull25323225HER2-Positive Gynecologic Cancers — Proceedings from a Session Held During the 2025 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer®️HER2-Positive Gynecologic Cancers — Proceedings from a Session Held During the 2025 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer®️Drs Kathleen N Moore and Alessandro D Santin and moderator Dr David M O’Malley summarize and share their perspectives on data guiding the management of HER2-positive gynecologic cancers that were presented at the Society of Gynecologic Oncology 2025 annual meeting. 

CME information and select publications here.

]]>Drs Kathleen N Moore and Alessandro D Santin and moderator Dr David M O’Malley summarize and share their perspectives on data guiding the management of HER2-positive gynecologic cancers that were presented at the Society of Gynecologic Oncology 2025 annual meeting. 

CME information and select publications here.

]]>edcdf5ad-6dd4-4643-96af-77663887660aWed, 02 Apr 2025 09:00:00 -040001:29:21falsefull25313125HR-Positive Breast Cancer — An Interview with Dr Sara A Hurvitz on the Role of Endocrine-Based TherapyHR-Positive Breast Cancer — An Interview with Dr Sara A Hurvitz on the Role of Endocrine-Based TherapyDr Sara A Hurvitz from the Fred Hutchinson Cancer Center in Seattle, Washington, summarizes data presented at the recent 2024 San Antonio Breast Cancer Symposium applicable to the management of HR-positive breast cancer.   

CME information and select publications here.

]]>Dr Sara A Hurvitz from the Fred Hutchinson Cancer Center in Seattle, Washington, summarizes data presented at the recent 2024 San Antonio Breast Cancer Symposium applicable to the management of HR-positive breast cancer.   

CME information and select publications here.

]]>f3373555-05c8-465b-91f8-c5951cd07bbaThu, 27 Mar 2025 14:00:00 -040001:03:10falsefull25303025For Oncology Nurses: Bispecific Antibodies in Multiple Myeloma — An Interview with Dr Tiffany A RichardsFor Oncology Nurses: Bispecific Antibodies in Multiple Myeloma — An Interview with Dr Tiffany A RichardsDr Tiffany Richards from The University of Texas MD Anderson Cancer Center in Houston discusses the current and emerging role of bispecific antibodies in the treatment of multiple myeloma.

NCPD information and select publications here.

]]>Dr Tiffany Richards from The University of Texas MD Anderson Cancer Center in Houston discusses the current and emerging role of bispecific antibodies in the treatment of multiple myeloma.

NCPD information and select publications here.

]]>30476923-2563-41ed-a5db-564e4f4c3173Mon, 24 Mar 2025 12:00:00 -040001:05:16falsefull252929255-Minute Journal Club Issue 6 with Dr Komal Jhaveri: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer5-Minute Journal Club Issue 6 with Dr Komal Jhaveri: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast CancerDr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. 

CME information and select publications here.

]]>Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. 

CME information and select publications here.

]]>3feb7ab7-35ef-4eb4-996a-3309a0a643a7Fri, 21 Mar 2025 11:03:00 -040016:10falsefull25282825Neurofibromatosis Type 1 Plexiform Neurofibromas — An interview with Dr Christopher L MoertelNeurofibromatosis Type 1 Plexiform Neurofibromas — An interview with Dr Christopher L MoertelDr Christopher L Moertel from the University of Minnesota in Minneapolis discusses the clinical presentation of and optimal management strategies for plexiform neurofibromas and malignancies associated with neurofibromatosis type 1. 

CME information and select publications here.

]]>Dr Christopher L Moertel from the University of Minnesota in Minneapolis discusses the clinical presentation of and optimal management strategies for plexiform neurofibromas and malignancies associated with neurofibromatosis type 1. 

CME information and select publications here.

]]>f52d8b0b-581d-4533-8fb4-5ae208bfed3eThu, 20 Mar 2025 14:01:00 -040049:28falsefull25272725Oncology Nursing Update Special 2-Part Edition: Bispecific Antibodies in Lymphoma — Part 1Oncology Nursing Update Special 2-Part Edition: Bispecific Antibodies in Lymphoma — Part 1Ms Robin Klebig from the Mayo Clinic in Rochester, Minnesota, discusses the emerging role of bispecific antibodies in the treatment of non-Hodgkin lymphoma. 

NCPD information and select publications here.

]]>Ms Robin Klebig from the Mayo Clinic in Rochester, Minnesota, discusses the emerging role of bispecific antibodies in the treatment of non-Hodgkin lymphoma. 

NCPD information and select publications here.

]]>12bf7391-9e3f-4109-a1ca-9ad134e20f4fMon, 17 Mar 2025 06:00:00 -040001:05:59falsefull25262625Renal Cell Carcinoma — Proceedings from a Session Held in Conjunction with the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU)Renal Cell Carcinoma — Proceedings from a Session Held in Conjunction with the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU)Dr Thomas Hutson from UMC Cancer Center in Lubbock, Texas, Dr Rana McKay from UC San Diego Moores Cancer Center in California, Dr Tian Zhang from UT Southwestern Medical Center in Dallas, and moderator Dr Sumanta Kumar Pal from City of Hope Comprehensive Cancer Center in Duarte, California, discuss published data and updates from the 2025 ASCO Genitourinary Cancers Symposium meeting on management strategies for clear cell and non-clear cell renal cell carcinoma.  

CME information and select publications here.

]]>Dr Thomas Hutson from UMC Cancer Center in Lubbock, Texas, Dr Rana McKay from UC San Diego Moores Cancer Center in California, Dr Tian Zhang from UT Southwestern Medical Center in Dallas, and moderator Dr Sumanta Kumar Pal from City of Hope Comprehensive Cancer Center in Duarte, California, discuss published data and updates from the 2025 ASCO Genitourinary Cancers Symposium meeting on management strategies for clear cell and non-clear cell renal cell carcinoma.  

CME information and select publications here.

]]>b4438faf-10cc-485a-b2ef-10581a66efa2Fri, 14 Mar 2025 06:00:00 -040001:58:34falsefull25252525Colorectal Cancer — Year in Review Series on Relevant New Datasets and AdvancesColorectal Cancer — Year in Review Series on Relevant New Datasets and AdvancesDr Scott Kopetz from The University of Texas MD Anderson Cancer Center in Houston and Dr Jeffrey Meyerhardt from Dana-Farber Cancer Institute in Boston summarize the most clinically relevant research findings and data presented over the past year for patients with colorectal cancer. 

CME information and select publications here.

]]>Dr Scott Kopetz from The University of Texas MD Anderson Cancer Center in Houston and Dr Jeffrey Meyerhardt from Dana-Farber Cancer Institute in Boston summarize the most clinically relevant research findings and data presented over the past year for patients with colorectal cancer. 

CME information and select publications here.

]]>70567edd-39f3-4068-95a4-08e7fdee3226Thu, 13 Mar 2025 08:00:00 -040058:40falsefull25242425Localized Breast Cancer — Examining the Current Use of Genetic Testing and Related Clinical ManagementLocalized Breast Cancer — Examining the Current Use of Genetic Testing and Related Clinical ManagementDr Kevin S Hughes from the Medical University of South Carolina in Charleston and Dr Mark Robson from Memorial Sloan Kettering Cancer Center in New York discuss current BRCA1/2 genetic testing practices and the clinical management of localized breast cancer with alterations in these genes.   

CME information and select publications here.

]]>Dr Kevin S Hughes from the Medical University of South Carolina in Charleston and Dr Mark Robson from Memorial Sloan Kettering Cancer Center in New York discuss current BRCA1/2 genetic testing practices and the clinical management of localized breast cancer with alterations in these genes.   

CME information and select publications here.

]]>ec11c129-23d4-4ffa-abad-3ca95bbb75e2Tue, 11 Mar 2025 06:00:00 -040059:43falsefull25232325Urothelial Bladder Cancer and Prostate Cancer — Proceedings from a Session Held in Conjunction with the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU)Urothelial Bladder Cancer and Prostate Cancer — Proceedings from a Session Held in Conjunction with the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU)Drs Terence Friedlander, Matthew D Galsky, Neeraj Agarwal, Andrew J Armstrong and Elisabeth I Heath discuss recent updates on available and novel treatment strategies for bladder cancer and prostate cancer. 

CME information and select publications here.

]]>Drs Terence Friedlander, Matthew D Galsky, Neeraj Agarwal, Andrew J Armstrong and Elisabeth I Heath discuss recent updates on available and novel treatment strategies for bladder cancer and prostate cancer. 

CME information and select publications here.

]]>d304d54d-6365-48cc-9bc9-216603714b12Thu, 06 Mar 2025 11:00:00 -040001:57:43falsefull252222255-Minute Journal Club Issue 5 with Dr Komal Jhaveri: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer5-Minute Journal Club Issue 5 with Dr Komal Jhaveri: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast CancerDr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. 

CME information and select publications here.

]]>Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. 

CME information and select publications here.

]]>c1d1a8bc-3f93-40b3-ad46-d7f9d1132043Fri, 28 Feb 2025 10:00:00 -040018:31falsefull25212125Biliary Tract Cancers — Reviewing Patient Cases with Prof John Bridgewater: Part 1 of 2Biliary Tract Cancers — Reviewing Patient Cases with Prof John Bridgewater: Part 1 of 2Dr John Bridgewater from the UCL Cancer Institute in London, United Kingdom, discusses patient cases and summarizes current treatment approaches for cholangiocarcinoma and other biliary tract cancers. 

CME information and select publications here.

]]>Dr John Bridgewater from the UCL Cancer Institute in London, United Kingdom, discusses patient cases and summarizes current treatment approaches for cholangiocarcinoma and other biliary tract cancers. 

CME information and select publications here.

]]>17ad88d7-3149-48de-8b1a-e64e4a749c59Thu, 27 Feb 2025 00:00:00 -040058:00falsefull25202025Relapsed/Refractory Diffuse Large B-Cell Lymphoma — A Roundtable Discussion on Current and Future Management StrategiesRelapsed/Refractory Diffuse Large B-Cell Lymphoma — A Roundtable Discussion on Current and Future Management StrategiesProf Martin Hutchings from Copenhagen University Hospital in Denmark, Dr Manali Kamdar from the University of Colorado Cancer Center, Dr Matthew Lunning from the University of Nebraska Medical Center and Prof Gilles Salles from Memorial Sloan Kettering Cancer Center in New York summarize currently available data guiding treatment decision-making for patients with relapsed/refractory diffuse large B-cell lymphoma and present cases from their practices.

CME information and select publications here.

]]>Prof Martin Hutchings from Copenhagen University Hospital in Denmark, Dr Manali Kamdar from the University of Colorado Cancer Center, Dr Matthew Lunning from the University of Nebraska Medical Center and Prof Gilles Salles from Memorial Sloan Kettering Cancer Center in New York summarize currently available data guiding treatment decision-making for patients with relapsed/refractory diffuse large B-cell lymphoma and present cases from their practices.

CME information and select publications here.

]]>40843701-0f2a-40eb-b6eb-91a860a434daFri, 21 Feb 2025 13:00:00 -040002:33:01falsefull25191925Colorectal Cancer — Proceedings from a Session Held in Conjunction with the 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI)Colorectal Cancer — Proceedings from a Session Held in Conjunction with the 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI)Dr Arvind Dasari, Dr Van Morris, Dr Jenny Seligmann, Prof Eric Van Cutsem and moderator Dr Christopher Lieu summarize research findings guiding the application of biomarker-driven therapy for patients with colorectal cancers during a session at the 2025 ASCO Gastrointestinal Cancers Symposium. 

CME information and select publications here.

]]>Dr Arvind Dasari, Dr Van Morris, Dr Jenny Seligmann, Prof Eric Van Cutsem and moderator Dr Christopher Lieu summarize research findings guiding the application of biomarker-driven therapy for patients with colorectal cancers during a session at the 2025 ASCO Gastrointestinal Cancers Symposium. 

CME information and select publications here.

]]>6ddb0cb3-5659-4a2a-9e6d-f9152208619fThu, 20 Feb 2025 14:00:00 -040001:57:20falsefull25181825Multiple Myeloma — An Interview with Dr Surbhi Sidana on Optimizing the Role of CAR T-Cell TherapyMultiple Myeloma — An Interview with Dr Surbhi Sidana on Optimizing the Role of CAR T-Cell TherapyDr Surbhi Sidana from Stanford University in California discusses recent updates on chimeric antigen receptor T-cell therapy for the treatment of multiple myeloma. 

CME information and select publications here.

]]>Dr Surbhi Sidana from Stanford University in California discusses recent updates on chimeric antigen receptor T-cell therapy for the treatment of multiple myeloma. 

CME information and select publications here.

]]>0e00b41d-1afc-446f-bc46-4cea4e55d6adTue, 18 Feb 2025 13:00:00 -040046:45falsefull25171725HER2-Low and HER2-Ultralow Breast Cancer — A Roundtable Discussion on Current and Future Management StrategiesHER2-Low and HER2-Ultralow Breast Cancer — A Roundtable Discussion on Current and Future Management StrategiesDr Joyce O’Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, Dr Mark D Pegram from Stanford Cancer Institute in California, and Prof Peter Schmid from Barts Cancer Institute in London, United Kingdom, summarize currently available data guiding treatment decision-making for patients with low and ultralow HER2 expression and present cases from their practices. 

CME information and select publications here.

]]>Dr Joyce O’Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, Dr Mark D Pegram from Stanford Cancer Institute in California, and Prof Peter Schmid from Barts Cancer Institute in London, United Kingdom, summarize currently available data guiding treatment decision-making for patients with low and ultralow HER2 expression and present cases from their practices. 

CME information and select publications here.

]]>7e66bb36-731f-4a77-97a2-2e947c5acc98Fri, 14 Feb 2025 11:00:00 -040002:02:17falsefull25161625Hepatocellular Carcinoma — Proceedings From a Session Held in Conjunction with the 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI)Hepatocellular Carcinoma — Proceedings From a Session Held in Conjunction with the 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI)Dr Anthony El-Khoueiry, Dr Richard Finn, Dr Aiwu Ruth He, Dr Stacey Stein and moderator Dr Stephen “Fred” Divers discuss data from the 2025 ASCO GI meeting and other published studies guiding the care of patients with hepatocellular carcinoma.

CME information and select publications here.

]]>Dr Anthony El-Khoueiry, Dr Richard Finn, Dr Aiwu Ruth He, Dr Stacey Stein and moderator Dr Stephen “Fred” Divers discuss data from the 2025 ASCO GI meeting and other published studies guiding the care of patients with hepatocellular carcinoma.

CME information and select publications here.

]]>d45b367c-1cc4-4d73-a07b-f9088b3f2261Wed, 12 Feb 2025 12:00:00 -040001:58:47falsefull251515255-Minute Journal Club Issue 4 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer5-Minute Journal Club Issue 4 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast CancerDr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. 

CME information and select publications here

]]>Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. 

CME information and select publications here

]]>ee908ad0-6dd3-4b8c-93f3-aa3494415dd8Fri, 07 Feb 2025 08:00:00 -040010:06falsefull25141425EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and AdvancesEGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and AdvancesDr Enriqueta Felip from the Vall d’Hebron Institute of Oncology in Barcelona, Spain, and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, discuss current and emerging treatment approaches for patients with EGFR-mutant non-small cell lung cancer. 

CME information and select publications here

]]>Dr Enriqueta Felip from the Vall d’Hebron Institute of Oncology in Barcelona, Spain, and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, discuss current and emerging treatment approaches for patients with EGFR-mutant non-small cell lung cancer. 

CME information and select publications here

]]>f6a49ddd-e63d-490a-bb00-9d1765611c5bWed, 05 Feb 2025 11:00:00 -040001:00:02falsefull25131325Multiple Myeloma — Optimizing the Selection of First-Line Therapy with Dr Saad Zafar UsmaniMultiple Myeloma — Optimizing the Selection of First-Line Therapy with Dr Saad Zafar UsmaniDr Saad Zafar Usmani from Memorial Sloan Kettering Cancer Center in New York discusses available data guiding treatment decision-making for patients with newly diagnosed multiple myeloma. 

CME information and select publications here.

]]>Dr Saad Zafar Usmani from Memorial Sloan Kettering Cancer Center in New York discusses available data guiding treatment decision-making for patients with newly diagnosed multiple myeloma. 

CME information and select publications here.

]]>881d7ab9-de34-499a-96bc-2a7f1809d54dMon, 03 Feb 2025 16:00:00 -040046:45falsefull251212255-Minute Journal Club Issue 3 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer5-Minute Journal Club Issue 3 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast CancerDr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. 

CME information and select publications here

]]>Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. 

CME information and select publications here

]]>dbe44419-6d32-4612-8bd3-3acc7ff7c34fFri, 31 Jan 2025 13:00:00 -040011:58falsefull25111125Chronic Lymphocytic Leukemia with Dr Jennifer Woyach: Part 3 of a 3-Part Meet The Professor SeriesChronic Lymphocytic Leukemia with Dr Jennifer Woyach: Part 3 of a 3-Part Meet The Professor SeriesDr Jennifer Woyach from The Ohio State University Comprehensive Cancer Center in Columbus reviews existing and emerging treatment strategies for chronic lymphocytic leukemia. 

CME information and select publications here

]]>Dr Jennifer Woyach from The Ohio State University Comprehensive Cancer Center in Columbus reviews existing and emerging treatment strategies for chronic lymphocytic leukemia. 

CME information and select publications here

]]>f5cb322f-60ca-4b3c-81f4-2f0518cbb7edWed, 29 Jan 2025 10:00:00 -040059:28falsefull25101025Metastatic Triple-Negative Breast Cancer — Oncology Q&A for Clinicians: Discussing Common Questions Posed by PatientsMetastatic Triple-Negative Breast Cancer — Oncology Q&A for Clinicians: Discussing Common Questions Posed by PatientsDr Lisa A Carey from UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, and Dr Rita Nanda from the University of Chicago in Illinois address commonly asked questions from patients diagnosed with metastatic triple-negative breast cancer.   

CME information and select publications here

]]>Dr Lisa A Carey from UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, and Dr Rita Nanda from the University of Chicago in Illinois address commonly asked questions from patients diagnosed with metastatic triple-negative breast cancer.   

CME information and select publications here

]]>7014e9b9-039f-4c60-8cbd-f59bd123bfcfFri, 24 Jan 2025 08:00:00 -040001:00:17falsefull259925Data + Perspectives: Clinical Investigators Discuss the Role of CAR T-Cell Therapy for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic LeukemiaData + Perspectives: Clinical Investigators Discuss the Role of CAR T-Cell Therapy for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic LeukemiaDr Joshua Brody from The Tisch Cancer Institute in New York, Dr Matthew Lunning from the University of Nebraska Medical Center in Omaha and Dr Jason Westin from The University of Texas MD Anderson Cancer Center in Houston discuss chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Joshua Brody from The Tisch Cancer Institute in New York, Dr Matthew Lunning from the University of Nebraska Medical Center in Omaha and Dr Jason Westin from The University of Texas MD Anderson Cancer Center in Houston discuss chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia. Produced by Research To Practice.

CME information and select publications here.

]]>1d6b8a26-46ab-427f-8f18-debcb94a7f66Wed, 22 Jan 2025 10:00:00 -040059:32falsefull258825Dr Joshua Brody from the Tisch Cancer in New York, Dr Matthew Lunning from the University of Nebraska Medical Center in Omaha and Dr Jason Westin from the University of Texas MD Anderson Cancer Center in Houston discuss chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia. Produced by Research To Practice. CME information and select publications https://www.researchtopractice.com/SOHO2024/CARTCell/Video (here).Oncology Q&A for Patients with Metastatic Triple-Negative Breast CancerOncology Q&A for Patients with Metastatic Triple-Negative Breast CancerFor this patient-focused webinar, medical oncologist Dr Neil Love is joined by Dr Lisa A Carey from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill and Dr Rita Nanda from The University of Chicago to discuss the patient experience associated with the diagnosis and treatment of metastatic triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

Select publications here.

]]>For this patient-focused webinar, medical oncologist Dr Neil Love is joined by Dr Lisa A Carey from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill and Dr Rita Nanda from The University of Chicago to discuss the patient experience associated with the diagnosis and treatment of metastatic triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

Select publications here.

]]>24736245-2784-41e1-94cb-b69340f6820aFri, 17 Jan 2025 06:00:00 -040001:00:59falsefull257725For this patient-focused webinar, medical oncologist Dr Neil Love is joined by Dr Lisa A Carey from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill and Dr Rita Nanda from The University of Chicago to discuss the patient experience associated with the diagnosis and treatment of metastatic triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. Select publications https://www.researchtopractice.com/PatientProject2024/mTNBCPatients (here).CAR T-Cell and Bispecific Therapy for Lymphoma — Part 3 of Our 6-Part ASH 2024 Friday Satellite Symposia SeriesCAR T-Cell and Bispecific Therapy for Lymphoma — Part 3 of Our 6-Part ASH 2024 Friday Satellite Symposia SeriesDr Jennifer Crombie from Dana-Farber Cancer Institute, Prof Martin Hutchings from Copenhagen University Hospital, Dr Matthew Lunning from the University of Nebraska Medical Center, Dr Tycel Phillips from City of Hope and moderator Dr Jeremy S Abramson from Massachusetts General Hospital discuss recently updated data on the role of CAR T-cell therapy and bispecific antibodies in the management of diffuse large B-cell, mantle cell and follicular lymphoma. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Jennifer Crombie from Dana-Farber Cancer Institute, Prof Martin Hutchings from Copenhagen University Hospital, Dr Matthew Lunning from the University of Nebraska Medical Center, Dr Tycel Phillips from City of Hope and moderator Dr Jeremy S Abramson from Massachusetts General Hospital discuss recently updated data on the role of CAR T-cell therapy and bispecific antibodies in the management of diffuse large B-cell, mantle cell and follicular lymphoma. Produced by Research To Practice.

CME information and select publications here.

]]>e66c5bf6-dfa9-4617-95c4-494905d30836Wed, 15 Jan 2025 09:00:00 -040002:00:29falsefull256625Dr Jennifer Crombie from Dana-Farber Cancer Institute, Prof Martin Hutchings from Copenhagen University Hospital, Dr Matthew Lunning from the University of Nebraska Medical Center, Dr Tycel Phillips from City of Hope and moderator Dr Jeremy S Abramson from Massachusetts General Hospital discuss recently updated data on the role of CAR T-cell therapy and bispecific antibodies in the management of diffuse large B-cell, mantle cell and follicular lymphoma. Produced by Research To Practice. CME information and select publications https://www.researchtopractice.com/ASHCART24 (here).Myelofibrosis — Part 4 of Our 6-Part ASH 2024 Friday Satellite Symposia SeriesMyelofibrosis — Part 4 of Our 6-Part ASH 2024 Friday Satellite Symposia SeriesDr Prithviraj Bose from The University of Texas MD Anderson Cancer Center in Houston, Dr Angela G Fleischman from UC Irvine Health in Irvine, California, Dr Abdulraheem Yacoub from The University of Kansas Cancer Center in Westwood and Dr Andrew T Kuykendall from Moffitt Cancer Center in Tampa, Florida, discuss recent updates on available and novel treatment strategies for myelofibrosis, moderated by Dr Kuykendall. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Prithviraj Bose from The University of Texas MD Anderson Cancer Center in Houston, Dr Angela G Fleischman from UC Irvine Health in Irvine, California, Dr Abdulraheem Yacoub from The University of Kansas Cancer Center in Westwood and Dr Andrew T Kuykendall from Moffitt Cancer Center in Tampa, Florida, discuss recent updates on available and novel treatment strategies for myelofibrosis, moderated by Dr Kuykendall. Produced by Research To Practice.

CME information and select publications here.

]]>69e00614-3519-4065-8f44-362cb760b510Mon, 13 Jan 2025 09:00:00 -040001:59:15falsefull255525Dr Prithviraj Bose from The University of Texas MD Anderson Cancer Center in Houston, Dr Angela G Fleischman from UC Irvine Health in Irvine, California, Dr Abdulraheem Yacoub from The University of Kansas Cancer Center in Westwood and Dr Andrew T Kuykendall from Moffitt Cancer Center in Tampa, Florida, discuss recent updates on available and novel treatment strategies for myelofibrosis, moderated by Dr Kuykendall. Produced by Research To Practice. CME information and select publications https://www.researchtopractice.com/ASHMF24 (here).Metastatic Breast Cancer — San Antonio 2024 symposium series proceedings Part 3Metastatic Breast Cancer — San Antonio 2024 symposium series proceedings Part 3Dr Erika Hamilton from the Sarah Cannon Research Institute in Nashville, Tennessee, Dr Kevin Kalinsky from the Winship Cancer Institute of Emory University in Atlanta, Georgia, Dr Ian E Krop from the Yale Cancer Center in New Haven, Connecticut, Dr Joyce O’Shaughnessy from the Sarah Cannon Research Institute in Dallas, Texas, and Dr Sara M Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, discuss available and novel treatment strategies for metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Erika Hamilton from the Sarah Cannon Research Institute in Nashville, Tennessee, Dr Kevin Kalinsky from the Winship Cancer Institute of Emory University in Atlanta, Georgia, Dr Ian E Krop from the Yale Cancer Center in New Haven, Connecticut, Dr Joyce O’Shaughnessy from the Sarah Cannon Research Institute in Dallas, Texas, and Dr Sara M Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, discuss available and novel treatment strategies for metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>c6dae69b-6e05-49d6-9714-a2c5c9c0e8bbFri, 10 Jan 2025 09:00:00 -040002:01:00falsefull254425Dr Erika Hamilton from the Sarah Cannon Research Institute in Nashville, Tennessee, Dr Kevin Kalinsky from the Winship Cancer Institute of Emory University in Atlanta, Georgia, Dr Ian E Krop from the Yale Cancer Center in New Haven, Connecticut, Dr Joyce O’Shaughnessy from the Sarah Cannon Research Institute in Dallas, Texas, and Dr Sara M Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, discuss available and novel treatment strategies for metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications https://www.researchtopractice.com/SABCS2024/mBC (here).Chronic Myeloid Leukemia — Part 1 of Our 6-Part ASH 2024 Friday Satellite Symposia SeriesChronic Myeloid Leukemia — Part 1 of Our 6-Part ASH 2024 Friday Satellite Symposia SeriesProf Andreas Hochhaus from Jena University Hospital in Germany, Dr B Douglas Smith from the Sidney Kimmel Comprehensive Cancer Center at John Hopkins in Baltimore, Maryland, and moderator Dr Michael J Mauro from Memorial Sloan Kettering Cancer Center in New York, New York, discuss recent updates on available and novel treatment strategies for chronic myeloid leukemia. Produced by Research To Practice.

CME information and select publications here.

]]>Prof Andreas Hochhaus from Jena University Hospital in Germany, Dr B Douglas Smith from the Sidney Kimmel Comprehensive Cancer Center at John Hopkins in Baltimore, Maryland, and moderator Dr Michael J Mauro from Memorial Sloan Kettering Cancer Center in New York, New York, discuss recent updates on available and novel treatment strategies for chronic myeloid leukemia. Produced by Research To Practice.

CME information and select publications here.

]]>cc7c5588-e6e8-4069-8935-57a86c60401dWed, 08 Jan 2025 09:00:00 -040001:27:00falsefull253325Prof Andreas Hochhaus from Jena University Hospital in Germany, Dr B Douglas Smith from the Sidney Kimmel Comprehensive Cancer Center at John Hopkins in Baltimore, Maryland, and moderator Dr Michael J Mauro from Memorial Sloan Kettering Cancer Center in New York, New York, discuss recent updates on available and novel treatment strategies for chronic myeloid leukemia. Produced by Research To Practice. CME information and select publications https://www.researchtopractice.com/ASHCML24 (here).Acute Myeloid Leukemia — Part 5 of Our 6-Part ASH 2024 Friday Satellite Symposia SeriesAcute Myeloid Leukemia — Part 5 of Our 6-Part ASH 2024 Friday Satellite Symposia SeriesDr Alexander Perl from Abramson Cancer Center in Philadelphia, Pennsylvania, Dr Richard M Stone from Dana-Farber Cancer Institute in Boston, Massachusetts, Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, Prof Andrew H Wei from Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, and moderator Dr Eytan M Stein from Memorial Sloan Kettering Cancer Center in New York, New York, discuss updated data from ASH 2024 influencing the current and future treatment paradigm for treatment-naïve and relapsed/refractory acute myeloid leukemia. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Alexander Perl from Abramson Cancer Center in Philadelphia, Pennsylvania, Dr Richard M Stone from Dana-Farber Cancer Institute in Boston, Massachusetts, Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, Prof Andrew H Wei from Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, and moderator Dr Eytan M Stein from Memorial Sloan Kettering Cancer Center in New York, New York, discuss updated data from ASH 2024 influencing the current and future treatment paradigm for treatment-naïve and relapsed/refractory acute myeloid leukemia. Produced by Research To Practice.

CME information and select publications here.

]]>41a1d535-4244-428c-92fa-96fb8ec93880Mon, 06 Jan 2025 10:00:00 -040001:58:51falsefull252225Dr Alexander Perl from Abramson Cancer Center in Philadelphia, Pennsylvania, Dr Richard M Stone from Dana-Farber Cancer Institute in Boston, Massachusetts, Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, Prof Andrew H Wei from Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, and moderator Dr Eytan M Stein from Memorial Sloan Kettering Cancer Center in New York, New York, discuss updated data from ASH 2024 influencing the current and future treatment paradigm for treatment-naïve and relapsed/refractory acute myeloid leukemia. Produced by Research To Practice. CME information and select publications https://www.researchtopractice.com/ASHAML24 (here).The Role of Endocrine-Based Therapy in the Management of Breast Cancer — San Antonio 2024 symposium series proceedings Part 2The Role of Endocrine-Based Therapy in the Management of Breast Cancer — San Antonio 2024 symposium series proceedings Part 2Dr Matthew Goetz from Mayo Clinic Comprehensive Cancer Center in Rochester, Minnesota, Dr Sara Hurvitz from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas, and Dr Seth Wander from Massachusetts General Hospital in Boston share their perspectives on the management of hormone receptor-positive breast cancers and the potential role of emerging data from SABCS 2024, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Matthew Goetz from Mayo Clinic Comprehensive Cancer Center in Rochester, Minnesota, Dr Sara Hurvitz from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas, and Dr Seth Wander from Massachusetts General Hospital in Boston share their perspectives on the management of hormone receptor-positive breast cancers and the potential role of emerging data from SABCS 2024, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>d445a654-b5e6-44c8-b176-47cc5d49ababFri, 03 Jan 2025 10:00:00 -040002:00:37falsefull251125Dr Matthew Goetz from Mayo Clinic Comprehensive Cancer Center in Rochester, Minnesota, Dr Sara Hurvitz from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas, and Dr Seth Wander from Massachusetts General Hospital in Boston share their perspectives on the management of hormone receptor-positive breast cancers and the potential role of emerging data from SABCS 2024, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications https://www.researchtopractice.com/SABCS2024/HRPosEndocrine (here).HER2-Low and HER2-Ultralow Breast Cancer — San Antonio 2024 symposium series proceedings Part 1HER2-Low and HER2-Ultralow Breast Cancer — San Antonio 2024 symposium series proceedings Part 1Featuring a discussion on data from SABCS 2024 and the management of HER2-low breast cancer with Drs Bardia, Curigliano, Rugo and Wolff, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here

]]>Featuring a discussion on data from SABCS 2024 and the management of HER2-low breast cancer with Drs Bardia, Curigliano, Rugo and Wolff, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here

]]>0ab29e8a-d7ae-4e83-9b94-b08a5fe2b5e4Mon, 23 Dec 2024 07:00:00 -040001:31:29falsefull11Featuring a discussion on data from SABCS 2024 and the management of HER2-low breast cancer with Drs Bardia, Curigliano, Rugo and Wolff, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications https://www.researchtopractice.com/SABCS2024/HER2LowBC (here) Multiple Myeloma — Part 6 of Our 6-Part ASH 2024 Friday Satellite Symposia SeriesMultiple Myeloma — Part 6 of Our 6-Part ASH 2024 Friday Satellite Symposia SeriesProf Philippe Moreau of University Hospital – CHU de Nantes in France, Dr Robert Z Orlowski of The University of Texas MD Anderson Cancer Center in Houston, Dr Noopur Raje of Massachusetts General Hospital Cancer Center in Boston, Dr Paul G Richardson of Dana-Farber Cancer Institute in Boston, and Dr Sagar Lonial of Winship Cancer Institute of Emory University in Atlanta, Georgia, discuss current questions and controversies in the management of multiple myeloma. Produced by Research To Practice.

CME information and select publications here.

]]>Prof Philippe Moreau of University Hospital – CHU de Nantes in France, Dr Robert Z Orlowski of The University of Texas MD Anderson Cancer Center in Houston, Dr Noopur Raje of Massachusetts General Hospital Cancer Center in Boston, Dr Paul G Richardson of Dana-Farber Cancer Institute in Boston, and Dr Sagar Lonial of Winship Cancer Institute of Emory University in Atlanta, Georgia, discuss current questions and controversies in the management of multiple myeloma. Produced by Research To Practice.

CME information and select publications here.

]]>9af020bd-b78b-433c-8b56-289ffd64c8ffFri, 20 Dec 2024 06:00:00 -040001:57:11falsefull11 <p>Prof Philippe Moreau of University Hospital – CHU de Nantes in France, Dr Robert Z Orlowski of The University of Texas MD Anderson Cancer Center in Houston, Dr Noopur Raje of Massachusetts General Hospital Cancer Center in Boston, Dr Paul G Richardson of Dana-Farber Cancer Institute in Boston, and Dr Sagar Lonial of Winship Cancer Institute of Emory University in Atlanta, Georgia, discuss current questions and controversies in the management of multiple myeloma. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/ASHMM24" rel="nofollow">here</a>.</p> Chronic Lymphocytic Leukemia — Part 2 of Our 6-Part ASH 2024 Friday Satellite Symposia SeriesChronic Lymphocytic Leukemia — Part 2 of Our 6-Part ASH 2024 Friday Satellite Symposia SeriesDr Farrukh Awan from Harold C Simmons Comprehensive Cancer Center in Dallas, Texas, Dr Bita Fakhri from Stanford University School of Medicine in California, Dr Kerry A Rogers from the Ohio State University in Columbus, Dr William Wierda from the University of Texas MD Anderson Cancer Center in Houston, and moderator Dr Jeff Sharman from the Sarah Cannon Research Institute discuss updated data from ASH 2024 influencing the current and future treatment paradigm for treatment-naïve and relapsed/refractory chronic lymphocytic leukemia. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Farrukh Awan from Harold C Simmons Comprehensive Cancer Center in Dallas, Texas, Dr Bita Fakhri from Stanford University School of Medicine in California, Dr Kerry A Rogers from the Ohio State University in Columbus, Dr William Wierda from the University of Texas MD Anderson Cancer Center in Houston, and moderator Dr Jeff Sharman from the Sarah Cannon Research Institute discuss updated data from ASH 2024 influencing the current and future treatment paradigm for treatment-naïve and relapsed/refractory chronic lymphocytic leukemia. Produced by Research To Practice.

CME information and select publications here.

]]>ab0d68e4-a979-458b-b2eb-73fe33f6e999Wed, 18 Dec 2024 13:00:00 -040001:57:07falsefull11 <p>Dr Farrukh Awan from Harold C Simmons Comprehensive Cancer Center in Dallas, Texas, Dr Bita Fakhri from Stanford University School of Medicine in California, Dr Kerry A Rogers from the Ohio State University in Columbus, Dr William Wierda from the University of Texas MD Anderson Cancer Center in Houston, and moderator Dr Jeff Sharman from the Sarah Cannon Research Institute discuss updated data from ASH 2024 influencing the current and future treatment paradigm for treatment-naïve and relapsed/refractory chronic lymphocytic leukemia. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/ASHCLL24" rel="nofollow">here</a>. </p> Cases from the Community: Integrating New Research Findings into Current Practice — Colorectal and Gastroesophageal CancersCases from the Community: Integrating New Research Findings into Current Practice — Colorectal and Gastroesophageal CancersDr Christopher Lieu shares his perspectives on the evolving therapeutic landscape for patients with colorectal and gastroesophageal cancers, moderated by Dr Stephen "Fred" Divers. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Christopher Lieu shares his perspectives on the evolving therapeutic landscape for patients with colorectal and gastroesophageal cancers, moderated by Dr Stephen "Fred" Divers. Produced by Research To Practice.

CME information and select publications here.

]]>f6d7c981-06b6-4145-bf74-8718644c56e0Wed, 18 Dec 2024 08:30:00 -040049:11falsefull11 <p>Dr Christopher Lieu shares his perspectives on the evolving therapeutic landscape for patients with colorectal and gastroesophageal cancers, moderated by Dr Stephen &quot;Fred&quot; Divers. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/AON24" rel="nofollow">here</a>. </p> Cases from the Community: Integrating New Research Findings into Current Practice — Hepatobiliary CancersCases from the Community: Integrating New Research Findings into Current Practice — Hepatobiliary CancersDr Daneng Li shares his perspectives on the evolving therapeutic landscape for patients with hepatobiliary cancers, moderated by Dr Stephen "Fred" Divers. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Daneng Li shares his perspectives on the evolving therapeutic landscape for patients with hepatobiliary cancers, moderated by Dr Stephen "Fred" Divers. Produced by Research To Practice.

CME information and select publications here.

]]>3785b6fc-a9c6-40b0-be7e-340087fc5d82Wed, 18 Dec 2024 08:00:00 -040055:50falsefull11 <p>Dr Daneng Li shares his perspectives on the evolving therapeutic landscape for patients with hepatobiliary cancers, moderated by Dr Stephen &quot;Fred&quot; Divers. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/AON24" rel="nofollow">here</a>. </p> Cases from the Community: Integrating New Research Findings into Current Practice — Gynecologic CancersCases from the Community: Integrating New Research Findings into Current Practice — Gynecologic CancersDr Kathleen N Moore shares her perspectives on the evolving therapeutic landscape for patients with gynecologic cancers, moderated by Dr Stephen "Fred" Divers. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Kathleen N Moore shares her perspectives on the evolving therapeutic landscape for patients with gynecologic cancers, moderated by Dr Stephen "Fred" Divers. Produced by Research To Practice.

CME information and select publications here.

]]>61067c11-7e62-44e7-886b-e6276bac7889Tue, 17 Dec 2024 10:00:00 -040046:41falsefull11 <p>Dr Kathleen N Moore shares her perspectives on the evolving therapeutic landscape for patients with gynecologic cancers, moderated by Dr Stephen &quot;Fred&quot; Divers. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/AON24" rel="nofollow">here</a>. </p> Cases from the Community: Integrating New Research Findings into Current Practice — MyelofibrosisCases from the Community: Integrating New Research Findings into Current Practice — MyelofibrosisDr Stephen T Oh shares his perspectives on the evolving therapeutic landscape for patients with myelofibrosis, moderated by Dr Stephen "Fred" Divers. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Stephen T Oh shares his perspectives on the evolving therapeutic landscape for patients with myelofibrosis, moderated by Dr Stephen "Fred" Divers. Produced by Research To Practice.

CME information and select publications here.

]]>d97edf34-7128-4db9-8e21-9c22da6d69ebTue, 17 Dec 2024 09:00:00 -040051:43falsefull11 <p>Dr Stephen T Oh shares his perspectives on the evolving therapeutic landscape for patients with myelofibrosis, moderated by Dr Stephen &quot;Fred&quot; Divers. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/AON24" rel="nofollow">here</a>. </p> Cases from the Community: Integrating New Research Findings into Current Practice — Leukemia and Myelodysplastic SyndromesCases from the Community: Integrating New Research Findings into Current Practice — Leukemia and Myelodysplastic SyndromesDr Harry Paul Erba shares his perspectives on the evolving therapeutic landscape for patients with leukemia and myelodysplastic syndromes, moderated by Dr Stephen "Fred" Divers. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Harry Paul Erba shares his perspectives on the evolving therapeutic landscape for patients with leukemia and myelodysplastic syndromes, moderated by Dr Stephen "Fred" Divers. Produced by Research To Practice.

CME information and select publications here.

]]>2815f8d3-6cfe-4a00-8ca2-f6c9523d3a94Fri, 13 Dec 2024 12:15:00 -040051:45falsefull11 <p>Dr Harry Paul Erba shares his perspectives on the evolving therapeutic landscape for patients with leukemia and myelodysplastic syndromes, moderated by Dr Stephen &quot;Fred&quot; Divers. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/AON24" rel="nofollow">here</a>. </p> Cases from the Community: Integrating New Research Findings into Current Practice — Lung CancerCases from the Community: Integrating New Research Findings into Current Practice — Lung CancerDr Edward B Garon shares his perspectives on the evolving therapeutic landscape for patients with lung cancer, moderated by Dr Stephen “Fred” Divers. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Edward B Garon shares his perspectives on the evolving therapeutic landscape for patients with lung cancer, moderated by Dr Stephen “Fred” Divers. Produced by Research To Practice.

CME information and select publications here.

]]>7abcd2ce-fe25-48e6-9461-b8ee373c4ff5Fri, 13 Dec 2024 12:00:00 -040048:03falsefull11 <p>Dr Edward B Garon shares his perspectives on the evolving therapeutic landscape for patients with lung cancer, moderated by Dr Stephen “Fred” Divers. Produced by Research To Practice. </p> <p>CME information and select publications here. </p> 5-Minute Journal Club Issue 2 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer5-Minute Journal Club Issue 2 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast CancerDr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>1baaeec7-dc6a-4543-b468-103467e0db6bFri, 13 Dec 2024 09:00:00 -040011:59falsefull11 <p>Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/5MJC2024/OralSERDsmBC/2" rel="nofollow">here</a>.</p> Meet The Professor: Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer — A 2024 World Conference on Lung Cancer ReviewMeet The Professor: Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer — A 2024 World Conference on Lung Cancer ReviewDr Heather Wakelee from Stanford University School of Medicine in California discusses the implications of recent datasets for the current and future use of nontargeted therapy for metastatic non-small cell lung cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Heather Wakelee from Stanford University School of Medicine in California discusses the implications of recent datasets for the current and future use of nontargeted therapy for metastatic non-small cell lung cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>0f20880b-0bee-4551-ac16-b11609e40541Tue, 10 Dec 2024 10:00:00 -040058:47falsefull11 <p>Dr Heather Wakelee from Stanford University School of Medicine in California discusses the implications of recent datasets for the current and future use of nontargeted therapy for metastatic non-small cell lung cancer, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/MTPWLE24" rel="nofollow">here</a>.</p> Exploring the Current Management Paradigm for Patients with Metastatic Triple-Negative Breast Cancer Exploring the Current Management Paradigm for Patients with Metastatic Triple-Negative Breast Cancer Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood and Dr Sara M Tolaney from Dana-Farber Cancer Center in Boston discuss recent updates on available and novel treatment strategies for metastatic triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood and Dr Sara M Tolaney from Dana-Farber Cancer Center in Boston discuss recent updates on available and novel treatment strategies for metastatic triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>fc6e378c-a020-4d3e-9268-9ffc32597521Wed, 04 Dec 2024 09:00:00 -040059:42falsefull11 <p>Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood and Dr Sara M Tolaney from Dana-Farber Cancer Center in Boston discuss recent updates on available and novel treatment strategies for metastatic triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/FCS2024mTNBC" rel="nofollow">here</a>.</p> Practical Perspectives: Investigators Discuss the Current Management of Paroxysmal Nocturnal HemoglobinuriaPractical Perspectives: Investigators Discuss the Current Management of Paroxysmal Nocturnal HemoglobinuriaDr Gloria Gerber, Dr Jamie Koprivnikar, Prof Alexander Röth and Dr Jamile Shammo discuss available and emerging research, patient cases from participating junior clinical investigator faculty and senior clinical investigator faculty perspectives of relevant research data informing clinical decision-making for paroxysmal nocturnal hemoglobinuria, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Gloria Gerber, Dr Jamie Koprivnikar, Prof Alexander Röth and Dr Jamile Shammo discuss available and emerging research, patient cases from participating junior clinical investigator faculty and senior clinical investigator faculty perspectives of relevant research data informing clinical decision-making for paroxysmal nocturnal hemoglobinuria, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>f4dc54bf-2462-48d1-a989-5bc8e5593dadTue, 03 Dec 2024 10:00:00 -040001:46:37falsefull11 <p>Dr Gloria Gerber, Dr Jamie Koprivnikar, Prof Alexander Röth and Dr Jamile Shammo discuss available and emerging research, patient cases from participating junior clinical investigator faculty and senior clinical investigator faculty perspectives of relevant research data informing clinical decision-making for paroxysmal nocturnal hemoglobinuria, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/PNH2024/CaseRoundtable" rel="nofollow">here</a>.</p> Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Multiple MyelomaData + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Multiple MyelomaSpecialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with multiple myeloma, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

 

]]>Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with multiple myeloma, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

 

]]>9c054708-54b4-4973-bf5e-9e0474612f13Tue, 26 Nov 2024 08:00:00 -040052:45falsefull11 <p>Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with multiple myeloma, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/FCS2024" rel="nofollow">here</a>.</p> <p>  </p> 5-Minute Journal Club Issue 1 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer5-Minute Journal Club Issue 1 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast CancerDr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral selective estrogen receptor degraders for ER-positive metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral selective estrogen receptor degraders for ER-positive metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>c3b9bfb0-24eb-42a9-b475-fb5803873832Mon, 25 Nov 2024 12:00:00 -040010:56falsefull11 <p>Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral selective estrogen receptor degraders for ER-positive metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/5MJC2024/OralSERDsmBC/1" rel="nofollow">here</a>.</p> The Implications of Recent Datasets for the Current and Future Management of Lung Cancer — A Review of Information from ESMO Congress 2024 and Other ConferencesThe Implications of Recent Datasets for the Current and Future Management of Lung Cancer — A Review of Information from ESMO Congress 2024 and Other ConferencesDr Suresh S Ramalingam from the Emory University School of Medicine in Atlanta, Georgia, and Dr Gregory J Riely from Memorial Sloan Kettering Cancer Center in New York, New York, discuss the implications of recent data sets for the current and future management of lung cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Suresh S Ramalingam from the Emory University School of Medicine in Atlanta, Georgia, and Dr Gregory J Riely from Memorial Sloan Kettering Cancer Center in New York, New York, discuss the implications of recent data sets for the current and future management of lung cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>1e9ebc6d-c881-4e29-b65f-a867f32608a4Fri, 22 Nov 2024 07:30:00 -040001:00:12falsefull11 <p>Dr Suresh S Ramalingam from the Emory University School of Medicine in Atlanta, Georgia, and Dr Gregory J Riely from Memorial Sloan Kettering Cancer Center in New York, New York, discuss the implications of recent data sets for the current and future management of lung cancer, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/PostESMO24/Lung" rel="nofollow">here</a>.</p> Meet The Professor: Optimizing the Management of Chronic Lymphocytic Leukemia — Part 2 of a 3-Part SeriesMeet The Professor: Optimizing the Management of Chronic Lymphocytic Leukemia — Part 2 of a 3-Part SeriesDr Nicole Lamanna from the Columbia University Herbert Irving Comprehensive Cancer Center in New York, New York, discusses recent updates on available and novel treatment strategies for chronic lymphocytic leukemia, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Nicole Lamanna from the Columbia University Herbert Irving Comprehensive Cancer Center in New York, New York, discusses recent updates on available and novel treatment strategies for chronic lymphocytic leukemia, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>a89238c8-5129-484e-a29b-9e242facf924Fri, 22 Nov 2024 07:15:00 -040058:36falsefull11 <p>Dr Nicole Lamanna from the Columbia University Herbert Irving Comprehensive Cancer Center in New York, New York, discusses recent updates on available and novel treatment strategies for chronic lymphocytic leukemia, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/MTPCLL24/Part2" rel="nofollow">here</a>.</p> Optimizing the Management of Tenosynovial Giant Cell TumorOptimizing the Management of Tenosynovial Giant Cell TumorDr Emanuela Palmerini from the IRCCS Istituto Ortopedico Rizzoli in Bologna, Italy, discusses the current and future clinical treatment of tenosynovial giant cell tumor, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Emanuela Palmerini from the IRCCS Istituto Ortopedico Rizzoli in Bologna, Italy, discusses the current and future clinical treatment of tenosynovial giant cell tumor, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>fa51cdbb-70cf-4a16-8091-563422cecb11Wed, 20 Nov 2024 10:00:00 -040001:03:55falsefull11 <p>Dr Emanuela Palmerini from the IRCCS Istituto Ortopedico Rizzoli in Bologna, Italy, discusses the current and future clinical treatment of tenosynovial giant cell tumor, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayTGCT24" rel="nofollow">here</a>. </p> Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Prostate CancerData + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Prostate CancerSpecialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with prostate cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with prostate cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>ac268d20-2dd5-4a21-8565-d34d6d726738Wed, 20 Nov 2024 08:15:00 -040057:10falsefull11 <p>Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with prostate cancer, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/FCS2024" rel="nofollow">here</a>. </p> Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>b5dfdd24-e677-4cb4-9294-e346c60b598cWed, 20 Nov 2024 08:00:00 -040056:11falsefull11 <p>Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/FCS2024" rel="nofollow">here</a>. </p> Optimizing Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Harboring PI3K/AKT/PTEN Pathway AbnormalitiesOptimizing Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Harboring PI3K/AKT/PTEN Pathway AbnormalitiesDr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Hope S Rugo from the UCSF Helen Diller Family Comprehensive Cancer Center discuss treatment decision-making for HR-positive metastatic breast cancer in patients who harbor PI3K/AKT/PTEN pathway mutations, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Hope S Rugo from the UCSF Helen Diller Family Comprehensive Cancer Center discuss treatment decision-making for HR-positive metastatic breast cancer in patients who harbor PI3K/AKT/PTEN pathway mutations, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>5461d98c-a020-427b-893f-35a607666b74Mon, 18 Nov 2024 09:00:00 -040056:49falsefull11 <p>Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Hope S Rugo from the UCSF Helen Diller Family Comprehensive Cancer Center discuss treatment decision-making for HR-positive metastatic breast cancer in patients who harbor PI3K/AKT/PTEN pathway mutations, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/PI3KAKTPTENmBC24" rel="nofollow">here</a>. </p> Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Lung CancerData + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Lung CancerSpecialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with lung cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with lung cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>e2601a55-799c-4471-a50e-7a38b134da0eFri, 15 Nov 2024 11:30:00 -040001:05:42falsefull11 <p>Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with lung cancer, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/FCS2024" rel="nofollow">here</a>. </p> Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care — Breast CancerData + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care — Breast CancerSpecialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with HR-positive breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with HR-positive breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>7d0a9126-9951-4737-be2a-96ff05f8d310Fri, 15 Nov 2024 10:00:00 -040001:03:53falsefull11 <p>Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with HR-positive breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/FCS2024" rel="nofollow">here</a>.</p> What Clinicians Want to Know About the Current and Future Role of EZH1/2 Inhibitors in the Care of Patients with LymphomaWhat Clinicians Want to Know About the Current and Future Role of EZH1/2 Inhibitors in the Care of Patients with LymphomaDr Gilles Salles from the Memorial Sloan Kettering Cancer Center in New York, New York, reviews current and novel EZH1/2 inhibitor-based treatment strategies for follicular lymphoma, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Gilles Salles from the Memorial Sloan Kettering Cancer Center in New York, New York, reviews current and novel EZH1/2 inhibitor-based treatment strategies for follicular lymphoma, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>2a8d8caf-61b0-4e0f-8180-0fbfa348d4d8Fri, 08 Nov 2024 09:00:00 -040056:15falsefull11 <p>Dr Gilles Salles from the Memorial Sloan Kettering Cancer Center in New York, New York, reviews current and novel EZH1/2 inhibitor-based treatment strategies for follicular lymphoma, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/WCWtK2024/EZH2Lymphoma" rel="nofollow">here</a>. </p> Special Edition — Key Presentations on Lung Cancer from Recent Major Conferences Special Edition — Key Presentations on Lung Cancer from Recent Major Conferences Dr Stephen V Liu from Georgetown University Hospital in Washington, DC, reviews recently presented data with and newly approved therapies for localized and advanced lung cancers, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Stephen V Liu from Georgetown University Hospital in Washington, DC, reviews recently presented data with and newly approved therapies for localized and advanced lung cancers, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>fc8ffb1a-cdb0-4500-ae66-5f409e07fd60Wed, 06 Nov 2024 10:00:00 -040054:40falsefull11 <p>Dr Stephen V Liu from Georgetown University Hospital in Washington, DC, reviews recently presented data with and newly approved therapies for localized and advanced lung cancers, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayPostConf24/Lung" rel="nofollow">here</a>. </p> The Implications of Recent Datasets for the Current and Future Management of Gastrointestinal Cancers — An ESMO Congress 2024 Review The Implications of Recent Datasets for the Current and Future Management of Gastrointestinal Cancers — An ESMO Congress 2024 Review Dr Tanios Bekaii-Saab from Mayo Clinic in Phoenix, Arizona, and Dr Philip A Philip from the Henry Ford Cancer Institute in Detroit, Michigan, discuss recent research presentations on the treatment of gastrointestinal cancers, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Tanios Bekaii-Saab from Mayo Clinic in Phoenix, Arizona, and Dr Philip A Philip from the Henry Ford Cancer Institute in Detroit, Michigan, discuss recent research presentations on the treatment of gastrointestinal cancers, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>a9a9a439-0b47-4950-a1dc-c146cd733c20Tue, 05 Nov 2024 08:00:00 -040001:02:25falsefull11 <p>Dr Tanios Bekaii-Saab from Mayo Clinic in Phoenix, Arizona, and Dr Philip A Philip from the Henry Ford Cancer Institute in Detroit, Michigan, discuss recent research presentations on the treatment of gastrointestinal cancers, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/PostESMO24/GI" rel="nofollow">here</a>. </p> Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Negative Metastatic Breast CancerImproving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Negative Metastatic Breast CancerProf Francois-Clement Bidard from Institut Curie in Paris and Dr Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta discuss improving the outcomes of first-line endocrine-based therapy for patients with HR-positive, HER2-negative metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Prof Francois-Clement Bidard from Institut Curie in Paris and Dr Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta discuss improving the outcomes of first-line endocrine-based therapy for patients with HR-positive, HER2-negative metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>81daf8a8-033d-44cd-89ac-efd0ed32998cFri, 01 Nov 2024 10:00:00 -040059:29falsefull11 <p>Prof Francois-Clement Bidard from Institut Curie in Paris and Dr Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta discuss improving the outcomes of first-line endocrine-based therapy for patients with HR-positive, HER2-negative metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/FirstLineTherapymBC24" rel="nofollow">here</a>.</p> Practical Perspectives: Optimizing the Role of BTK Inhibitors in the Management of Mantle Cell LymphomaPractical Perspectives: Optimizing the Role of BTK Inhibitors in the Management of Mantle Cell LymphomaDr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Michael Wang from the University of Texas MD Anderson Cancer Center in Houston discuss the current role of Bruton tyrosine kinase inhibitors for the management of newly diagnosed and relapsed/refractory mantle cell lymphoma, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Michael Wang from the University of Texas MD Anderson Cancer Center in Houston discuss the current role of Bruton tyrosine kinase inhibitors for the management of newly diagnosed and relapsed/refractory mantle cell lymphoma, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>841f45b4-6975-4eb1-959f-bc425b838078Tue, 29 Oct 2024 11:00:00 -040057:58falsefull11 <p>Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Michael Wang from the University of Texas MD Anderson Cancer Center in Houston discuss the current role of Bruton tyrosine kinase inhibitors for the management of newly diagnosed and relapsed/refractory mantle cell lymphoma, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/BTKInhibitorsMCL24" rel="nofollow">here</a>.</p> Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast CancerPotential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast CancerDr Erika Hamilton from Sarah Cannon Research Institute in Nashville discusses emerging evidence with proteolysis-targeting chimera estrogen receptor degraders for HR-positive metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville discusses emerging evidence with proteolysis-targeting chimera estrogen receptor degraders for HR-positive metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>542003be-4515-4ad3-9783-2003e8f0354fFri, 25 Oct 2024 10:00:00 -040045:46falsefull11 <p>Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville discusses emerging evidence with proteolysis-targeting chimera estrogen receptor degraders for HR-positive metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayPROTACmBC24" rel="nofollow">here</a>.</p> Practical Perspectives: Current Management of Chronic Myeloid LeukemiaPractical Perspectives: Current Management of Chronic Myeloid LeukemiaDrs Bhavana (Tina) Bhatnagar, Amanda Blackmon, Jorge Cortes, Michael J Mauro and Neil P Shah discuss recent updates on clinical treatment strategies for chronic myeloid leukemia, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Drs Bhavana (Tina) Bhatnagar, Amanda Blackmon, Jorge Cortes, Michael J Mauro and Neil P Shah discuss recent updates on clinical treatment strategies for chronic myeloid leukemia, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>61a0ee77-ec6e-44bb-95e1-cc7f6d316a66Wed, 23 Oct 2024 09:00:00 -040001:49:21falsefull11 <p>Drs Bhavana (Tina) Bhatnagar, Amanda Blackmon, Jorge Cortes, Michael J Mauro and Neil P Shah discuss recent updates on clinical treatment strategies for chronic myeloid leukemia, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/CML2024/CaseRoundtable" rel="nofollow">here</a>. </p> The Implications of Recent Datasets for the Current and Future Management of Small Cell Lung Cancer — A 2024 World Conference on Lung Cancer ReviewThe Implications of Recent Datasets for the Current and Future Management of Small Cell Lung Cancer — A 2024 World Conference on Lung Cancer ReviewDr Jacob Sands from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent presentations on approved and investigational therapies in small cell lung cancer from the 2024 World Conference on Lung Cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Jacob Sands from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent presentations on approved and investigational therapies in small cell lung cancer from the 2024 World Conference on Lung Cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>79e45b5a-aa88-4188-9b23-ed598eb01893Tue, 22 Oct 2024 09:00:00 -040042:46falsefull11 <p>Dr Jacob Sands from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent presentations on approved and investigational therapies in small cell lung cancer from the 2024 World Conference on Lung Cancer, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/WCLC2024/SCLC" rel="nofollow">here</a>.</p> Practical Perspectives: Optimizing Diagnosis and Treatment for Patients with Desmoid TumorsPractical Perspectives: Optimizing Diagnosis and Treatment for Patients with Desmoid TumorsDr Thierry Alcindor from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Mrinal Gounder from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for desmoid tumors and review novel options for targeted therapy, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Thierry Alcindor from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Mrinal Gounder from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for desmoid tumors and review novel options for targeted therapy, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>91c80db5-2448-459d-b4f2-aebc5058e6efFri, 18 Oct 2024 10:00:00 -040059:22falsefull11 <p>Dr Thierry Alcindor from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Mrinal Gounder from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for desmoid tumors and review novel options for targeted therapy, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/DesmoidTumors24" rel="nofollow">here</a>. </p> Peripheral T-Cell LymphomaPeripheral T-Cell LymphomaDr Stephen Horwitz from Memorial Sloan Kettering Cancer Center in New York, New York, discusses management strategies for previously untreated and relapsed peripheral T-cell lymphomas, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Stephen Horwitz from Memorial Sloan Kettering Cancer Center in New York, New York, discusses management strategies for previously untreated and relapsed peripheral T-cell lymphomas, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>6e7e22b0-e9bf-427c-810e-7b942b52712bWed, 16 Oct 2024 11:00:00 -040046:33falsefull11 <p>Dr Stephen Horwitz from Memorial Sloan Kettering Cancer Center in New York, New York, discusses management strategies for previously untreated and relapsed peripheral T-cell lymphomas, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayPTCL24" rel="nofollow">here</a>.</p> The Implications of Recent Datasets for the Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung CancerThe Implications of Recent Datasets for the Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung CancerDr Edward Garon from UCLA Health Jonsson Comprehensive Cancer Center and Dr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid share their perspectives on recent datasets from the 2024 World Conference on Lung Cancer on the management of non-small cell lung cancer without actionable genomic alterations, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Edward Garon from UCLA Health Jonsson Comprehensive Cancer Center and Dr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid share their perspectives on recent datasets from the 2024 World Conference on Lung Cancer on the management of non-small cell lung cancer without actionable genomic alterations, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>40443d82-ac38-4512-bcde-52a735750495Tue, 15 Oct 2024 09:00:00 -040001:00:08falsefull11 <p>Dr Edward Garon from UCLA Health Jonsson Comprehensive Cancer Center and Dr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid share their perspectives on recent datasets from the 2024 World Conference on Lung Cancer on the management of non-small cell lung cancer without actionable genomic alterations, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/WCLC2024/NontargetedLung" rel="nofollow">here</a>.</p> Meet The Professor: Optimizing the Management of Chronic Lymphocytic Leukemia — Part 1 of a 3-Part SeriesMeet The Professor: Optimizing the Management of Chronic Lymphocytic Leukemia — Part 1 of a 3-Part SeriesDr Matthew S Davids from Dana-Farber Cancer Institute in Boston, Massachusetts, reviews current available data and ongoing investigational treatment approaches for chronic lymphocytic leukemia, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Matthew S Davids from Dana-Farber Cancer Institute in Boston, Massachusetts, reviews current available data and ongoing investigational treatment approaches for chronic lymphocytic leukemia, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>4476b8af-6c98-4513-9ac8-32357540081eThu, 10 Oct 2024 09:00:00 -040058:59falsefull11 <p>Dr Matthew S Davids from Dana-Farber Cancer Institute in Boston, Massachusetts, reviews current available data and ongoing investigational treatment approaches for chronic lymphocytic leukemia, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/MTPCLL24/Part1" rel="nofollow">here</a>. </p> The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with Actionable Targets Beyond EGFRThe Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with Actionable Targets Beyond EGFRDr Ibiayi Dagogo-Jack from Massachusetts General Hospital in Boston and Dr Corey J Langer from the Abramson Cancer Center in Philadelphia, Pennsylvania, discuss the implications of recent datasets for the current and future management of non-small cell lung cancer with actionable targets beyond EGFR, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Ibiayi Dagogo-Jack from Massachusetts General Hospital in Boston and Dr Corey J Langer from the Abramson Cancer Center in Philadelphia, Pennsylvania, discuss the implications of recent datasets for the current and future management of non-small cell lung cancer with actionable targets beyond EGFR, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>a5d3bb14-74e6-48f0-955f-3990743124f5Tue, 08 Oct 2024 09:00:00 -040058:14falsefull11 <p>Dr Ibiayi Dagogo-Jack from Massachusetts General Hospital in Boston and Dr Corey J Langer from the Abramson Cancer Center in Philadelphia, Pennsylvania, discuss the implications of recent datasets for the current and future management of non-small cell lung cancer with actionable targets beyond EGFR, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/WCLC2024/TargetedLung" rel="nofollow">here</a>.</p> The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with EGFR MutationsThe Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with EGFR MutationsDr Joshua K Sabari from the NYU Langone Health Perlmutter Cancer Center and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for non-small cell lung cancer with EGFR mutations, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Joshua K Sabari from the NYU Langone Health Perlmutter Cancer Center and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for non-small cell lung cancer with EGFR mutations, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>8bdf7e6f-5316-4f7d-a2c8-5cb031ebe728Tue, 01 Oct 2024 10:00:00 -040058:19falsefull11 <p>Dr Joshua K Sabari from the NYU Langone Health Perlmutter Cancer Center and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for non-small cell lung cancer with EGFR mutations, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/WCLC2024/EGFRNSCLC" rel="nofollow">here</a>. </p> Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast CancerOptimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast CancerDr Tiffany Traina from the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College in New York, New York, discusses optimizing the management of metastatic BRCA-negative, triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Tiffany Traina from the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College in New York, New York, discusses optimizing the management of metastatic BRCA-negative, triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>6dae340a-d282-4550-9c94-069c75c0d54bTue, 24 Sep 2024 08:00:00 -040049:55falsefull11 <p>Dr Tiffany Traina from the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College in New York, New York, discusses optimizing the management of metastatic BRCA-negative, triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayBRCANegTNBC24" rel="nofollow">here</a>. </p> Striving for Consensus: Optimizing the Current and Future Management of Biliary Tract CancersStriving for Consensus: Optimizing the Current and Future Management of Biliary Tract CancersDr Lipika Goyal from Stanford Cancer Center in Palo Alto, California, Dr James J Harding from Memorial Sloan Kettering Cancer Center in New York, New York, Dr Milind Javle from The University of Texas MD Anderson Cancer Center in Houston, Texas, and Dr Robin K (Katie) Kelley from UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, summarize the treatment landscape for patients with biliary tract cancers and review recent advancements in the field, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Lipika Goyal from Stanford Cancer Center in Palo Alto, California, Dr James J Harding from Memorial Sloan Kettering Cancer Center in New York, New York, Dr Milind Javle from The University of Texas MD Anderson Cancer Center in Houston, Texas, and Dr Robin K (Katie) Kelley from UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, summarize the treatment landscape for patients with biliary tract cancers and review recent advancements in the field, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>bd97ab59-01a8-4243-a1de-c9b958aae93bFri, 20 Sep 2024 14:00:00 -040002:14:52falsefull11 <p>Dr Lipika Goyal from Stanford Cancer Center in Palo Alto, California, Dr James J Harding from Memorial Sloan Kettering Cancer Center in New York, New York, Dr Milind Javle from The University of Texas MD Anderson Cancer Center in Houston, Texas, and Dr Robin K (Katie) Kelley from UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, summarize the treatment landscape for patients with biliary tract cancers and review recent advancements in the field, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/BTCThinkTank2024" rel="nofollow">here</a>. </p> Inside the Issue: Optimizing the Diagnosis and Treatment of Neuroendocrine TumorsInside the Issue: Optimizing the Diagnosis and Treatment of Neuroendocrine TumorsDr Pamela Kunz from the Yale School of Medicine and Yale Cancer Center in New Haven, Connecticut, and Dr Simron Singh from the Odette Cancer Centre and Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada, discuss optimizing the diagnosis and treatment of neuroendocrine tumors, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Pamela Kunz from the Yale School of Medicine and Yale Cancer Center in New Haven, Connecticut, and Dr Simron Singh from the Odette Cancer Centre and Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada, discuss optimizing the diagnosis and treatment of neuroendocrine tumors, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>1d23221c-730f-4971-a8f8-0fe2c6fa7366Tue, 17 Sep 2024 10:00:00 -040059:20falsefull11 <p>Dr Pamela Kunz from the Yale School of Medicine and Yale Cancer Center in New Haven, Connecticut, and Dr Simron Singh from the Odette Cancer Centre and Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada, discuss optimizing the diagnosis and treatment of neuroendocrine tumors, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/InsideTheIssue2024/Neuroendocrine" rel="nofollow">here</a>. </p> Inside the Issue: Integrating HER2-Targeted Strategies into the Management of Gastrointestinal CancersInside the Issue: Integrating HER2-Targeted Strategies into the Management of Gastrointestinal CancersDr Tanios Bekaii-Saab from the Mayo Clinic Cancer Center in Phoenix, Arizona, and Dr John Strickler from Duke University in Durham, North Carolina, review clinical data supporting the application of HER2-targeted therapies for patients with gastrointestinal cancers, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Tanios Bekaii-Saab from the Mayo Clinic Cancer Center in Phoenix, Arizona, and Dr John Strickler from Duke University in Durham, North Carolina, review clinical data supporting the application of HER2-targeted therapies for patients with gastrointestinal cancers, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>dab29bd2-48cb-4912-add9-baf34973b045Wed, 11 Sep 2024 11:00:00 -040001:00:59falsefull11 <p>Dr Tanios Bekaii-Saab from the Mayo Clinic Cancer Center in Phoenix, Arizona, and Dr John Strickler from Duke University in Durham, North Carolina, review clinical data supporting the application of HER2-targeted therapies for patients with gastrointestinal cancers, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/InsideTheIssue2024/HER2GI" rel="nofollow">here</a>. </p> Optimizing the Management of Dedifferentiated LiposarcomaOptimizing the Management of Dedifferentiated LiposarcomaDr Mrinal Gounder from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent updates on available and emerging treatment strategies for dedifferentiated liposarcoma and other sarcomas, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Mrinal Gounder from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent updates on available and emerging treatment strategies for dedifferentiated liposarcoma and other sarcomas, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>928b8695-09d8-4a6b-b23a-79d9a5a80f03Mon, 09 Sep 2024 08:00:00 -040001:15:13falsefull11 <p>Dr Mrinal Gounder from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent updates on available and emerging treatment strategies for dedifferentiated liposarcoma and other sarcomas, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayLiposarcoma24" rel="nofollow">here</a>.</p> Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast CancerInside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast CancerProf Peter Schmid from the Barts Cancer Institute in London, United Kingdom, and Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, review clinical trials investigating the role of antibody-drug conjugate-mediated therapies in the treatment of metastatic breast cancer.

CME information and select publications here

]]>Prof Peter Schmid from the Barts Cancer Institute in London, United Kingdom, and Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, review clinical trials investigating the role of antibody-drug conjugate-mediated therapies in the treatment of metastatic breast cancer.

CME information and select publications here

]]>d8779e93-98a7-410b-9e40-58c1bcde3b5bFri, 06 Sep 2024 08:00:00 -040001:02:34falsefull11 <p>Prof Peter Schmid from the Barts Cancer Institute in London, United Kingdom, and Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, review clinical trials investigating the role of antibody-drug conjugate-mediated therapies in the treatment of metastatic breast cancer.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/InsideTheIssue2024/ADCsmBC" rel="nofollow">here</a></p> Current and Future Management of Non-Small Cell Lung Cancer with an EGFR MutationCurrent and Future Management of Non-Small Cell Lung Cancer with an EGFR MutationDr Pasi Jänne from the Dana-Farber Cancer Institute in Boston, Massachusetts, Prof Tom John from the Peter MacCallum Cancer Centre in Melbourne, Australia, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, Massachusetts, and Dr Alexander Spira from the Virginia Cancer Specialists Research Program in Fairfax, discuss recent updates on available and emerging treatment strategies for non-small cell lung cancer with an EGFR mutation.

CME information and select publications here

]]>Dr Pasi Jänne from the Dana-Farber Cancer Institute in Boston, Massachusetts, Prof Tom John from the Peter MacCallum Cancer Centre in Melbourne, Australia, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, Massachusetts, and Dr Alexander Spira from the Virginia Cancer Specialists Research Program in Fairfax, discuss recent updates on available and emerging treatment strategies for non-small cell lung cancer with an EGFR mutation.

CME information and select publications here

]]>55acdf87-56d0-4ae4-85ec-bc5702d224a3Wed, 04 Sep 2024 08:00:00 -040002:03:23falsefull11 <p>Dr Pasi Jänne from the Dana-Farber Cancer Institute in Boston, Massachusetts, Prof Tom John from the Peter MacCallum Cancer Centre in Melbourne, Australia, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, Massachusetts, and Dr Alexander Spira from the Virginia Cancer Specialists Research Program in Fairfax, discuss recent updates on available and emerging treatment strategies for non-small cell lung cancer with an EGFR mutation.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/EGFRNSCLCThinkTank2024" rel="nofollow">here</a></p> Management of Metastatic Urothelial Bladder CancerManagement of Metastatic Urothelial Bladder CancerDr Michiel van der Heijden from the Netherlands Cancer Institute in Amsterdam discusses the management of metastatic urothelial bladder cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Michiel van der Heijden from the Netherlands Cancer Institute in Amsterdam discusses the management of metastatic urothelial bladder cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>e985700e-4bba-46b3-ba5f-26f098648fd0Fri, 30 Aug 2024 08:00:00 -040030:46falsefull11 <p>Dr Michiel van der Heijden from the Netherlands Cancer Institute in Amsterdam discusses the management of metastatic urothelial bladder cancer, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodaymUBC24" rel="nofollow">here</a>.</p> Special Edition — Key Presentations on Breast Cancer from the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingSpecial Edition — Key Presentations on Breast Cancer from the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingDr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, discusses recent advances in the treatment of breast cancer following the 2024 ASCO Annual Meeting, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, discusses recent advances in the treatment of breast cancer following the 2024 ASCO Annual Meeting, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>85a489ec-7dbb-42fb-aa45-81e4d43d1345Wed, 28 Aug 2024 11:00:00 -040001:15:59falsefull11 <p>Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, discusses recent advances in the treatment of breast cancer following the 2024 ASCO Annual Meeting, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayPostASCO24/BreastCancer" rel="nofollow">here</a>. </p> An interview with Professor Giuseppe Curigliano, MD, PhD — Management of Metastatic Breast CancerAn interview with Professor Giuseppe Curigliano, MD, PhD — Management of Metastatic Breast CancerProf Giuseppe Curigliano from the European Institute of Oncology in Milano, Italy discusses current questions and controversies in the management of metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Prof Giuseppe Curigliano from the European Institute of Oncology in Milano, Italy discusses current questions and controversies in the management of metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>17bff86d-0365-4074-a730-636479e9cfffFri, 23 Aug 2024 08:00:00 -040046:13falsefull11 <p>Prof Giuseppe Curigliano from the European Institute of Oncology in Milano, Italy discusses current questions and controversies in the management of metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayASCOmBC24" rel="nofollow">here</a>. </p> An interview with Angeles Alvarez Secord, MD, MHSc — Management of Ovarian and Endometrial CancerAn interview with Angeles Alvarez Secord, MD, MHSc — Management of Ovarian and Endometrial CancerDr Angeles Alvarez Secord from the Duke Cancer Institute in Durham, North Carolina, provides her perspectives on recent datasets from ASCO 2024 on the management of ovarian and endometrial cancers, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Angeles Alvarez Secord from the Duke Cancer Institute in Durham, North Carolina, provides her perspectives on recent datasets from ASCO 2024 on the management of ovarian and endometrial cancers, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>94638989-38b0-4a81-9524-4a9f509939e0Wed, 21 Aug 2024 10:00:00 -040052:37falsefull11 <p>Dr Angeles Alvarez Secord from the Duke Cancer Institute in Durham, North Carolina, provides her perspectives on recent datasets from ASCO 2024 on the management of ovarian and endometrial cancers, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayASCOOvarianEndo24" rel="nofollow">here</a>. </p> Inside the Issue: Integrating ALK-Targeted Therapy into the Management of Localized Non-Small Cell Lung CancerInside the Issue: Integrating ALK-Targeted Therapy into the Management of Localized Non-Small Cell Lung CancerProf Solange Peters from the Lausanne University Hospital in Lausanne, Switzerland, and Professor Ben Solomon from the Peter MacCallum Cancer Centre in Melbourne, Australia, discuss treatment approaches for ALK-rearranged non-small cell lung cancer in the localized disease setting, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Prof Solange Peters from the Lausanne University Hospital in Lausanne, Switzerland, and Professor Ben Solomon from the Peter MacCallum Cancer Centre in Melbourne, Australia, discuss treatment approaches for ALK-rearranged non-small cell lung cancer in the localized disease setting, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>e5ab696f-1978-4eee-9ef9-e99a25676192Tue, 20 Aug 2024 10:00:00 -040001:01:24falsefull11 <p>Prof Solange Peters from the Lausanne University Hospital in Lausanne, Switzerland, and Professor Ben Solomon from the Peter MacCallum Cancer Centre in Melbourne, Australia, discuss treatment approaches for ALK-rearranged non-small cell lung cancer in the localized disease setting, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/InsideTheIssue2024/ALKPosNSCLC" rel="nofollow">here</a>. </p> Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast CancerIntegrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast CancerDr Sara A Hurvitz from the Fred Hutchinson Cancer Center in Seattle, Washington, summarizes recent trials investigating the integration of antibody-drug conjugates for HR-positive and triple-negative metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Sara A Hurvitz from the Fred Hutchinson Cancer Center in Seattle, Washington, summarizes recent trials investigating the integration of antibody-drug conjugates for HR-positive and triple-negative metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>477115ef-23d2-460a-976b-e540694fe135Fri, 16 Aug 2024 07:00:00 -040054:18falsefull11 <p>Dr Sara A Hurvitz from the Fred Hutchinson Cancer Center in Seattle, Washington, summarizes recent trials investigating the integration of antibody-drug conjugates for HR-positive and triple-negative metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayADCsmBC24" rel="nofollow">here</a>. </p> Novel Agents and Strategies in Lung CancerNovel Agents and Strategies in Lung CancerDr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, Dr Ticiana Leal from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Manish Patel from Florida Cancer Specialists & Research Institute in Sarasota, Florida, summarize recently presented advancements, including novel strategies, in the treatment of lung cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, Dr Ticiana Leal from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Manish Patel from Florida Cancer Specialists & Research Institute in Sarasota, Florida, summarize recently presented advancements, including novel strategies, in the treatment of lung cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>cfdbdeb6-38cc-4352-bef9-0bc10036992fTue, 13 Aug 2024 10:00:00 -040001:01:44falsefull11 <p>Dr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, Dr Ticiana Leal from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Manish Patel from Florida Cancer Specialists &amp; Research Institute in Sarasota, Florida, summarize recently presented advancements, including novel strategies, in the treatment of lung cancer, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyToday24/NovelLung" rel="nofollow">here</a>. </p> Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple MyelomaYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple MyelomaDr Jesús G Berdeja from the Greco-Hainsworth Tennessee Oncology Centers for Research in Nashville and Dr Thomas Martin from UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco discuss the most relevant new data sets and advances in multiple myeloma, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Jesús G Berdeja from the Greco-Hainsworth Tennessee Oncology Centers for Research in Nashville and Dr Thomas Martin from UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco discuss the most relevant new data sets and advances in multiple myeloma, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>3d782682-056f-4651-9341-241f6136dfe7Fri, 09 Aug 2024 12:00:00 -040001:02:04falsefull11 <p>Dr Jesús G Berdeja from the Greco-Hainsworth Tennessee Oncology Centers for Research in Nashville and Dr Thomas Martin from UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco discuss the most relevant new data sets and advances in multiple myeloma, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/YiR2023/MM" rel="nofollow">here</a>. </p> Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Melanoma and Nonmelanoma Skin CancersYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Melanoma and Nonmelanoma Skin CancersDr Evan J Lipson from the Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland, summarizes major clinical advances over the past year for treating skin cancers, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Evan J Lipson from the Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland, summarizes major clinical advances over the past year for treating skin cancers, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>a4c15ba6-d3cb-42e9-ba1d-b95461e42fe8Thu, 08 Aug 2024 14:00:00 -040059:36falsefull11 <p>Dr Evan J Lipson from the Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland, summarizes major clinical advances over the past year for treating skin cancers, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/YiR2023/Skin" rel="nofollow">here</a>.</p> Individualizing the Selection of First-Line Therapy for Patients with Hormone Receptor-Positive Metastatic Breast CancerIndividualizing the Selection of First-Line Therapy for Patients with Hormone Receptor-Positive Metastatic Breast CancerDr Joyce O’Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, summarizes risk factors and targeted therapy options for patients with HR-positive metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Joyce O’Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, summarizes risk factors and targeted therapy options for patients with HR-positive metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>ae8881ad-440f-44fb-b8dc-309a9d8d5cd2Tue, 06 Aug 2024 09:00:00 -040001:15:00falsefull11 <p>Dr Joyce O’Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, summarizes risk factors and targeted therapy options for patients with HR-positive metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/HRPosmBC24" rel="nofollow">here</a>. </p> An interview with Matthew R Smith, MD, PhD — Management of Prostate CancerAn interview with Matthew R Smith, MD, PhD — Management of Prostate CancerDr Matthew R Smith from the Massachusetts General Hospital Cancer Center in Boston summarizes recent developments presented at ASCO 2024 for prostate cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Matthew R Smith from the Massachusetts General Hospital Cancer Center in Boston summarizes recent developments presented at ASCO 2024 for prostate cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>0e2bb5f8-bff8-4ad0-b73c-5c7425d5a96bFri, 02 Aug 2024 10:00:00 -040053:36falsefull11 <p>Dr Matthew R Smith from the Massachusetts General Hospital Cancer Center in Boston summarizes recent developments presented at ASCO 2024 for prostate cancer, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayASCOProstate24" rel="nofollow">here</a>. </p> Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung CancerYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung CancerDr Matthew Gubens from the University of California, San Francisco summarizes important 2023 data sets guiding the use of immunotherapy and other nontargeted approaches for patients with NSCLC and no actionable mutations, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Matthew Gubens from the University of California, San Francisco summarizes important 2023 data sets guiding the use of immunotherapy and other nontargeted approaches for patients with NSCLC and no actionable mutations, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>fcf27be2-761c-4208-a9f5-dbf653142385Tue, 30 Jul 2024 10:00:00 -040001:00:53falsefull11 <p>Dr Matthew Gubens from the University of California, San Francisco summarizes important 2023 data sets guiding the use of immunotherapy and other nontargeted approaches for patients with NSCLC and no actionable mutations, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/YiR2023/NontargetedLung" rel="nofollow">here</a>. </p> Optimizing the Identification of HER2-Low Breast CancerOptimizing the Identification of HER2-Low Breast CancerDr Kimberly H Allison from the Stanford Cancer Institute in Stanford, California discusses the optimal identification, pathologic reporting and treatment of HER2-low breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Kimberly H Allison from the Stanford Cancer Institute in Stanford, California discusses the optimal identification, pathologic reporting and treatment of HER2-low breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>3056a648-ef55-4090-a3fb-4661a47f6d02Tue, 30 Jul 2024 09:00:00 -040023:49falsefull11 <p>Dr Kimberly H Allison from the Stanford Cancer Institute in Stanford, California discusses the optimal identification, pathologic reporting and treatment of HER2-low breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayTestingHER2LowBC24" rel="nofollow">here</a>. </p> Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Gynecologic OncologyYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Gynecologic OncologyDr Dana M Chase from the David Geffen School of Medicine at UCLA in Los Angeles, California, discusses select 2023 data sets on the management of ovarian, endometrial and cervical cancers, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Dana M Chase from the David Geffen School of Medicine at UCLA in Los Angeles, California, discusses select 2023 data sets on the management of ovarian, endometrial and cervical cancers, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>dd674d7b-968e-465a-aea9-dae0a6cdffafFri, 26 Jul 2024 11:00:00 -040059:17falsefull11 <p>Dr Dana M Chase from the David Geffen School of Medicine at UCLA in Los Angeles, California, discusses select 2023 data sets on the management of ovarian, endometrial and cervical cancers, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/YiR2023/Gyn" rel="nofollow">here</a>. </p> An interview with Jonathan W Goldman, MD — Management of Non-Small Cell Lung Cancer with an EGFR MutationAn interview with Jonathan W Goldman, MD — Management of Non-Small Cell Lung Cancer with an EGFR MutationDr Jonathan W Goldman from UCLA Health in Santa Monica, California, summarizes recent developments presented at ASCO 2024 for patients with non-small cell lung cancer with an EGFR mutation, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Jonathan W Goldman from UCLA Health in Santa Monica, California, summarizes recent developments presented at ASCO 2024 for patients with non-small cell lung cancer with an EGFR mutation, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>659e5a75-6096-4ade-a058-abda1c620b22Wed, 24 Jul 2024 13:00:00 -040047:35falsefull11 <p>Dr Jonathan W Goldman from UCLA Health in Santa Monica, California, summarizes recent developments presented at ASCO 2024 for patients with non-small cell lung cancer with an EGFR mutation, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayASCOEGFRNSCLC24" rel="nofollow">here</a>. </p> Investigator Perspectives on Available Research and Challenging Questions in Melanoma and Nonmelanoma Skin Cancers: A Post-ASCO 2024 Annual ReviewInvestigator Perspectives on Available Research and Challenging Questions in Melanoma and Nonmelanoma Skin Cancers: A Post-ASCO 2024 Annual ReviewDr Nikhil I Khushalani from Moffitt Cancer Center in Tampa, Florida and Dr Jason J Luke from UPMC Hillman Cancer Center in Pittsburgh, Pennsylvania discuss recently presented findings from ASCO on the management of melanoma and nonmelanoma skin cancers, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Nikhil I Khushalani from Moffitt Cancer Center in Tampa, Florida and Dr Jason J Luke from UPMC Hillman Cancer Center in Pittsburgh, Pennsylvania discuss recently presented findings from ASCO on the management of melanoma and nonmelanoma skin cancers, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>6d7abd27-c3b0-4bd4-8364-97425a44d40fFri, 19 Jul 2024 12:00:00 -040001:06:09falsefull11 <p>Dr Nikhil I Khushalani from Moffitt Cancer Center in Tampa, Florida and Dr Jason J Luke from UPMC Hillman Cancer Center in Pittsburgh, Pennsylvania discuss recently presented findings from ASCO on the management of melanoma and nonmelanoma skin cancers, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/PostASCO2024/Skin" rel="nofollow">here</a>. </p> Investigator Perspectives on Available Research and Challenging Questions in Renal Cell Carcinoma: A Post-ASCO Annual ReviewInvestigator Perspectives on Available Research and Challenging Questions in Renal Cell Carcinoma: A Post-ASCO Annual ReviewDr Rana R McKay from Moores Cancer Center in La Jolla, California, and Prof Thomas Powles from Barts Cancer Institute in London, United Kingdom, discuss recent updates on available and novel treatment strategies for renal cell carcinoma, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Rana R McKay from Moores Cancer Center in La Jolla, California, and Prof Thomas Powles from Barts Cancer Institute in London, United Kingdom, discuss recent updates on available and novel treatment strategies for renal cell carcinoma, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>ae32d2a6-ff21-47be-a8a0-d907d2b099c2Wed, 17 Jul 2024 12:00:00 -040001:02:25falsefull11 <p>Dr Rana R McKay from Moores Cancer Center in La Jolla, California, and Prof Thomas Powles from Barts Cancer Institute in London, United Kingdom, discuss recent updates on available and novel treatment strategies for renal cell carcinoma, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/PostASCO2024/RCC" rel="nofollow">here.</a></p> RTP Live from Chicago: Investigator Perspectives on Recent Advances and Challenging Questions in the Management of Colorectal CancerRTP Live from Chicago: Investigator Perspectives on Recent Advances and Challenging Questions in the Management of Colorectal CancerDr Scott Kopetz from The University of Texas MD Anderson Cancer Center in Houston, and Dr John Strickler from Duke University in Durham, North Carolina, discuss recent updates on available and novel treatment strategies for colorectal cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Scott Kopetz from The University of Texas MD Anderson Cancer Center in Houston, and Dr John Strickler from Duke University in Durham, North Carolina, discuss recent updates on available and novel treatment strategies for colorectal cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>f6395141-0d44-4009-a165-4aa461f2031fFri, 12 Jul 2024 14:00:00 -040001:02:36falsefull11 <p>Dr Scott Kopetz from The University of Texas MD Anderson Cancer Center in Houston, and Dr John Strickler from Duke University in Durham, North Carolina, discuss recent updates on available and novel treatment strategies for colorectal cancer, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/ASCO2024/CRC" rel="nofollow">here</a>. </p> RTP Live from Chicago: Investigator Perspectives on the Role of Bispecific Antibodies in the Management of LymphomaRTP Live from Chicago: Investigator Perspectives on the Role of Bispecific Antibodies in the Management of LymphomaDr Joshua Brody from the Tisch Cancer Institute at Mount Sinai in New York, New York, Dr Ian W Flinn from OneOncology in Nashville, Tennessee, and Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss recent updates on available and novel treatment strategies for various lymphomas, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Joshua Brody from the Tisch Cancer Institute at Mount Sinai in New York, New York, Dr Ian W Flinn from OneOncology in Nashville, Tennessee, and Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss recent updates on available and novel treatment strategies for various lymphomas, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>f675624d-bf5c-4b6b-8abd-34411ff41b52Fri, 12 Jul 2024 12:00:00 -040001:00:49falsefull11 <p>Dr Joshua Brody from the Tisch Cancer Institute at Mount Sinai in New York, New York, Dr Ian W Flinn from OneOncology in Nashville, Tennessee, and Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss recent updates on available and novel treatment strategies for various lymphomas, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/ASCO2024/BispecificLymphoma" rel="nofollow">here</a>. </p> What Clinicians Want to Know About the Management of Triple-Negative Breast CancerWhat Clinicians Want to Know About the Management of Triple-Negative Breast CancerDr Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Heather McArthur from UT Southwestern Medical Center in Dallas, Texas, summarize the evolution of biomarker-driven treatment approaches for triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Heather McArthur from UT Southwestern Medical Center in Dallas, Texas, summarize the evolution of biomarker-driven treatment approaches for triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>4b482e23-2778-49f3-a0fe-523974df76e1Wed, 10 Jul 2024 10:00:00 -040001:03:58falsefull11 <p>Dr Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Heather McArthur from UT Southwestern Medical Center in Dallas, Texas, summarize the evolution of biomarker-driven treatment approaches for triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/WCWtK2024/TNBC" rel="nofollow">here</a>. </p> Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in MyelofibrosisYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in MyelofibrosisDr Aaron T Gerds from the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, discusses recent updates on available and novel treatment strategies for myelofibrosis, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Aaron T Gerds from the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, discusses recent updates on available and novel treatment strategies for myelofibrosis, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>bb96d66a-c514-48ea-8cfc-58b9e2b76765Mon, 01 Jul 2024 10:00:00 -040001:00:07falsefull11 <p>Dr Aaron T Gerds from the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, discusses recent updates on available and novel treatment strategies for myelofibrosis, moderated by Dr Neil Love. Produced by Research To Practice.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/YiR2023/MF" rel="nofollow">here</a>. </p> Clinical Update on the Current Management of Advanced Urothelial Bladder CancerClinical Update on the Current Management of Advanced Urothelial Bladder CancerDr Petros Grivas from the Fred Hutchinson Cancer Center in Seattle, Washington, discusses the current management of advanced urothelial bladder cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Petros Grivas from the Fred Hutchinson Cancer Center in Seattle, Washington, discusses the current management of advanced urothelial bladder cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>a05158cc-30f8-4316-866c-e721989df417Mon, 17 Jun 2024 14:00:00 -040001:23:42falsefull11 <p>Dr Petros Grivas from the Fred Hutchinson Cancer Center in Seattle, Washington, discusses the current management of advanced urothelial bladder cancer, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayPostAUA24/UBC" rel="nofollow">here</a>. </p> Striving for Consensus: Exploring the Current Role of Ovarian Suppression in the Management of Breast CancerStriving for Consensus: Exploring the Current Role of Ovarian Suppression in the Management of Breast CancerDr William J Gradishar from Northwestern Medicine Feinberg School of Medicine in Chicago, Illinois, Dr Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas, Dr Erica Mayer from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Seth Wander from Massachusetts General Hospital in Boston, discuss key findings and practical considerations with ovarian function suppression for hormone receptor-positive breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr William J Gradishar from Northwestern Medicine Feinberg School of Medicine in Chicago, Illinois, Dr Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas, Dr Erica Mayer from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Seth Wander from Massachusetts General Hospital in Boston, discuss key findings and practical considerations with ovarian function suppression for hormone receptor-positive breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>7cfefb9c-244e-48d2-b966-22c18ee809baWed, 12 Jun 2024 14:00:00 -040002:35:49falsefull11 <p>Dr William J Gradishar from Northwestern Medicine Feinberg School of Medicine in Chicago, Illinois, Dr Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas, Dr Erica Mayer from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Seth Wander from Massachusetts General Hospital in Boston, discuss key findings and practical considerations with ovarian function suppression for hormone receptor-positive breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OvarianSuppressionBCThinkTank" rel="nofollow">here</a>. </p> Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung CancerYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung CancerDr Justin F Gainor from Massachusetts General Hospital in Boston and Dr Karen Reckamp from Cedars-Sinai Center in Los Angeles, California, summarize recently presented data on targeted therapy strategies for non-small cell lung cancer harboring actionable therapeutic targets, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Justin F Gainor from Massachusetts General Hospital in Boston and Dr Karen Reckamp from Cedars-Sinai Center in Los Angeles, California, summarize recently presented data on targeted therapy strategies for non-small cell lung cancer harboring actionable therapeutic targets, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>64710efc-2894-40de-b239-b41c9c78050cTue, 11 Jun 2024 11:00:00 -040001:00:48falsefull11 <p>Dr Justin F Gainor from Massachusetts General Hospital in Boston and Dr Karen Reckamp from Cedars-Sinai Center in Los Angeles, California, summarize recently presented data on targeted therapy strategies for non-small cell lung cancer harboring actionable therapeutic targets, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/YiR2023/TargetedLung" rel="nofollow">here</a>.</p> Second Opinion: Urologic Oncology Investigators Discuss How They Apply Clinical Research in the Care of Patients with Urothelial Bladder CancerSecond Opinion: Urologic Oncology Investigators Discuss How They Apply Clinical Research in the Care of Patients with Urothelial Bladder CancerDr Matthew Galsky from The Tisch Cancer Institute in New York and Dr Ashish Kamat from The University of Texas MD Anderson Cancer Center in Houston summarize recent clinical advances in the management of urothelial bladder cancer, including data from the 2024 AUA annual meeting, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Matthew Galsky from The Tisch Cancer Institute in New York and Dr Ashish Kamat from The University of Texas MD Anderson Cancer Center in Houston summarize recent clinical advances in the management of urothelial bladder cancer, including data from the 2024 AUA annual meeting, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>f1f840a3-fb38-4715-ac91-1ec416a0ee02Fri, 07 Jun 2024 11:00:00 -040001:02:32falsefull11 <p>Dr Matthew Galsky from The Tisch Cancer Institute in New York and Dr Ashish Kamat from The University of Texas MD Anderson Cancer Center in Houston summarize recent clinical advances in the management of urothelial bladder cancer, including data from the 2024 AUA annual meeting, moderated by Dr Neil Love. Produced by Research To Practice.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/AUA2024/UBC" rel="nofollow">here</a>.</p> Key Presentations on Lymphoma from Recent Major ConferencesKey Presentations on Lymphoma from Recent Major ConferencesDr Andrew D Zelenetz from Memorial Sloan Kettering Cancer Center in New York City discusses recent updates on available and emerging treatment strategies for various lymphomas, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Andrew D Zelenetz from Memorial Sloan Kettering Cancer Center in New York City discusses recent updates on available and emerging treatment strategies for various lymphomas, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>4b9a56af-8735-4489-98d7-958800ae884fTue, 28 May 2024 12:15:00 -040001:16:46falsefull11 <p>Dr Andrew D Zelenetz from Memorial Sloan Kettering Cancer Center in New York City discusses recent updates on available and emerging treatment strategies for various lymphomas, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayPostConf24/Lymphoma" rel="nofollow">here</a>. </p> Bispecific Antibodies in the Management of Multiple MyelomaBispecific Antibodies in the Management of Multiple MyelomaDr Joshua Richter from the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai in New York, New York, discusses the role of bispecific antibodies in multiple myeloma.

CME information and select publications here.

]]>Dr Joshua Richter from the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai in New York, New York, discusses the role of bispecific antibodies in multiple myeloma.

CME information and select publications here.

]]>94437fab-cdc4-40a7-bdf4-8794813f6d51Fri, 24 May 2024 11:45:00 -040042:09falsefull11 <p>Dr Joshua Richter from the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai in New York, New York, discusses the role of bispecific antibodies in multiple myeloma.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayBispecificMM24" rel="nofollow">here</a>.</p> Recent Advances in the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaRecent Advances in the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaDr Elias Jabbour from the University of Texas MD Anderson Cancer Center in Houston discusses recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Elias Jabbour from the University of Texas MD Anderson Cancer Center in Houston discusses recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>0102fc87-e75c-4baa-8703-73a19a9302dbFri, 24 May 2024 11:00:00 -040033:54falsefull11 <p>Dr Elias Jabbour from the University of Texas MD Anderson Cancer Center in Houston discusses recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayPHPosALL24" rel="nofollow">here</a>. </p> Understanding the Risk of Recurrence and Related Management for Patients with Localized HER2-Positive Breast CancerUnderstanding the Risk of Recurrence and Related Management for Patients with Localized HER2-Positive Breast CancerDr Adam M Brufsky from UPMC Hillman Cancer Center in Pittsburgh summarizes the history of and modern advances in treating localized HER2-positive breast cancers, including strategies for monitoring and managing treatment-related toxicities.

CME information and select publications here.

]]>Dr Adam M Brufsky from UPMC Hillman Cancer Center in Pittsburgh summarizes the history of and modern advances in treating localized HER2-positive breast cancers, including strategies for monitoring and managing treatment-related toxicities.

CME information and select publications here.

]]>2f17c989-4425-4521-aed0-8ea5495ae159Mon, 20 May 2024 14:00:00 -040001:16:31falsefull11 <p>Dr Adam M Brufsky from UPMC Hillman Cancer Center in Pittsburgh summarizes the history of and modern advances in treating localized HER2-positive breast cancers, including strategies for monitoring and managing treatment-related toxicities.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayLocHER2PosBC24" rel="nofollow">here</a>. </p> Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid LeukemiaYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid LeukemiaDrs Naval Daver and Courtney D DiNardo, both from The University of Texas MD Anderson Cancer Center in Houston, summarize the clinical progress in diagnosing and treating acute myeloid leukemia over the past year, as well as practical considerations for patients with the disease, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Drs Naval Daver and Courtney D DiNardo, both from The University of Texas MD Anderson Cancer Center in Houston, summarize the clinical progress in diagnosing and treating acute myeloid leukemia over the past year, as well as practical considerations for patients with the disease, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>c72f1c9c-1596-45c3-b8e6-c95ba00b6a87Mon, 13 May 2024 10:00:00 -040001:02:22falsefull11 <p>Drs Naval Daver and Courtney D DiNardo, both from The University of Texas MD Anderson Cancer Center in Houston, summarize the clinical progress in diagnosing and treating acute myeloid leukemia over the past year, as well as practical considerations for patients with the disease, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/YiR2023/AML" rel="nofollow">here</a>.</p> Virtual Case Library: Metastatic Triple-Negative Breast CancerVirtual Case Library: Metastatic Triple-Negative Breast CancerDrs Rita Nanda, Sara M Tolaney, Julia Foldi, Laura Huppert and Saba Shaikh discuss available and emerging research, patient cases from participating junior clinical investigators and senior clinical investigator perspectives on relevant research data informing clinical decision-making for patients with metastatic triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Drs Rita Nanda, Sara M Tolaney, Julia Foldi, Laura Huppert and Saba Shaikh discuss available and emerging research, patient cases from participating junior clinical investigators and senior clinical investigator perspectives on relevant research data informing clinical decision-making for patients with metastatic triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>99c0bb78-f3fa-4d24-96fa-98567ad2e666Wed, 08 May 2024 14:00:00 -040002:13:01falsefull11 <p>Drs Rita Nanda, Sara M Tolaney, Julia Foldi, Laura Huppert and Saba Shaikh discuss available and emerging research, patient cases from participating junior clinical investigators and senior clinical investigator perspectives on relevant research data informing clinical decision-making for patients with metastatic triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/MetastaticTNBC2023/CaseLibrary" rel="nofollow">here</a>. </p> Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Urothelial Bladder Cancer — Part 3 of a Special 3-Part EditionRole of HER2-Directed Therapy in the Treatment of HER2-Expressing Urothelial Bladder Cancer — Part 3 of a Special 3-Part EditionDr Matthew D Galsky from Icahn School of Medicine at Mount Sinai in New York, New York, summarizes treatment options for patients with HER2-altered genitourinary cancers and reviews recent emerging clinical trial data in the field, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Matthew D Galsky from Icahn School of Medicine at Mount Sinai in New York, New York, summarizes treatment options for patients with HER2-altered genitourinary cancers and reviews recent emerging clinical trial data in the field, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>9b3ed58a-99d1-4319-a369-95e5d5f56afeMon, 06 May 2024 08:00:00 -040001:07:29falsefull11 <p>Dr Matthew D Galsky from Icahn School of Medicine at Mount Sinai in New York, New York, summarizes treatment options for patients with HER2-altered genitourinary cancers and reviews recent emerging clinical trial data in the field, moderated by Dr Neil Love. Produced by Research To Practice.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayHER2PanTumor23/3GU" rel="nofollow">here</a>. </p> Year in Review: Novel Treatments and Strategies in Gastroesophageal CancerYear in Review: Novel Treatments and Strategies in Gastroesophageal CancerProf Eric Van Cutsem from University Hospitals Leuven in Leuven, Belgium, discusses recent updates on available and novel treatment strategies for gastroesophageal cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Prof Eric Van Cutsem from University Hospitals Leuven in Leuven, Belgium, discusses recent updates on available and novel treatment strategies for gastroesophageal cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>c923c224-c51c-459c-9241-d5f6ece95a8fFri, 03 May 2024 11:00:00 -040059:47falsefull11 <p>Prof Eric Van Cutsem from University Hospitals Leuven in Leuven, Belgium, discusses recent updates on available and novel treatment strategies for gastroesophageal cancer, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/YiR2023/Gastroesophageal2" rel="nofollow">here</a>. </p> Meet The Professor: Optimizing the Management of Myelofibrosis — Part 2 of a 2-Part SeriesMeet The Professor: Optimizing the Management of Myelofibrosis — Part 2 of a 2-Part SeriesDr Ruben A Mesa from Wake Forest University School of Medicine in Winston-Salem, North Carolina, discusses recent updates on available and novel treatment strategies for myelofibrosis, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Ruben A Mesa from Wake Forest University School of Medicine in Winston-Salem, North Carolina, discusses recent updates on available and novel treatment strategies for myelofibrosis, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>b2790ffd-3ae0-40c6-9d67-6b951d8168f1Wed, 01 May 2024 16:00:00 -040001:00:54falsefull11 <p>Dr Ruben A Mesa from Wake Forest University School of Medicine in Winston-Salem, North Carolina, discusses recent updates on available and novel treatment strategies for myelofibrosis, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/MTPMF23/Part2" rel="nofollow">here</a>. </p> Striving for Consensus: Current and Future Management of Paroxysmal Nocturnal HemoglobinuriaStriving for Consensus: Current and Future Management of Paroxysmal Nocturnal HemoglobinuriaDr Carlos de Castro, Prof Alexander Röth and Dr Ilene Weitz summarize the biology of paroxysmal nocturnal hemoglobinuria, current treatment approaches, and practical considerations for patients with the disease, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Carlos de Castro, Prof Alexander Röth and Dr Ilene Weitz summarize the biology of paroxysmal nocturnal hemoglobinuria, current treatment approaches, and practical considerations for patients with the disease, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>2c02caba-814b-4e95-85fe-59d38c256b05Fri, 26 Apr 2024 11:00:00 -040001:37:17falsefull11 <p>Dr Carlos de Castro, Prof Alexander Röth and Dr Ilene Weitz summarize the biology of paroxysmal nocturnal hemoglobinuria, current treatment approaches, and practical considerations for patients with the disease, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/PNHThinkTank2024" rel="nofollow">here</a>. </p> Special Edition – Prostate Cancer Updates from a CME Program Held at the 2024 Genitourinary Cancers SymposiumSpecial Edition – Prostate Cancer Updates from a CME Program Held at the 2024 Genitourinary Cancers SymposiumDr Emmanuel Antonarakis from the University of Minnesota in Minneapolis reviews research findings presented at the 2024 Genitourinary Cancers Symposium and provides his perspectives on current and novel treatment approaches for prostate cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Emmanuel Antonarakis from the University of Minnesota in Minneapolis reviews research findings presented at the 2024 Genitourinary Cancers Symposium and provides his perspectives on current and novel treatment approaches for prostate cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>8b3649f9-94ad-45f4-84d7-5fee3876d060Wed, 24 Apr 2024 11:00:00 -040059:59falsefull11 <p>Dr Emmanuel Antonarakis from the University of Minnesota in Minneapolis reviews research findings presented at the 2024 Genitourinary Cancers Symposium and provides his perspectives on current and novel treatment approaches for prostate cancer, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/ASCOGU24/Review/Prostate" rel="nofollow">here</a>. </p> Key Presentations on Myeloproliferative Neoplasms from Recent Major ConferencesKey Presentations on Myeloproliferative Neoplasms from Recent Major ConferencesDr Naveen Pemmaraju from The University of Texas MD Anderson Cancer Center in Houston discusses updated findings from ASH 2023 on management approaches for myelofibrosis and polycythemia vera, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Naveen Pemmaraju from The University of Texas MD Anderson Cancer Center in Houston discusses updated findings from ASH 2023 on management approaches for myelofibrosis and polycythemia vera, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>e97d241a-a066-4270-af66-33af80a9b864Tue, 23 Apr 2024 16:00:00 -040001:04:36falsefull11 <p>Dr Naveen Pemmaraju from The University of Texas MD Anderson Cancer Center in Houston discusses updated findings from ASH 2023 on management approaches for myelofibrosis and polycythemia vera, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayPostASH24/MPN" rel="nofollow">here</a>.</p> Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Gastrointestinal Cancers — Part 2 of a Special 3-Part EditionRole of HER2-Directed Therapy in the Treatment of HER2-Expressing Gastrointestinal Cancers — Part 2 of a Special 3-Part EditionDr Kanwal Raghav from The University of Texas MD Anderson Cancer Center in Houston discusses the role of HER2-directed therapy in the treatment of gastrointestinal tumors beyond gastroesophageal cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Kanwal Raghav from The University of Texas MD Anderson Cancer Center in Houston discusses the role of HER2-directed therapy in the treatment of gastrointestinal tumors beyond gastroesophageal cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>ad81eedc-4dbc-4dc6-8829-8ae795806e02Mon, 15 Apr 2024 12:00:00 -040037:24falsefull11 <p>Dr Kanwal Raghav from The University of Texas MD Anderson Cancer Center in Houston discusses the role of HER2-directed therapy in the treatment of gastrointestinal tumors beyond gastroesophageal cancer, moderated by Dr Neil Love. Produced by Research To Practice.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayHER2PanTumor23/2GI" rel="nofollow">here</a>.</p> Key Presentations on Chronic Lymphocytic Leukemia from Recent Major ConferencesKey Presentations on Chronic Lymphocytic Leukemia from Recent Major ConferencesDr Bita Fakhri from Stanford University in Stanford, California, discusses recent updates from ASH 2023 for the management of chronic lymphocytic leukemia and Richter’s syndrome, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Bita Fakhri from Stanford University in Stanford, California, discusses recent updates from ASH 2023 for the management of chronic lymphocytic leukemia and Richter’s syndrome, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>65a1c764-6aa9-404f-a552-a0285acc630bFri, 12 Apr 2024 16:00:00 -040001:35:12falsefull11 <p>Dr Bita Fakhri from Stanford University in Stanford, California, discusses recent updates from ASH 2023 for the management of chronic lymphocytic leukemia and Richter’s syndrome, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayPostASH24/CLL" rel="nofollow">here</a>. </p> Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Colorectal CancerYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Colorectal CancerProfessor Thierry André from the Hôpital Saint-Antoine in Paris, France, and Dr Arvind Dasari from MD Anderson Cancer Center in Houston, Texas, discuss recent developments regarding available and novel treatment strategies for colorectal cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Professor Thierry André from the Hôpital Saint-Antoine in Paris, France, and Dr Arvind Dasari from MD Anderson Cancer Center in Houston, Texas, discuss recent developments regarding available and novel treatment strategies for colorectal cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>77c8a047-4537-420f-8493-66fdb8386eddFri, 05 Apr 2024 11:15:00 -040058:43falsefull11 <p>Professor Thierry André from the Hôpital Saint-Antoine in Paris, France, and Dr Arvind Dasari from MD Anderson Cancer Center in Houston, Texas, discuss recent developments regarding available and novel treatment strategies for colorectal cancer, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/YiR2023/CRC" rel="nofollow">here</a>. </p> Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Urothelial Bladder CancerYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Urothelial Bladder CancerDr Shilpa Gupta from the Taussig Cancer Institute in Cleveland, Ohio, and Prof Thomas Powles from the Barts Cancer Institute in London, United Kingdom, discuss clinical decision-making with numerous treatment strategies for urothelial bladder cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Shilpa Gupta from the Taussig Cancer Institute in Cleveland, Ohio, and Prof Thomas Powles from the Barts Cancer Institute in London, United Kingdom, discuss clinical decision-making with numerous treatment strategies for urothelial bladder cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>5e6236fc-d197-4b13-abf2-ffee9f29b2c9Fri, 05 Apr 2024 11:00:00 -040001:00:56falsefull11 <p>Dr Shilpa Gupta from the Taussig Cancer Institute in Cleveland, Ohio, and Prof Thomas Powles from the Barts Cancer Institute in London, United Kingdom, discuss clinical decision-making with numerous treatment strategies for urothelial bladder cancer, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/YiR2023/Bladder" rel="nofollow">here</a>. </p> The Emerging Role of B7-H3-Targeted Antibody-Drug ConjugatesThe Emerging Role of B7-H3-Targeted Antibody-Drug ConjugatesDr Manish Patel from the Florida Cancer Specialists & Research Institute in Sarasota, Florida, discusses drug development, early-phase clinical trials and the emerging field of B7-H3-targeted antibody-drug conjugates for solid tumors, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Manish Patel from the Florida Cancer Specialists & Research Institute in Sarasota, Florida, discusses drug development, early-phase clinical trials and the emerging field of B7-H3-targeted antibody-drug conjugates for solid tumors, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>6b27fcb8-2415-42f9-b0e1-a4bf2f3c8c9bWed, 03 Apr 2024 11:00:00 -040001:14:03falsefull11 <p>Dr Manish Patel from the Florida Cancer Specialists &amp; Research Institute in Sarasota, Florida, discusses drug development, early-phase clinical trials and the emerging field of B7-H3-targeted antibody-drug conjugates for solid tumors, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayB7H3ADCs23" rel="nofollow">here</a>.</p> Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Prostate CancerYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Prostate CancerDr Andrew J Armstrong from the Duke Cancer Institute Center in Durham, North Carolina and Dr Maha Hussain from Robert H Lurie Comprehensive Cancer Center in Chicago summarize recent data sets from 2023 on hormonal therapies and other emerging treatment approaches for patients with prostate cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Andrew J Armstrong from the Duke Cancer Institute Center in Durham, North Carolina and Dr Maha Hussain from Robert H Lurie Comprehensive Cancer Center in Chicago summarize recent data sets from 2023 on hormonal therapies and other emerging treatment approaches for patients with prostate cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>7a61c358-909f-42bd-bd6d-3ac133cb1422Wed, 27 Mar 2024 14:00:00 -040001:01:37falsefull11 <p>Dr Andrew J Armstrong from the Duke Cancer Institute Center in Durham, North Carolina and Dr Maha Hussain from Robert H Lurie Comprehensive Cancer Center in Chicago summarize recent data sets from 2023 on hormonal therapies and other emerging treatment approaches for patients with prostate cancer, moderated by Dr Neil Love. Produced by Research To Practice.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/YiR2023/Prostate" rel="nofollow">here</a>.</p> Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in LymphomaYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in LymphomaDr Andrew M Evens from the Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Sonali M Smith from the University of Chicago in Illinois discuss clinical decision-making with numerous treatment strategies for lymphoma, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Andrew M Evens from the Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Sonali M Smith from the University of Chicago in Illinois discuss clinical decision-making with numerous treatment strategies for lymphoma, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>f9c4411d-f122-44fd-a804-7c9d9d63d1fcTue, 26 Mar 2024 15:00:00 -040001:00:13falsefull11 <p>Dr Andrew M Evens from the Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Sonali M Smith from the University of Chicago in Illinois discuss clinical decision-making with numerous treatment strategies for lymphoma, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/YiR2023/Lymphoma" rel="nofollow">here</a>.</p> Overcoming Endocrine Resistance in ER-Positive Metastatic Breast CancerOvercoming Endocrine Resistance in ER-Positive Metastatic Breast CancerDr Seth Wander from Harvard Medical School in Boston, Massachusetts, discusses mechanisms underlying endocrine resistance in breast cancer and optimal therapeutic approaches for patients who experience disease progression while or after receiving endocrine therapy, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Seth Wander from Harvard Medical School in Boston, Massachusetts, discusses mechanisms underlying endocrine resistance in breast cancer and optimal therapeutic approaches for patients who experience disease progression while or after receiving endocrine therapy, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>e400ac8a-70a3-46c1-8835-4661f56fe7deMon, 25 Mar 2024 15:00:00 -040001:19:56falsefull11 <p>Dr Seth Wander from Harvard Medical School in Boston, Massachusetts, discusses mechanisms underlying endocrine resistance in breast cancer and optimal therapeutic approaches for patients who experience disease progression while or after receiving endocrine therapy, moderated by Dr Neil Love. Produced by Research To Practice.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayEndocrineERPosmBC23" rel="nofollow">here</a>.</p> Consensus or Controversy? Immune Checkpoint Inhibitors in the Management of Hepatobiliary Cancers — A 2024 Post-ASCO Gastrointestinal Cancers Symposium ReviewConsensus or Controversy? Immune Checkpoint Inhibitors in the Management of Hepatobiliary Cancers — A 2024 Post-ASCO Gastrointestinal Cancers Symposium ReviewDr Robin K (Katie) Kelley from the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, and Dr Mark Yarchoan from the Johns Hopkins Sidney Kimmel Cancer Center in Baltimore, Maryland, discuss clinical decision-making with numerous treatment strategies for hepatocellular carcinoma and biliary tract cancers.

CME information and select publications here.

]]>Dr Robin K (Katie) Kelley from the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, and Dr Mark Yarchoan from the Johns Hopkins Sidney Kimmel Cancer Center in Baltimore, Maryland, discuss clinical decision-making with numerous treatment strategies for hepatocellular carcinoma and biliary tract cancers.

CME information and select publications here.

]]>8fb083a6-5a38-4bfd-96d9-c28b0bcebb2fThu, 21 Mar 2024 13:00:00 -040001:01:41falsefull11 <p>Dr Robin K (Katie) Kelley from the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, and Dr Mark Yarchoan from the Johns Hopkins Sidney Kimmel Cancer Center in Baltimore, Maryland, discuss clinical decision-making with numerous treatment strategies for hepatocellular carcinoma and biliary tract cancers.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/ASCOGI24/Hepatobiliary2" rel="nofollow">here</a>.</p> Promising Therapeutic Strategies for Patients with Progressive Metastatic Non-Small Cell Lung CancerPromising Therapeutic Strategies for Patients with Progressive Metastatic Non-Small Cell Lung CancerDr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, discusses available data with antibody-drug conjugates with established and investigational targets in patients with non-small cell lung cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, discusses available data with antibody-drug conjugates with established and investigational targets in patients with non-small cell lung cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>32fc3332-9644-49eb-9eb2-d1ece6154d52Tue, 19 Mar 2024 13:00:00 -040001:02:58falsefull11 <p>Dr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, discusses available data with antibody-drug conjugates with established and investigational targets in patients with non-small cell lung cancer, moderated by Dr Neil Love. Produced by Research To Practice.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayCEACAM5NSCLC23" rel="nofollow">here</a>.</p> Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in HER2-Positive and Triple-Negative Breast CancerYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in HER2-Positive and Triple-Negative Breast CancerDr Ian E Krop from the Yale Cancer Center in New Haven, Connecticut, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood, Kansas, discuss patient cases and treatment strategies for HER2-positive and triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Ian E Krop from the Yale Cancer Center in New Haven, Connecticut, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood, Kansas, discuss patient cases and treatment strategies for HER2-positive and triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>8ed67a48-0c54-402d-830d-65b7bd6e3737Fri, 15 Mar 2024 10:00:00 -040001:05:47falsefull11 <p>Dr Ian E Krop from the Yale Cancer Center in New Haven, Connecticut, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood, Kansas, discuss patient cases and treatment strategies for HER2-positive and triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/YiR2023/HER2PosTNBC" rel="nofollow">here</a>.</p> Virtual Case Library: Metastatic Urothelial Bladder CancerVirtual Case Library: Metastatic Urothelial Bladder CancerDrs Petros Grivas, Vadim S Koshkin, Kriti Mittal, Mamta Parikh and Scott T Tagawa discuss available and emerging research, patient cases from participating junior clinical investigators and the perspectives of senior clinical investigator faculty on data informing their decision-making for patients with metastatic urothelial bladder cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Drs Petros Grivas, Vadim S Koshkin, Kriti Mittal, Mamta Parikh and Scott T Tagawa discuss available and emerging research, patient cases from participating junior clinical investigators and the perspectives of senior clinical investigator faculty on data informing their decision-making for patients with metastatic urothelial bladder cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>d508a905-b1b7-4d27-8ba3-b0dbac2a665aWed, 13 Mar 2024 15:00:00 -040002:08:14falsefull11 <p>Drs Petros Grivas, Vadim S Koshkin, Kriti Mittal, Mamta Parikh and Scott T Tagawa discuss available and emerging research, patient cases from participating junior clinical investigators and the perspectives of senior clinical investigator faculty on data informing their decision-making for patients with metastatic urothelial bladder cancer, moderated by Dr Neil Love. Produced by Research To Practice.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/MetastaticBladder2023/CaseLibrary" rel="nofollow">here</a>.</p> Understanding the Current and Future Role of Oral SERDs (Selective Estrogen Receptor Degraders) in the Management of ER-Positive Metastatic Breast CancerUnderstanding the Current and Future Role of Oral SERDs (Selective Estrogen Receptor Degraders) in the Management of ER-Positive Metastatic Breast CancerDr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York City discusses available and emerging data with oral SERDs for patients with ER-positive metastatic breast cancer.

CME information and select publications here.

]]>Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York City discusses available and emerging data with oral SERDs for patients with ER-positive metastatic breast cancer.

CME information and select publications here.

]]>76dc83ce-a64c-45da-bd5f-d8a1967310a6Mon, 11 Mar 2024 11:00:00 -040037:38falsefull11 <p>Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York City discusses available and emerging data with oral SERDs for patients with ER-positive metastatic breast cancer.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayOralSERDsmBC23" rel="nofollow">here</a>.</p> Meet The Professor: Optimizing the Management of Myelofibrosis — Part 1 of a 2-Part SeriesMeet The Professor: Optimizing the Management of Myelofibrosis — Part 1 of a 2-Part SeriesDr Stephen T Oh from Washington University School of Medicine in St Louis, Missouri, discusses current and emerging monitoring and management strategies for myelofibrosis, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Stephen T Oh from Washington University School of Medicine in St Louis, Missouri, discusses current and emerging monitoring and management strategies for myelofibrosis, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>0c8ddb9a-3691-4cd8-903f-9b6ccabd3286Fri, 08 Mar 2024 10:00:00 -040001:00:13falsefull11 <p>Dr Stephen T Oh from Washington University School of Medicine in St Louis, Missouri, discusses current and emerging monitoring and management strategies for myelofibrosis, moderated by Dr Neil Love. Produced by Research To Practice.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/MTPMF23/Part1" rel="nofollow">here</a>.</p> Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Gastroesophageal CancersYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Gastroesophageal CancersDr Yelena Y Janjigian from Memorial Sloan Kettering Cancer Center in New York and Dr Zev Wainberg from UCLA Jonsson Comprehensive Cancer Center in Los Angeles discuss the management of gastroesophageal cancers and review emerging data sets in the field, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Yelena Y Janjigian from Memorial Sloan Kettering Cancer Center in New York and Dr Zev Wainberg from UCLA Jonsson Comprehensive Cancer Center in Los Angeles discuss the management of gastroesophageal cancers and review emerging data sets in the field, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>68a90834-cbaa-4bef-9f31-b1807f729c6dWed, 06 Mar 2024 12:00:00 -040001:02:36falsefull11 <p>Dr Yelena Y Janjigian from Memorial Sloan Kettering Cancer Center in New York and Dr Zev Wainberg from UCLA Jonsson Comprehensive Cancer Center in Los Angeles discuss the management of gastroesophageal cancers and review emerging data sets in the field, moderated by Dr Neil Love. Produced by Research To Practice.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/YiR2023/Gastroesophageal" rel="nofollow">here</a>.</p> Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Chronic Lymphocytic LeukemiaYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Chronic Lymphocytic LeukemiaDr Lindsey Roeker from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Jeff Sharman of the US Oncology Network in Eugene, Oregon, discuss relevant datasets from 2023 on the management of chronic lymphocytic leukemia, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Lindsey Roeker from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Jeff Sharman of the US Oncology Network in Eugene, Oregon, discuss relevant datasets from 2023 on the management of chronic lymphocytic leukemia, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>a48eb2da-9f4f-457c-8b74-273518384401Mon, 26 Feb 2024 14:30:00 -040058:02falsefull11 <p>Dr Lindsey Roeker from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Jeff Sharman of the US Oncology Network in Eugene, Oregon, discuss relevant datasets from 2023 on the management of chronic lymphocytic leukemia, moderated by Dr Neil Love. Produced by Research To Practice.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/YiR2023/CLL" rel="nofollow">here</a>.</p> Consensus or Controversy? Investigator Perspectives on the Current and Future Role of Immune Checkpoint Inhibitors in the Management of Hepatobiliary CancersConsensus or Controversy? Investigator Perspectives on the Current and Future Role of Immune Checkpoint Inhibitors in the Management of Hepatobiliary CancersDr Ahmed Omar Kaseb from the University of Texas MD Anderson Cancer Center in Houston, Texas, and Prof Arndt Vogel from Schwartz Reisman Liver Research Centre in Toronto, Ontario, discuss the optimal selection and sequencing of checkpoint inhibitor therapy for patients with hepatobiliary cancers, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Ahmed Omar Kaseb from the University of Texas MD Anderson Cancer Center in Houston, Texas, and Prof Arndt Vogel from Schwartz Reisman Liver Research Centre in Toronto, Ontario, discuss the optimal selection and sequencing of checkpoint inhibitor therapy for patients with hepatobiliary cancers, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>d3450b21-8a01-4af8-8f14-a35d43dcd87aFri, 23 Feb 2024 15:00:00 -040001:00:34falsefull11 <p>Dr Ahmed Omar Kaseb from the University of Texas MD Anderson Cancer Center in Houston, Texas, and Prof Arndt Vogel from Schwartz Reisman Liver Research Centre in Toronto, Ontario, discuss the optimal selection and sequencing of checkpoint inhibitor therapy for patients with hepatobiliary cancers, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/ASCOGI24/Hepatobiliary1" rel="nofollow">here</a>.</p> Meet The Professor: Optimizing the Management of Ovarian Cancer — Part 4 of a 4-Part SeriesMeet The Professor: Optimizing the Management of Ovarian Cancer — Part 4 of a 4-Part SeriesDr Bradley J Monk from the Florida Cancer Specialists & Research Institute in West Palm Beach, Florida, discusses real-world patient cases and treatment strategies for ovarian cancer.

CME information and select publications here.

]]>Dr Bradley J Monk from the Florida Cancer Specialists & Research Institute in West Palm Beach, Florida, discusses real-world patient cases and treatment strategies for ovarian cancer.

CME information and select publications here.

]]>5a5637f0-8be8-4cd7-8e2e-e828e5eddc82Fri, 16 Feb 2024 12:00:00 -040059:53falsefull11 <p>Dr Bradley J Monk from the Florida Cancer Specialists &amp; Research Institute in West Palm Beach, Florida, discusses real-world patient cases and treatment strategies for ovarian cancer.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/MTPOvarian23/Part4" rel="nofollow">here</a>.</p> Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hormone Receptor-Positive Breast CancerYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hormone Receptor-Positive Breast CancerDr Stephanie L Graff from the Legorreta Cancer Center at Brown University in Providence, Rhode Island, and Dr Erica Mayer from Dana-Farber Cancer Institute in Boston discuss treatment decision-making involving approved and investigational strategies for the management of hormone receptor-positive breast cancer.

CME information and select publications here.

]]>Dr Stephanie L Graff from the Legorreta Cancer Center at Brown University in Providence, Rhode Island, and Dr Erica Mayer from Dana-Farber Cancer Institute in Boston discuss treatment decision-making involving approved and investigational strategies for the management of hormone receptor-positive breast cancer.

CME information and select publications here.

]]>cb2db1b1-2cf7-473c-a24c-e22cfbeaf962Wed, 31 Jan 2024 12:00:00 -040001:04:53falsefull11 <p>Dr Stephanie L Graff from the Legorreta Cancer Center at Brown University in Providence, Rhode Island, and Dr Erica Mayer from Dana-Farber Cancer Institute in Boston discuss treatment decision-making involving approved and investigational strategies for the management of hormone receptor-positive breast cancer.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/YiR2023/HRPosBC" rel="nofollow">here</a>.</p> Meet The Professor: Optimizing the Management of Ovarian Cancer — Part 3 of a 4-Part SeriesMeet The Professor: Optimizing the Management of Ovarian Cancer — Part 3 of a 4-Part SeriesDr Antonio González-Martín from the Clínica Universidad de Navarra in Madrid, Spain, discusses real-world patient cases and treatment strategies for ovarian cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Antonio González-Martín from the Clínica Universidad de Navarra in Madrid, Spain, discusses real-world patient cases and treatment strategies for ovarian cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>f655e626-eb09-41fa-a271-b03e72aecad4Tue, 23 Jan 2024 09:00:00 -040001:01:37falsefull11 <p>Dr Antonio González-Martín from the Clínica Universidad de Navarra in Madrid, Spain, discusses real-world patient cases and treatment strategies for ovarian cancer, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/MTPOvarian23/Part3" rel="nofollow">here</a>.</p> Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 3 of a 3-Part SeriesMeet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 3 of a 3-Part SeriesDr Richard M Stone from Dana-Farber Cancer Institute in Boston discusses the optimal selection and sequencing of systemic therapies for patients with acute myeloid leukemia and myelodysplastic syndromes, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Richard M Stone from Dana-Farber Cancer Institute in Boston discusses the optimal selection and sequencing of systemic therapies for patients with acute myeloid leukemia and myelodysplastic syndromes, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>cb47eb12-1715-494d-97b3-84ca9b1ecef8Tue, 16 Jan 2024 16:00:00 -040001:00:25falsefull11 <p>Dr Richard M Stone from Dana-Farber Cancer Institute in Boston discusses the optimal selection and sequencing of systemic therapies for patients with acute myeloid leukemia and myelodysplastic syndromes, moderated by Dr Neil Love. Produced by Research To Practice.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/MTPAMLMDS23/Part3" rel="nofollow">here</a>.</p> Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Gynecologic Cancers — Part 1 of a Special 3-Part EditionRole of HER2-Directed Therapy in the Treatment of HER2-Expressing Gynecologic Cancers — Part 1 of a Special 3-Part EditionDr David M O’Malley from The Ohio State University and the James Comprehensive Cancer Center in Columbus, Ohio discusses the role of HER2-directed therapy in the treatment of gynecologic cancers.

CME information and select publications here.

]]>Dr David M O’Malley from The Ohio State University and the James Comprehensive Cancer Center in Columbus, Ohio discusses the role of HER2-directed therapy in the treatment of gynecologic cancers.

CME information and select publications here.

]]>3c24afe5-1c47-424d-8df6-2f06fa8c4ebbTue, 19 Dec 2023 14:00:00 -040001:05:36falsefull11 <p>Dr David M O’Malley from The Ohio State University and the James Comprehensive Cancer Center in Columbus, Ohio discusses the role of HER2-directed therapy in the treatment of gynecologic cancers.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayHER2PanTumor23/1Gyn" rel="nofollow">here</a>.</p> Inside the Issue: Targeted and Immunotherapeutic Approaches for Biliary Tract CancersInside the Issue: Targeted and Immunotherapeutic Approaches for Biliary Tract CancersDr Lipika Goyal from The Stanford Cancer Center and Dr Milind Javle from The University of Texas MD Anderson Cancer Center in Houston discuss targeted and immunotherapeutic approaches for biliary tract cancers, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Lipika Goyal from The Stanford Cancer Center and Dr Milind Javle from The University of Texas MD Anderson Cancer Center in Houston discuss targeted and immunotherapeutic approaches for biliary tract cancers, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>d6266240-3d5a-43df-9a05-7d54326676d3Wed, 13 Dec 2023 14:00:00 -040001:00:26falsefull11 <p>Dr Lipika Goyal from The Stanford Cancer Center and Dr Milind Javle from The University of Texas MD Anderson Cancer Center in Houston discuss targeted and immunotherapeutic approaches for biliary tract cancers, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://researchtopractice.com/InsideTheIssue2023/BTC" rel="nofollow">here</a>.</p> Implications of Recent Data Sets for the Current and Future Management of Lung CancerImplications of Recent Data Sets for the Current and Future Management of Lung CancerDr Luis Paz-Ares from the National Oncology Research Center in Madrid, Spain, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, and Dr David R Spigel from the Sarah Cannon Research Institute in Nashville, Tennessee, discuss key presentations from the 2023 ESMO Congress for the management of lung cancer, moderated by Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Luis Paz-Ares from the National Oncology Research Center in Madrid, Spain, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, and Dr David R Spigel from the Sarah Cannon Research Institute in Nashville, Tennessee, discuss key presentations from the 2023 ESMO Congress for the management of lung cancer, moderated by Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>d988c9e3-1a2d-49f4-90fc-65f69550c094Fri, 08 Dec 2023 14:00:00 -040001:30:17falsefull11 <p>Dr Luis Paz-Ares from the National Oncology Research Center in Madrid, Spain, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, and Dr David R Spigel from the Sarah Cannon Research Institute in Nashville, Tennessee, discuss key presentations from the 2023 ESMO Congress for the management of lung cancer, moderated by Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/PostESMO23/Lung" rel="nofollow">here</a>. </p> Meet The Professor: Optimizing the Management of Gastroesophageal Cancers — Part 3 of a 3-Part SeriesMeet The Professor: Optimizing the Management of Gastroesophageal Cancers — Part 3 of a 3-Part SeriesFeaturing a discussion on optimizing the management of gastroesophageal cancers with Dr Samuel J Klempner, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Featuring a discussion on optimizing the management of gastroesophageal cancers with Dr Samuel J Klempner, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>75d3bb91-f3f1-40f3-822c-675fb7efcfbeTue, 05 Dec 2023 01:00:00 -040001:01:54falsefull11 <p>Featuring a discussion on optimizing the management of gastroesophageal cancers with Dr Samuel J Klempner, moderated by Dr Neil Love. Produced by Research To Practice.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/MTPGastroesophageal23/Part3" rel="nofollow">here</a>.</p> Implications of Recent Data Sets for the Current and Future Management of Breast CancerImplications of Recent Data Sets for the Current and Future Management of Breast CancerDr Aditya Bardia from Massachusetts General Hospital and Dr Sara M Tolaney from the Dana-Farber Cancer Institute, both in Boston, Massachusetts, discuss key presentations on the management of breast cancer from the 2023 ESMO Congress, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Aditya Bardia from Massachusetts General Hospital and Dr Sara M Tolaney from the Dana-Farber Cancer Institute, both in Boston, Massachusetts, discuss key presentations on the management of breast cancer from the 2023 ESMO Congress, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>f0e3bd52-63bc-4726-a898-0c2c5351724fWed, 29 Nov 2023 12:00:00 -040001:03:09falsefull11 <p>Dr Aditya Bardia from Massachusetts General Hospital and Dr Sara M Tolaney from the Dana-Farber Cancer Institute, both in Boston, Massachusetts, discuss key presentations on the management of breast cancer from the 2023 ESMO Congress, moderated by Dr Neil Love. Produced by Research To Practice.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/PostESMO23/Breast" rel="nofollow">here</a>.</p> Implications of Recent Data Sets for the Current and Future Management of Gynecologic CancersImplications of Recent Data Sets for the Current and Future Management of Gynecologic CancersDr Richard Penson from Massachusetts General Hospital in Boston, Massachusetts and Dr Krishnansu Tewari from the University of California, Irvine, discuss updated data from the 2023 ESMO Congress on optimal management approaches for gynecologic cancers.

CME information and select publications here.

]]>Dr Richard Penson from Massachusetts General Hospital in Boston, Massachusetts and Dr Krishnansu Tewari from the University of California, Irvine, discuss updated data from the 2023 ESMO Congress on optimal management approaches for gynecologic cancers.

CME information and select publications here.

]]>9f021442-cc09-411f-83c5-dee9d6810eb3Mon, 20 Nov 2023 08:00:00 -040001:01:30falsefull11 <p>Dr Richard Penson from Massachusetts General Hospital in Boston, Massachusetts and Dr Krishnansu Tewari from the University of California, Irvine, discuss updated data from the 2023 ESMO Congress on optimal management approaches for gynecologic cancers. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/PostESMO23/Gyn" rel="nofollow">here</a>.</p> Meet The Professor: Optimizing the Management of Gastroesophageal Cancers — Part 2 of a 3-Part SeriesMeet The Professor: Optimizing the Management of Gastroesophageal Cancers — Part 2 of a 3-Part SeriesProf Eric Van Cutsem from the University Hospitals Leuven in Leuven, Belgium, discusses optimizing the management of gastroesophageal cancers, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Prof Eric Van Cutsem from the University Hospitals Leuven in Leuven, Belgium, discusses optimizing the management of gastroesophageal cancers, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>782d27c6-398e-4f6e-9e9b-e2624cfb1b60Tue, 14 Nov 2023 10:00:00 -040001:02:51falsefull11 <p>Prof Eric Van Cutsem from the University Hospitals Leuven in Leuven, Belgium, discusses optimizing the management of gastroesophageal cancers, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/MTPGastroesophageal23/Part2" rel="nofollow">here</a>.</p> Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 2 of a 3-Part SeriesMeet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 2 of a 3-Part SeriesDr Gail J Roboz from Weill Cornell Medicine in New York discusses the optimal management of acute myeloid leukemia and myelodysplastic syndromes, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>Dr Gail J Roboz from Weill Cornell Medicine in New York discusses the optimal management of acute myeloid leukemia and myelodysplastic syndromes, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

]]>a086ba93-ead4-45d6-ab88-dc5e47cfe14aFri, 10 Nov 2023 14:00:00 -040001:01:31falsefull11 <p>Dr Gail J Roboz from Weill Cornell Medicine in New York discusses the optimal management of acute myeloid leukemia and myelodysplastic syndromes, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="http://www.ResearchToPractice.com/MTPAMLMDS23/Part2" rel="nofollow">here</a>.</p> Meet The Professor: Optimizing the Management of Ovarian Cancer — Part 2 of a 4-Part SeriesMeet The Professor: Optimizing the Management of Ovarian Cancer — Part 2 of a 4-Part SeriesDr David M O’Malley from the Ohio State University and the James Cancer Center in Columbus, Ohio, discusses optimizing the management of ovarian cancer moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here

]]>Dr David M O’Malley from the Ohio State University and the James Cancer Center in Columbus, Ohio, discusses optimizing the management of ovarian cancer moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here

]]>7d299170-80bf-41b4-be2f-3dfb671d23e3Wed, 01 Nov 2023 10:00:00 -040001:03:54falsefull11 <p>Dr David M O’Malley from the Ohio State University and the James Cancer Center in Columbus, Ohio, discusses optimizing the management of ovarian cancer moderated by Dr Neil Love. Produced by Research To Practice.</p> <p>CME information and select publications <a href="http://www.ResearchToPractice.com/MTPOvarian23/Part2" rel="nofollow">here</a></p> Inside the Issue: Optimizing the Management of Nonmelanoma Skin CancerInside the Issue: Optimizing the Management of Nonmelanoma Skin CancerDr Nikhil Khushalani from the Moffitt Cancer Center in Tampa, Florida, and Dr Anna Pavlick from the Weill Cornell Medicine Meyer Cancer Center in New York, New York, discuss available and novel treatment strategies for cutaneous squamous cell carcinoma and basal cell carcinoma.

CME information and select publications here

]]>Dr Nikhil Khushalani from the Moffitt Cancer Center in Tampa, Florida, and Dr Anna Pavlick from the Weill Cornell Medicine Meyer Cancer Center in New York, New York, discuss available and novel treatment strategies for cutaneous squamous cell carcinoma and basal cell carcinoma.

CME information and select publications here

]]>d7a521f3-0e41-4f5b-ace1-6efdebd3bbf5Tue, 24 Oct 2023 13:00:00 -040001:01:01falsefull11 <p>Dr Nikhil Khushalani from the Moffitt Cancer Center in Tampa, Florida, and Dr Anna Pavlick from the Weill Cornell Medicine Meyer Cancer Center in New York, New York, discuss available and novel treatment strategies for cutaneous squamous cell carcinoma and basal cell carcinoma.</p> <p>CME information and select publications <a href="https://researchtopractice.com/InsidetheIssue2023/NonmelanomaSkin" rel="nofollow">here</a></p> Meet The Professor: Optimizing the Management of Gastroesophageal Cancers — Part 1 of a 3-Part SeriesMeet The Professor: Optimizing the Management of Gastroesophageal Cancers — Part 1 of a 3-Part SeriesFeaturing a discussion on current and emerging strategies for the treatment of upper GI cancers with Dr Peter C Enzinger, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here

]]>Featuring a discussion on current and emerging strategies for the treatment of upper GI cancers with Dr Peter C Enzinger, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here

]]>192ce83d-6499-4f1d-aece-85c4b5877c5aFri, 20 Oct 2023 12:45:00 -040001:03:02falsefull11 <p>Featuring a discussion on current and emerging strategies for the treatment of upper GI cancers with Dr Peter C Enzinger, moderated by Dr Neil Love. Produced by Research To Practice.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/MTPGastroesophageal23/Part1" rel="nofollow">here</a></p> Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 1 of a 3-Part SeriesMeet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 1 of a 3-Part SeriesDr Naval Daver from The University of Texas MD Anderson Cancer Center in Houston, Texas, discusses current and emerging optimal management approaches for patients with acute myeloid leukemia and myelodysplastic syndromes.

CME information and select publications here

]]>Dr Naval Daver from The University of Texas MD Anderson Cancer Center in Houston, Texas, discusses current and emerging optimal management approaches for patients with acute myeloid leukemia and myelodysplastic syndromes.

CME information and select publications here

]]>6e021335-fa8c-466a-9c9e-d334eb390102Fri, 20 Oct 2023 12:00:00 -040001:01:44falsefull11 <p>Dr Naval Daver from The University of Texas MD Anderson Cancer Center in Houston, Texas, discusses current and emerging optimal management approaches for patients with acute myeloid leukemia and myelodysplastic syndromes.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/MTPAMLMDS23/Part1" rel="nofollow">here</a></p> What Clinicians Want to Know About the Management of Relapsed/Refractory Mantle Cell LymphomaWhat Clinicians Want to Know About the Management of Relapsed/Refractory Mantle Cell LymphomaDr Toby A Eyre from the Oxford University Hospitals NHS Foundation Trust in Oxford, United Kingdom, and Dr Brad S Kahl from Siteman Cancer Center in St Louis, Missouri, discuss the management of relapsed/refractory mantle cell lymphoma.

CME information and select publications here

]]>Dr Toby A Eyre from the Oxford University Hospitals NHS Foundation Trust in Oxford, United Kingdom, and Dr Brad S Kahl from Siteman Cancer Center in St Louis, Missouri, discuss the management of relapsed/refractory mantle cell lymphoma.

CME information and select publications here

]]>7af625b0-7991-4480-b641-f18621e4f59cWed, 18 Oct 2023 11:00:00 -040001:01:33falsefull11 <p>Dr Toby A Eyre from the Oxford University Hospitals NHS Foundation Trust in Oxford, United Kingdom, and Dr Brad S Kahl from Siteman Cancer Center in St Louis, Missouri, discuss the management of relapsed/refractory mantle cell lymphoma.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/RRMCL2023" rel="nofollow">here</a></p> Key Presentations on Multiple Myeloma from Recent Major Oncology/Hematology ConferencesKey Presentations on Multiple Myeloma from Recent Major Oncology/Hematology ConferencesDr Joseph Mikhael from the City of Hope Cancer Center in Phoenix, Arizona, discusses recent updates and future directions in the management of newly diagnosed and relapsed/refractory multiple myeloma.

CME information and select publications here

]]>Dr Joseph Mikhael from the City of Hope Cancer Center in Phoenix, Arizona, discusses recent updates and future directions in the management of newly diagnosed and relapsed/refractory multiple myeloma.

CME information and select publications here

]]>5758b10f-4b6e-49b0-be17-47af476e848eTue, 17 Oct 2023 12:00:00 -040001:19:48falsefull11 <p>Dr Joseph Mikhael from the City of Hope Cancer Center in Phoenix, Arizona, discusses recent updates and future directions in the management of newly diagnosed and relapsed/refractory multiple myeloma.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayPostConf23/MM" rel="nofollow">here</a></p> Inside the Issue: Integrating Targeted and Immunotherapy into the Management of Localized Non-Small Cell Lung CancerInside the Issue: Integrating Targeted and Immunotherapy into the Management of Localized Non-Small Cell Lung CancerDr Jamie Chaft and Dr John Heymach discuss the optimal integration of targeted therapy and immunotherapy into the care of patients with localized non-small cell lung cancer.

CME information and select publications here

]]>Dr Jamie Chaft and Dr John Heymach discuss the optimal integration of targeted therapy and immunotherapy into the care of patients with localized non-small cell lung cancer.

CME information and select publications here

]]>8220ecbc-a622-4324-820e-30942f87bd67Fri, 13 Oct 2023 10:00:00 -040001:01:40falsefull11 <p>Dr Jamie Chaft and Dr John Heymach discuss the optimal integration of targeted therapy and immunotherapy into the care of patients with localized non-small cell lung cancer. </p> <p>CME information and select publications <a href="https://researchtopractice.com/InsidetheIssue2023/NSCLC" rel="nofollow">here</a></p> Management of Metastatic Pancreatic Cancer with Dr Michael PishvaianManagement of Metastatic Pancreatic Cancer with Dr Michael PishvaianDr Michael Pishvaian from the Johns Hopkins University School of Medicine in Washington, DC, discusses recent updates on available and novel treatment strategies for pancreatic cancer.

CME information and select publications here

]]>Dr Michael Pishvaian from the Johns Hopkins University School of Medicine in Washington, DC, discusses recent updates on available and novel treatment strategies for pancreatic cancer.

CME information and select publications here

]]>bd3bd734-d61a-4579-8ef3-508cf64169acThu, 12 Oct 2023 10:00:00 -040057:57falsefull11 <p>Dr Michael Pishvaian from the Johns Hopkins University School of Medicine in Washington, DC, discusses recent updates on available and novel treatment strategies for pancreatic cancer.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodaymPancreatic23" rel="nofollow">here</a></p> Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma with Dr Matthew MatasarBispecific Antibodies in the Management of Non-Hodgkin Lymphoma with Dr Matthew MatasarDr Matthew Matasar from the Rutgers Cancer Institute of New Jersey in New York, New York, discusses the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma.

CME information and select publications here

]]>Dr Matthew Matasar from the Rutgers Cancer Institute of New Jersey in New York, New York, discusses the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma.

CME information and select publications here

]]>301bb1ff-5ccf-41ba-831f-fd2d2248f55eWed, 11 Oct 2023 11:00:00 -040046:28falsefull11 <p>Dr Matthew Matasar from the Rutgers Cancer Institute of New Jersey in New York, New York, discusses the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayBispecificNHL23" rel="nofollow">here</a></p> Meet The Professor: Optimizing the Management of Ovarian Cancer — Part 1 of a 4-Part SeriesMeet The Professor: Optimizing the Management of Ovarian Cancer — Part 1 of a 4-Part SeriesDr Kathleen Moore from OU Health Stephenson Cancer Center in Oklahoma City discusses treatment decision-making for real-world cases and approved and investigational treatment strategies for the management of ovarian cancer.

CME information and select publications here

]]>Dr Kathleen Moore from OU Health Stephenson Cancer Center in Oklahoma City discusses treatment decision-making for real-world cases and approved and investigational treatment strategies for the management of ovarian cancer.

CME information and select publications here

]]>cad622d3-f150-43e8-b94e-8575b34392ccMon, 09 Oct 2023 10:00:00 -040001:02:10falsefull11 <p>Dr Kathleen Moore from OU Health Stephenson Cancer Center in Oklahoma City discusses treatment decision-making for real-world cases and approved and investigational treatment strategies for the management of ovarian cancer.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/MTPOvarian23/Part1" rel="nofollow">here</a></p> What Clinicians Want to Know About Anti-CD38 Antibodies in the Management of Multiple MyelomaWhat Clinicians Want to Know About Anti-CD38 Antibodies in the Management of Multiple MyelomaProfessor Philippe Moreau from the University Hospital of Nantes in France discusses anti-CD38 antibody-based treatment approaches for newly diagnosed and relapsed/refractory multiple myeloma moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here

]]>Professor Philippe Moreau from the University Hospital of Nantes in France discusses anti-CD38 antibody-based treatment approaches for newly diagnosed and relapsed/refractory multiple myeloma moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here

]]>3a47157c-fff5-4b48-a634-c819fb593e65Fri, 06 Oct 2023 11:30:00 -040047:30falsefull11 <p>Professor Philippe Moreau from the University Hospital of Nantes in France discusses anti-CD38 antibody-based treatment approaches for newly diagnosed and relapsed/refractory multiple myeloma moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/MonoclonalAntibodiesMM23" rel="nofollow">here</a></p> Practical Perspectives: Investigators Discuss Current Management and Actual Cases of Relapsed/Refractory Metastatic Colorectal CancerPractical Perspectives: Investigators Discuss Current Management and Actual Cases of Relapsed/Refractory Metastatic Colorectal CancerDr Kristen K Ciombor from the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, and Dr J Randolph Hecht from UCLA’s David Geffen School of Medicine in Santa Monica, California, discuss the current management and actual cases of relapsed/refractory metastatic colorectal cancer moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here

]]>Dr Kristen K Ciombor from the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, and Dr J Randolph Hecht from UCLA’s David Geffen School of Medicine in Santa Monica, California, discuss the current management and actual cases of relapsed/refractory metastatic colorectal cancer moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here

]]>fe822d9a-ac27-421c-b10e-39c60de590d2Fri, 06 Oct 2023 10:00:00 -040001:05:23falsefull11 <p>Dr Kristen K Ciombor from the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, and Dr J Randolph Hecht from UCLA’s David Geffen School of Medicine in Santa Monica, California, discuss the current management and actual cases of relapsed/refractory metastatic colorectal cancer moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/RRmCRC2023" rel="nofollow">here</a> </p> Blastic Plasmacytoid Dendritic Cell NeoplasmBlastic Plasmacytoid Dendritic Cell NeoplasmDr Naveen Pemmaraju from the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses current and emerging management approaches for blastic plasmacytoid dendritic cell neoplasms moderated by Dr Neil Love.

CME information and select publications here

]]>Dr Naveen Pemmaraju from the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses current and emerging management approaches for blastic plasmacytoid dendritic cell neoplasms moderated by Dr Neil Love.

CME information and select publications here

]]>c537718f-bbbb-4e77-b2cc-1c7b0c3397e2Wed, 04 Oct 2023 10:00:00 -040033:52falsefull11 <p>Dr Naveen Pemmaraju from the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses current and emerging management approaches for blastic plasmacytoid dendritic cell neoplasms moderated by Dr Neil Love.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayBPDCN23" rel="nofollow">here</a></p> Inside the Issue: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast CancerInside the Issue: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast CancerDr Hope Rugo from the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, and Dr Tiffany Traina from Memorial Sloan Kettering Cancer Center in New York, New York, discuss current and emerging optimal management approaches for metastatic triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here

]]>Dr Hope Rugo from the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, and Dr Tiffany Traina from Memorial Sloan Kettering Cancer Center in New York, New York, discuss current and emerging optimal management approaches for metastatic triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here

]]>c87567b2-4009-4d1b-8661-344ca3d2503dFri, 29 Sep 2023 11:00:00 -040001:04:49falsefull11 <p>Dr Hope Rugo from the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, and Dr Tiffany Traina from Memorial Sloan Kettering Cancer Center in New York, New York, discuss current and emerging optimal management approaches for metastatic triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/InsideTheIssue2023/TNBC" rel="nofollow">here</a></p> Emerging Role of CELMoDs (Cereblon E3 Ligase Modulators) and Other Novel Approaches to Targeting Protein Degradation Pathways in Multiple MyelomaEmerging Role of CELMoDs (Cereblon E3 Ligase Modulators) and Other Novel Approaches to Targeting Protein Degradation Pathways in Multiple MyelomaDr Paul G Richardson from Dana-Farber Cancer Institute in Boston discusses the emerging role of CELMoDs and other novel approaches to targeting protein degradation pathways in the treatment of multiple myeloma, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here

]]>Dr Paul G Richardson from Dana-Farber Cancer Institute in Boston discusses the emerging role of CELMoDs and other novel approaches to targeting protein degradation pathways in the treatment of multiple myeloma, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here

]]>27db21e3-2c37-4be1-8919-9935e2a65251Wed, 27 Sep 2023 11:00:00 -040039:10falsefull11 <p>Dr Paul G Richardson from Dana-Farber Cancer Institute in Boston discusses the emerging role of CELMoDs and other novel approaches to targeting protein degradation pathways in the treatment of multiple myeloma, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayCELMoDsMM23" rel="nofollow">here</a></p> Novel Agents and Strategies in the Treatment of Ovarian CancerNovel Agents and Strategies in the Treatment of Ovarian CancerDr Debra L Richardson from OU Health Stephenson Cancer Center in Oklahoma City discusses novel agents and strategies for ovarian cancer moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here

]]>Dr Debra L Richardson from OU Health Stephenson Cancer Center in Oklahoma City discusses novel agents and strategies for ovarian cancer moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here

]]>3191b2c2-6efe-4fee-a94f-8f77cc1b2b28Mon, 25 Sep 2023 12:00:00 -040021:40falsefull11 <p>Dr Debra L Richardson from OU Health Stephenson Cancer Center in Oklahoma City discusses novel agents and strategies for ovarian cancer moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayNovelAgentsOvarian23" rel="nofollow">here</a></p> What Clinicians Want to Know About Toxicity Considerations Associated with BTK InhibitorsWhat Clinicians Want to Know About Toxicity Considerations Associated with BTK InhibitorsDr Nicole Lamanna from the Columbia University Herbert Irving Comprehensive Cancer Center in New York, New York, and Dr William G Wierda from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the spectrum of toxicities associated with BTK inhibitors and strategies for their mitigation and management for patients with chronic lymphocytic leukemia and mantle cell lymphoma, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here

]]>Dr Nicole Lamanna from the Columbia University Herbert Irving Comprehensive Cancer Center in New York, New York, and Dr William G Wierda from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the spectrum of toxicities associated with BTK inhibitors and strategies for their mitigation and management for patients with chronic lymphocytic leukemia and mantle cell lymphoma, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here

]]>5e5b4018-abd1-4e2a-9c4c-177eaf5ef73bFri, 22 Sep 2023 10:00:00 -040001:02:44falsefull11 <p>Dr Nicole Lamanna from the Columbia University Herbert Irving Comprehensive Cancer Center in New York, New York, and Dr William G Wierda from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the spectrum of toxicities associated with BTK inhibitors and strategies for their mitigation and management for patients with chronic lymphocytic leukemia and mantle cell lymphoma, moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/BTKToxicities23" rel="nofollow">here</a></p> Optimizing the Management of Metastatic Pancreatic Cancer Optimizing the Management of Metastatic Pancreatic Cancer Dr Eileen M O’Reilly from Memorial Sloan Kettering Cancer Center in New York City and Dr Zev A Wainberg from the UCLA Jonsson Comprehensive Cancer Center in Los Angeles discuss approved and novel treatment approaches for metastatic pancreatic cancer moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here

]]>Dr Eileen M O’Reilly from Memorial Sloan Kettering Cancer Center in New York City and Dr Zev A Wainberg from the UCLA Jonsson Comprehensive Cancer Center in Los Angeles discuss approved and novel treatment approaches for metastatic pancreatic cancer moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here

]]>b36c4313-f025-411b-a614-2ab6386e3affFri, 15 Sep 2023 10:00:00 -040001:03:48falsefull11 <p>Dr Eileen M O’Reilly from Memorial Sloan Kettering Cancer Center in New York City and Dr Zev A Wainberg from the UCLA Jonsson Comprehensive Cancer Center in Los Angeles discuss approved and novel treatment approaches for metastatic pancreatic cancer moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://researchtopractice.com/InsideTheIssue2023/mPancreatic" rel="nofollow">here</a></p> The Current and Future Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin LymphomaThe Current and Future Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin LymphomaDr Martin Hutchings from Rigshospitalet, Copenhagen University Hospital in Copenhagen, Denmark, and Dr Loretta Nastoupil from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here

]]>Dr Martin Hutchings from Rigshospitalet, Copenhagen University Hospital in Copenhagen, Denmark, and Dr Loretta Nastoupil from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here

]]>012458f5-da5c-48dd-ae5e-6f3a35b5b7c5Wed, 13 Sep 2023 10:00:00 -040001:00:42falsefull11 <p>Dr Martin Hutchings from Rigshospitalet, Copenhagen University Hospital in Copenhagen, Denmark, and Dr Loretta Nastoupil from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma moderated by Dr Neil Love. Produced by Research To Practice.</p> <p>CME information and select publications <a href="https://researchtopractice.com/InsidetheIssue2023/NHL" rel="nofollow">here</a></p> Meet The Professor: Optimizing the Management of MelanomaMeet The Professor: Optimizing the Management of MelanomaProf Georgina Long from the University of Sydney in Sydney, New South Wales, Australia, discusses optimizing the management of melanoma moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here

]]>Prof Georgina Long from the University of Sydney in Sydney, New South Wales, Australia, discusses optimizing the management of melanoma moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here

]]>ed232d31-5801-4db6-9ca4-333f3629dfd0Mon, 11 Sep 2023 11:00:00 -040001:03:01falsefull11 <p>Prof Georgina Long from the University of Sydney in Sydney, New South Wales, Australia, discusses optimizing the management of melanoma moderated by Dr Neil Love. Produced by Research To Practice. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/MTPMelanoma23" rel="nofollow">here</a></p> Striving for Consensus: Current and Future Management of Metastatic Non-Small Cell Lung Cancer in Patients Who Experience Disease Progression on Immune Checkpoint Inhibitor TherapyStriving for Consensus: Current and Future Management of Metastatic Non-Small Cell Lung Cancer in Patients Who Experience Disease Progression on Immune Checkpoint Inhibitor TherapyDr Corey Langer, Dr Ticiana Leal, Dr Karen Reckamp and Dr Jacob Sands discuss the optimal current management of relapsed NSCLC and provide perspectives on the future of care for patients with this disease, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here

]]>Dr Corey Langer, Dr Ticiana Leal, Dr Karen Reckamp and Dr Jacob Sands discuss the optimal current management of relapsed NSCLC and provide perspectives on the future of care for patients with this disease, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here

]]>404893ec-cb10-4293-82b7-862bed2ddbc6Fri, 08 Sep 2023 14:00:00 -040002:43:37falsefull11 <p>Dr Corey Langer, Dr Ticiana Leal, Dr Karen Reckamp and Dr Jacob Sands discuss the optimal current management of relapsed NSCLC and provide perspectives on the future of care for patients with this disease, moderated by Dr Neil Love. Produced by Research To Practice.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/RelapsedmNSCLCThinkTank2023" rel="nofollow">here</a></p> The Implications of Recent Data Sets for the Management of Hepatocellular CarcinomaThe Implications of Recent Data Sets for the Management of Hepatocellular CarcinomaDr Ghassan Abou-Alfa from Memorial Sloan Kettering Cancer Center in New York and Dr Daneng Li from City of Hope Comprehensive Cancer Center in Duarte, California, discuss the implications of recent data sets for the management of hepatocellular carcinoma moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here

]]>Dr Ghassan Abou-Alfa from Memorial Sloan Kettering Cancer Center in New York and Dr Daneng Li from City of Hope Comprehensive Cancer Center in Duarte, California, discuss the implications of recent data sets for the management of hepatocellular carcinoma moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here

]]>c9e84fd6-ec42-4b1c-a913-2ca8b2313877Tue, 05 Sep 2023 13:00:00 -040001:02:04falsefull11 <p>Dr Ghassan Abou-Alfa from Memorial Sloan Kettering Cancer Center in New York and Dr Daneng Li from City of Hope Comprehensive Cancer Center in Duarte, California, discuss the implications of recent data sets for the management of hepatocellular carcinoma moderated by Dr Neil Love. Produced by Research To Practice.</p> <p>CME information and select publications <a href="https://researchtopractice.com/PostESMOGI23/HCC" rel="nofollow">here</a></p> Exploring the Current and Future Management of High-Risk, Hormone-Sensitive Nonmetastatic Prostate CancerExploring the Current and Future Management of High-Risk, Hormone-Sensitive Nonmetastatic Prostate CancerDr Neal Shore from the Carolina Urologic Research Center in Myrtle Beach, South Carolina, and Dr Mary-Ellen Taplin from the Dana-Farber Cancer Institute in Boston, Massachusetts, discuss the current and future management of high-risk, hormone-sensitive nonmetastatic prostate cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here

]]>Dr Neal Shore from the Carolina Urologic Research Center in Myrtle Beach, South Carolina, and Dr Mary-Ellen Taplin from the Dana-Farber Cancer Institute in Boston, Massachusetts, discuss the current and future management of high-risk, hormone-sensitive nonmetastatic prostate cancer, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here

]]>5d2f773c-c442-4c65-bfda-f90cb3cc1e5bFri, 01 Sep 2023 11:00:00 -040001:01:01falsefull11 <p>Dr Neal Shore from the Carolina Urologic Research Center in Myrtle Beach, South Carolina, and Dr Mary-Ellen Taplin from the Dana-Farber Cancer Institute in Boston, Massachusetts, discuss the current and future management of high-risk, hormone-sensitive nonmetastatic prostate cancer, moderated by Dr Neil Love. Produced by Research To Practice.</p> <p>CME information and select publications <a href="https://researchtopractice.com/InsideTheIssue2023/HigherRiskProstate" rel="nofollow">here</a></p> Role of BTK Inhibitors in Therapy for Mantle Cell LymphomaRole of BTK Inhibitors in Therapy for Mantle Cell LymphomaFeaturing a discussion on BTK inhibitors for the management of mantle cell lymphoma with Dr Michael Wang, moderated by Dr Neil Love.

CME information and select publications here.

]]>Featuring a discussion on BTK inhibitors for the management of mantle cell lymphoma with Dr Michael Wang, moderated by Dr Neil Love.

CME information and select publications here.

]]>cc219fc3-2617-4bd9-9da5-8d68ffa5d283Wed, 30 Aug 2023 14:00:00 -040042:34falsefull11 <p>Featuring a discussion on BTK inhibitors for the management of mantle cell lymphoma with Dr Michael Wang, moderated by Dr Neil Love.</p> <p>CME information and select publications <a href="https://researchtopractice.com/OncologyTodayBTKInhibitorsMCL23" rel="nofollow">here</a>.</p> Meet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 2 of a 2-Part SeriesMeet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 2 of a 2-Part SeriesDr Richard F Riedel from Duke Cancer Institute in Durham, North Carolina, discusses approved and novel treatment approaches for soft tissue sarcoma, moderated by Dr Neil Love.

CME information and select publications here.

]]>Dr Richard F Riedel from Duke Cancer Institute in Durham, North Carolina, discusses approved and novel treatment approaches for soft tissue sarcoma, moderated by Dr Neil Love.

CME information and select publications here.

]]>59dd7b71-4939-4475-b4a2-8be5fe7d4909Tue, 29 Aug 2023 10:00:00 -040001:01:53falsefull11 <p>Dr Richard F Riedel from Duke Cancer Institute in Durham, North Carolina, discusses approved and novel treatment approaches for soft tissue sarcoma, moderated by Dr Neil Love.</p> <p>CME information and select publications <a href="http://www.ResearchToPractice.com/MTPSarcoma23/Part2" rel="nofollow">here</a>.</p> Special Edition — Key Presentations on Chronic Lymphocytic Leukemia and Lymphoma from Recent Major Oncology/Hematology Conferences Special Edition — Key Presentations on Chronic Lymphocytic Leukemia and Lymphoma from Recent Major Oncology/Hematology Conferences Dr Jeremy Abramson from Massachusetts General Hospital in Boston discusses key presentations on chronic lymphocytic leukemia and lymphomas from recent oncology/hematology conferences.

CME information and select publications here

]]>Dr Jeremy Abramson from Massachusetts General Hospital in Boston discusses key presentations on chronic lymphocytic leukemia and lymphomas from recent oncology/hematology conferences.

CME information and select publications here

]]>73b5057d-2c2e-48cf-be65-480218386fa1Mon, 28 Aug 2023 11:00:00 -040036:06falsefull11 <p>Dr Jeremy Abramson from Massachusetts General Hospital in Boston discusses key presentations on chronic lymphocytic leukemia and lymphomas from recent oncology/hematology conferences.</p> <p>CME information and select publications <a href="https://researchtopractice.com/OncologyTodayPostConf23/CLLLymphoma" rel="nofollow">here</a></p> Special Edition — Key Presentations on Genitourinary Cancers from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Special Edition — Key Presentations on Genitourinary Cancers from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Dr Rana McKay from UC San Diego Moores Cancer Center in La Jolla, California discusses key presentations on genitourinary cancers from the 2023 ASCO Annual Meeting.

CME information and select publications here

]]>Dr Rana McKay from UC San Diego Moores Cancer Center in La Jolla, California discusses key presentations on genitourinary cancers from the 2023 ASCO Annual Meeting.

CME information and select publications here

]]>49eafd29-67a9-4766-ac7c-2b631fd4a01aFri, 25 Aug 2023 09:00:00 -040001:20:38falsefull11 <p>Dr Rana McKay from UC San Diego Moores Cancer Center in La Jolla, California discusses key presentations on genitourinary cancers from the 2023 ASCO Annual Meeting. </p> <p>CME information and select publications <a href="https://researchtopractice.com/OncologyTodayPostASCO23/GU" rel="nofollow">here</a></p> Current and Future Management of ER-Positive Metastatic Breast Cancer After Disease Progression on a CDK4/6 InhibitorCurrent and Future Management of ER-Positive Metastatic Breast Cancer After Disease Progression on a CDK4/6 InhibitorDr Aditya Bardia from Massachusetts General Hospital in Boston, Massachusetts, and Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discuss approved and novel treatment approaches for ER-positive metastatic breast cancer that has progressed on prior CDK4/6 inhibitor therapy.

CME information and select publications here.

]]>Dr Aditya Bardia from Massachusetts General Hospital in Boston, Massachusetts, and Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discuss approved and novel treatment approaches for ER-positive metastatic breast cancer that has progressed on prior CDK4/6 inhibitor therapy.

CME information and select publications here.

]]>b50d845b-4abc-4e52-a296-d2d2e9267518Wed, 23 Aug 2023 12:00:00 -040001:01:15falsefull11 <p>Dr Aditya Bardia from Massachusetts General Hospital in Boston, Massachusetts, and Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discuss approved and novel treatment approaches for ER-positive metastatic breast cancer that has progressed on prior CDK4/6 inhibitor therapy.</p> <p>CME information and select publications <a href="https://researchtopractice.com/InsideTheIssue2023/ERPositivemBC" rel="nofollow">here</a>.</p> Integrating Bispecific Antibodies into the Management of Multiple Myeloma — Patient Selection and Toxicity ManagementIntegrating Bispecific Antibodies into the Management of Multiple Myeloma — Patient Selection and Toxicity ManagementDr Hans Lee from The University of Texas MD Anderson Cancer Center in Houston, Texas, and Dr Saad Zafar Usmani from Memorial Sloan Kettering Cancer Center in New York, New York, discuss approved and novel bispecific antibodies and their current and potential roles in the treatment of multiple myeloma.

CME information and select publications here.

]]>Dr Hans Lee from The University of Texas MD Anderson Cancer Center in Houston, Texas, and Dr Saad Zafar Usmani from Memorial Sloan Kettering Cancer Center in New York, New York, discuss approved and novel bispecific antibodies and their current and potential roles in the treatment of multiple myeloma.

CME information and select publications here.

]]>ebb0d628-ce1f-481c-ac99-d75550c55bdeTue, 22 Aug 2023 14:00:00 -040001:00:50falsefull11 <p>Dr Hans Lee from The University of Texas MD Anderson Cancer Center in Houston, Texas, and Dr Saad Zafar Usmani from Memorial Sloan Kettering Cancer Center in New York, New York, discuss approved and novel bispecific antibodies and their current and potential roles in the treatment of multiple myeloma.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/InsidetheIssue2023/MM" rel="nofollow">here</a>.</p> Special Edition — Key Presentations on Lung Cancer from the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingSpecial Edition — Key Presentations on Lung Cancer from the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingDr Matthew Gubens from the University of California in San Francisco, California, discusses key presentations on lung cancer from the 2023 ASCO Annual Meeting moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here

]]>Dr Matthew Gubens from the University of California in San Francisco, California, discusses key presentations on lung cancer from the 2023 ASCO Annual Meeting moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here

]]>2a9829f7-4b5e-48e0-b382-99ae407f238bMon, 21 Aug 2023 10:00:00 -040031:46falsefull11 <p>Dr Matthew Gubens from the University of California in San Francisco, California, discusses key presentations on lung cancer from the 2023 ASCO Annual Meeting moderated by Dr Neil Love. Produced by Research To Practice.</p> <p>CME information and select publications <a href="https://ResearchToPractice.com/OncologyTodayPostASCO23/Lung" rel="nofollow">here</a></p> Special Nursing Edition — What I Tell My Patients About New Treatments and Clinical Trials in Chronic Lymphocytic LeukemiaSpecial Nursing Edition — What I Tell My Patients About New Treatments and Clinical Trials in Chronic Lymphocytic LeukemiaDr Kerry Rogers from the Ohio State University in Columbus, Ohio, discusses the education and care of patients with chronic lymphocytic leukemia.

NCPD information and select publications here

]]>Dr Kerry Rogers from the Ohio State University in Columbus, Ohio, discusses the education and care of patients with chronic lymphocytic leukemia.

NCPD information and select publications here

]]>2dccb7c3-a2c0-445f-ad7d-574063ed3331Fri, 18 Aug 2023 10:00:00 -040001:09:31falsefull11 <p>Dr Kerry Rogers from the Ohio State University in Columbus, Ohio, discusses the education and care of patients with chronic lymphocytic leukemia.</p> <p>NCPD information and select publications <a href="https://www.researchtopractice.com/ONS2023CLLReview/InterviewAudio" rel="nofollow">here</a></p> Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Melanoma and Nonmelanoma Skin Cancers Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Melanoma and Nonmelanoma Skin Cancers Featuring perspectives from Dr Omid Hamid and Dr Evan J Lipson moderated by Dr Neil Love. Produced by Research to Practice.

CME information and select publications here.

]]>Featuring perspectives from Dr Omid Hamid and Dr Evan J Lipson moderated by Dr Neil Love. Produced by Research to Practice.

CME information and select publications here.

]]>1b00a01c-8127-445f-a77e-15bc8a53d1e5Wed, 16 Aug 2023 10:00:00 -040001:03:47falsefull11 <p>Featuring perspectives from Dr Omid Hamid and Dr Evan J Lipson moderated by Dr Neil Love. Produced by Research to Practice.</p> <p>CME information and select publications <a href="http://www.researchtopractice.com/YiR2022/SkinCancers" rel="nofollow">here</a>. </p> Special Edition — Key Presentations from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Gastrointestinal Cancers IssueSpecial Edition — Key Presentations from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Gastrointestinal Cancers IssueDr Philip Philip from Henry Ford Cancer - Detroit in Michigan discusses key presentations on GI cancers from the 2023 ASCO Annual Meeting moderated by Dr Neil Love. Produced by Research to Practice.

CME information and select publications here

]]>Dr Philip Philip from Henry Ford Cancer - Detroit in Michigan discusses key presentations on GI cancers from the 2023 ASCO Annual Meeting moderated by Dr Neil Love. Produced by Research to Practice.

CME information and select publications here

]]>55fdb47d-36e1-4d19-871c-5908cbe4979eTue, 15 Aug 2023 15:00:00 -040049:02falsefull11 <p>Dr Philip Philip from Henry Ford Cancer - Detroit in Michigan discusses key presentations on GI cancers from the 2023 ASCO Annual Meeting moderated by Dr Neil Love. Produced by Research to Practice.</p> <p>CME information and select publications <a href="https://researchtopractice.com/OncologyTodayPostASCO23/GI" rel="nofollow">here</a></p> Special Edition — Key Presentations on Gynecologic Cancers from the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingSpecial Edition — Key Presentations on Gynecologic Cancers from the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingDr Floor Backes from The James Cancer Hospital and Solove Research Institute in Columbus, Ohio, discusses recent updates from ASCO 2023 on the management of gynecologic cancers.

CME information and select publications here

]]>Dr Floor Backes from The James Cancer Hospital and Solove Research Institute in Columbus, Ohio, discusses recent updates from ASCO 2023 on the management of gynecologic cancers.

CME information and select publications here

]]>abf05135-93f2-4f83-bb43-af81e68719f2Fri, 11 Aug 2023 10:00:00 -040043:12falsefull11 <p>Dr Floor Backes from The James Cancer Hospital and Solove Research Institute in Columbus, Ohio, discusses recent updates from ASCO 2023 on the management of gynecologic cancers.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayPostASCO23/Gyn" rel="nofollow">here</a></p> Ready for Prime Time? Determining the Current and Future Role of PARP Inhibitor-Based Combinations in the Management of Prostate Cancer — A Clinical Investigator Think TankReady for Prime Time? Determining the Current and Future Role of PARP Inhibitor-Based Combinations in the Management of Prostate Cancer — A Clinical Investigator Think TankDrs Neeraj Agarwal, Emmanuel Antonarakis, Karim Fizazi and Susan Slovin discuss the current and future role of PARP inhibitors in the management of prostate cancer.

CME information and select publications here.

]]>Drs Neeraj Agarwal, Emmanuel Antonarakis, Karim Fizazi and Susan Slovin discuss the current and future role of PARP inhibitors in the management of prostate cancer.

CME information and select publications here.

]]>41313c50-cd58-481e-89c9-27c767557c74Fri, 11 Aug 2023 08:00:00 -040002:48:58falsefull11 <p>Drs Neeraj Agarwal, Emmanuel Antonarakis, Karim Fizazi and Susan Slovin discuss the current and future role of PARP inhibitors in the management of prostate cancer. </p> <p>CME information and select publications <a href="https://www.researchtopractice.com/PARPProstateThinkTank2023" rel="nofollow">here</a>.</p> Optimizing the Management of Metastatic Urothelial Bladder CancerOptimizing the Management of Metastatic Urothelial Bladder CancerDr Terence Friedlander from the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, and Dr Petros Grivas from the Fred Hutchinson Cancer Research Center in Seattle, Washington, discuss available and novel treatment strategies for metastatic urothelial bladder cancer moderated by Dr Neil Love.

CME informationa and select publications here.

]]>Dr Terence Friedlander from the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, and Dr Petros Grivas from the Fred Hutchinson Cancer Research Center in Seattle, Washington, discuss available and novel treatment strategies for metastatic urothelial bladder cancer moderated by Dr Neil Love.

CME informationa and select publications here.

]]>7b4dd1b1-797a-41a2-881b-181aba16e56dWed, 09 Aug 2023 12:00:00 -040001:02:12falsefull11 <p>Dr Terence Friedlander from the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, and Dr Petros Grivas from the Fred Hutchinson Cancer Research Center in Seattle, Washington, discuss available and novel treatment strategies for metastatic urothelial bladder cancer moderated by Dr Neil Love. </p> <p>CME informationa and select publications <a href="https://www.researchtopractice.com/InsideTheIssue2023/mUBC" rel="nofollow">here</a>.</p> Special Edition — Current and Future Management of Breast CancerSpecial Edition — Current and Future Management of Breast CancerDr Heather McArthur from the UT Southwestern Medical Center in Dallas, Texas discusses key presentations on breast cancer from the 2023 ASCO Annual meeting.

CME information and select publications here.

]]>Dr Heather McArthur from the UT Southwestern Medical Center in Dallas, Texas discusses key presentations on breast cancer from the 2023 ASCO Annual meeting.

CME information and select publications here.

]]>593f0322-f029-4216-8ea7-cafb24182e31Tue, 08 Aug 2023 12:00:00 -040001:25:35falsefull11 <p>Dr Heather McArthur from the UT Southwestern Medical Center in Dallas, Texas discusses key presentations on breast cancer from the 2023 ASCO Annual meeting.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayPostASCO23/BreastCancer" rel="nofollow">here</a>.</p> Special Edition — Key Presentations from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Ovarian Cancer IssueSpecial Edition — Key Presentations from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Ovarian Cancer IssueDr David O’Malley from The James Cancer Center in Columbus, Ohio, discusses recent advances in the management of ovarian cancer, including presentations from ASCO 2023.

CME information and select publications here

]]>Dr David O’Malley from The James Cancer Center in Columbus, Ohio, discusses recent advances in the management of ovarian cancer, including presentations from ASCO 2023.

CME information and select publications here

]]>c09fb39e-6800-4bdc-a793-b04d8c082f7fThu, 03 Aug 2023 12:00:00 -040057:27falsefull11 <p>Dr David O’Malley from The James Cancer Center in Columbus, Ohio, discusses recent advances in the management of ovarian cancer, including presentations from ASCO 2023.</p> <p>CME information and select publications <a href="https://researchtopractice.com/ASCO2023Ovarian/AudioInterview" rel="nofollow">here</a></p> Special Nursing Edition — What I Tell My Patients About New Treatments and Clinical Trials in Colorectal and Gastroesophageal Cancers Special Nursing Edition — What I Tell My Patients About New Treatments and Clinical Trials in Colorectal and Gastroesophageal Cancers Dr Tanios Bekaii-Saab from the Mayo Clinic in Phoenix, Arizona, discusses the role of novel therapeutic management approaches for patients with colorectal and gastroesophageal cancers.

NCPD information and select publications here

]]>Dr Tanios Bekaii-Saab from the Mayo Clinic in Phoenix, Arizona, discusses the role of novel therapeutic management approaches for patients with colorectal and gastroesophageal cancers.

NCPD information and select publications here

]]>55046ba5-9f57-4709-bf4c-76dd86cdf68cWed, 02 Aug 2023 16:00:00 -040058:45falsefull11 <p>Dr Tanios Bekaii-Saab from the Mayo Clinic in Phoenix, Arizona, discusses the role of novel therapeutic management approaches for patients with colorectal and gastroesophageal cancers.</p> <p>NCPD information and select publications <a href="https://www.researchtopractice.com/ONS2023GE/AudioInterview" rel="nofollow">here</a></p> Novel Agents, Approaches and Strategies in the Management of Higher-Risk Myelodysplastic Syndromes Novel Agents, Approaches and Strategies in the Management of Higher-Risk Myelodysplastic SyndromesFeaturing perspectives from Dr Guillermo Garcia-Manero and Dr David Sallman.

CME information and select publications here

]]>Featuring perspectives from Dr Guillermo Garcia-Manero and Dr David Sallman.

CME information and select publications here

]]>b64c95b0-f7bc-44a8-89ed-c4b7b73e114fWed, 02 Aug 2023 09:00:00 -040001:03:15falsefull11 <p>Featuring perspectives from Dr Guillermo Garcia-Manero and Dr David Sallman.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/InsidetheIssue2023/MDS" rel="nofollow">here</a></p> Immune Thrombocytopenia Edition with Dr Hanny Al-SamkariImmune Thrombocytopenia Edition with Dr Hanny Al-SamkariDr Hanny Al-Samkari from Harvard Medical School in Boston, Massachusetts, discusses the presentation and management of immune thrombocytopenia.

CME information and select publications here

]]>Dr Hanny Al-Samkari from Harvard Medical School in Boston, Massachusetts, discusses the presentation and management of immune thrombocytopenia.

CME information and select publications here

]]>5f506597-a978-4515-b7a1-9d8474565c91Fri, 28 Jul 2023 12:00:00 -040029:27falsefull11 <p>Dr Hanny Al-Samkari from Harvard Medical School in Boston, Massachusetts, discusses the presentation and management of immune thrombocytopenia.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayITP23" rel="nofollow">here</a></p> Paroxysmal Nocturnal Hemoglobinuria Edition with Dr Carlos de CastroParoxysmal Nocturnal Hemoglobinuria Edition with Dr Carlos de CastroDr Carlos de Castro from Duke Cancer Institute in Durham, North Carolina discusses the presentation, diagnosis and management of paroxysmal nocturnal hemoglobinuria.

CME information and select publications here

]]>Dr Carlos de Castro from Duke Cancer Institute in Durham, North Carolina discusses the presentation, diagnosis and management of paroxysmal nocturnal hemoglobinuria.

CME information and select publications here

]]>d2aef2d8-afb6-45ae-9f39-a97454130b14Tue, 25 Jul 2023 13:00:00 -040042:57falsefull11 <p>Dr Carlos de Castro from Duke Cancer Institute in Durham, North Carolina discusses the presentation, diagnosis and management of paroxysmal nocturnal hemoglobinuria.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayPNH23" rel="nofollow">here</a></p> Special Edition — Management of Hepatobiliary CancersSpecial Edition — Management of Hepatobiliary CancersDr Robin “Katie” Kelley from the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California discusses recent updates from ASCO 2023 on the management of hepatobiliary cancers, moderated by Dr Neil Love.

CME information and select publications here

]]>Dr Robin “Katie” Kelley from the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California discusses recent updates from ASCO 2023 on the management of hepatobiliary cancers, moderated by Dr Neil Love.

CME information and select publications here

]]>f20550f0-3044-4bcf-ba6a-6d32128131ccMon, 24 Jul 2023 11:00:00 -040053:24falsefull11 <p>Dr Robin “Katie” Kelley from the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California discusses recent updates from ASCO 2023 on the management of hepatobiliary cancers, moderated by Dr Neil Love.</p> <p>CME information and select publications <a href="http://www.ResearchToPractice.com/ASCO2023HBC/AudioInterview" rel="nofollow">here</a></p> Special Edition — Management of Urothelial Bladder Cancer Special Edition — Management of Urothelial Bladder Cancer Dr Matthew Galsky discusses recent updates from ASCO 2023 on the management of urothelial bladder cancer
moderated by Dr Neil Love. Produced by Research to Practice.

CME information and select publications here

]]>Dr Matthew Galsky discusses recent updates from ASCO 2023 on the management of urothelial bladder cancer
moderated by Dr Neil Love. Produced by Research to Practice.

CME information and select publications here

]]>e2e32e07-8e08-440d-aad0-5cee703e9753Fri, 21 Jul 2023 16:00:00 -040056:37falsefull11 <p>Dr Matthew Galsky discusses recent updates from ASCO 2023 on the management of urothelial bladder cancer<br> moderated by Dr Neil Love. Produced by Research to Practice.</p> <p>CME information and select publications <a href="http://www.ResearchToPractice.com/ASCO2023Bladder/AudioInterview" rel="nofollow">here</a></p> Special Edition — Current and Future Management of Breast CancerSpecial Edition — Current and Future Management of Breast CancerFeaturing a discussion on recent presentations in breast cancer from the 2023 ASCO annual meeting with Dr Kevin Kalinsky moderated by Dr Neil Love. Produced by Research to Practice.

CME information and select publications [here

]]>Featuring a discussion on recent presentations in breast cancer from the 2023 ASCO annual meeting with Dr Kevin Kalinsky moderated by Dr Neil Love. Produced by Research to Practice.

CME information and select publications [here

]]>1f4a5f75-cb51-4a37-88b5-1aa969f3bc31Fri, 21 Jul 2023 13:00:00 -040058:52falsefull11 <p>Featuring a discussion on recent presentations in breast cancer from the 2023 ASCO annual meeting with Dr Kevin Kalinsky moderated by Dr Neil Love. Produced by Research to Practice.</p> <p>CME information and select publications [here<a href="http://www.ResearchToPractice.com/ASCO2023Breast/AudioInterview" rel="nofollow"></a></p> Special Nursing Edition — What I Tell My Patients About New Treatments and Clinical Trials in Urothelial Bladder CancerSpecial Nursing Edition — What I Tell My Patients About New Treatments and Clinical Trials in Urothelial Bladder CancerDr Elizabeth Plimack from Fox Chase Cancer Center in Philadelphia, Pennsylvania, discusses available and emerging therapies for patients with urothelial bladder cancer.

CME information and select publications here

]]>Dr Elizabeth Plimack from Fox Chase Cancer Center in Philadelphia, Pennsylvania, discusses available and emerging therapies for patients with urothelial bladder cancer.

CME information and select publications here

]]>55ae57df-b00f-43fd-bd75-9637069543a6Thu, 20 Jul 2023 09:00:00 -040052:15falsefull11 <p>Dr Elizabeth Plimack from Fox Chase Cancer Center in Philadelphia, Pennsylvania, discusses available and emerging therapies for patients with urothelial bladder cancer.</p> <p>CME information and select publications <a href="https://www.researchtopractice.com/ONS2023Bladder/Audiointerview" rel="nofollow">here</a></p> The Implications of New Research Findings for the Management of Endometrial CancerThe Implications of New Research Findings for the Management of Endometrial CancerFeaturing perspectives from Dr Bradley J Monk and Dr Matthew A Powell moderated by Dr Neil Love. Produced by Research to Practice.

CME information and select publications here.

]]>Featuring perspectives from Dr Bradley J Monk and Dr Matthew A Powell moderated by Dr Neil Love. Produced by Research to Practice.

CME information and select publications here.

]]>fb3831d1-57b9-4181-959c-4d63705fe09bFri, 14 Jul 2023 08:00:00 -040001:01:16falsefull11 <p>Featuring perspectives from Dr Bradley J Monk and Dr Matthew A Powell moderated by Dr Neil Love. Produced by Research to Practice.</p> <p>CME information and select publications <a href="http://www.researchtopractice.com/PostSGO23Endometrial" rel="nofollow">here</a>.</p> Meet The Professor: The Current and Future Management of Hodgkin and Non-Hodgkin LymphomaMeet The Professor: The Current and Future Management of Hodgkin and Non-Hodgkin LymphomaDr Ian W Flinn discusses the management of Hodgkin and non-Hodgkin lymphoma.

CME information and select publications here

]]>Dr Ian W Flinn discusses the management of Hodgkin and non-Hodgkin lymphoma.

CME information and select publications here

]]>21a12bea-b062-49e6-8d5f-8a57c1032cc3Thu, 06 Jul 2023 12:00:00 -040001:01:23falsefull11 <p>Dr Ian W Flinn discusses the management of Hodgkin and non-Hodgkin lymphoma.</p> <p>CME information and select publications <a href="http://www.researchtopractice.com/MTPLymphoma23/" rel="nofollow">here</a></p> Meet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 1 of a 2 - Part SeriesMeet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 1 of a 2 - Part SeriesDr Brian Van Tine discusses new and future research in the management of soft tissue sarcoma and related connective tissue disorders.

CME information and select publications here

]]>Dr Brian Van Tine discusses new and future research in the management of soft tissue sarcoma and related connective tissue disorders.

CME information and select publications here

]]>f02acd7e-1bd6-463e-bb89-b5a8e4dcc6a6Fri, 16 Jun 2023 12:00:00 -040001:01:32falsefull11 <p>Dr Brian Van Tine discusses new and future research in the management of soft tissue sarcoma and related connective tissue disorders.</p> <p>CME information and select publications <a href="http://www.researchtopractice.com/MTPSarcoma23/Part1" rel="nofollow">here</a></p> Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting: Multiple Myeloma EditionKey Presentations from the 64th American Society of Hematology (ASH) Annual Meeting: Multiple Myeloma EditionDr Jacob Laubach from the Dana-Farber Cancer Institute discusses key presentations in multiple myeloma from the 2022 ASH Annual Meeting.

CME information and select publications here.

]]>Dr Jacob Laubach from the Dana-Farber Cancer Institute discusses key presentations in multiple myeloma from the 2022 ASH Annual Meeting.

CME information and select publications here.

]]>736f8390-6835-420a-9b1a-7e2c9bac7754Wed, 19 Apr 2023 08:00:00 -040001:14:49falsefull11 <p>Dr Jacob Laubach from the Dana-Farber Cancer Institute discusses key presentations in multiple myeloma from the 2022 ASH Annual Meeting.</p> <p>CME information and select publications <a href="http://www.researchtopractice.com/OncologyTodayPostASH23/MM" rel="nofollow">here</a>.</p> Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting: Chronic Lymphocytic Leukemia EditionKey Presentations from the 64th American Society of Hematology (ASH) Annual Meeting: Chronic Lymphocytic Leukemia EditionDr John Allan from Weill Cornell Medicine in New York City discusses the most important chronic lymphocytic leukemia studies presented at ASH 2022.

CME information and select publications here.

]]>Dr John Allan from Weill Cornell Medicine in New York City discusses the most important chronic lymphocytic leukemia studies presented at ASH 2022.

CME information and select publications here.

]]>9cf4448d-bc96-488c-a14b-44bb3fb3f2d6Wed, 12 Apr 2023 09:00:00 -040001:17:12falsefull11 <p>Dr John Allan from Weill Cornell Medicine in New York City discusses the most important chronic lymphocytic leukemia studies presented at ASH 2022.</p> <p>CME information and select publications <a href="http://www.researchtopractice.com/OncologyTodayPostASH23/CLL" rel="nofollow">here</a>.</p> Key Presentations in Hodgkin and Non-Hodgkin Lymphomas from the 2022 ASH Annual Meeting with Dr Matthew LunningKey Presentations in Hodgkin and Non-Hodgkin Lymphomas from the 2022 ASH Annual Meeting with Dr Matthew LunningDr Matthew Lunning from the University of Nebraska Medical Center in Omaha, Nebraska, discusses the most important lymphoma studies presented at the 2022 ASH Annual Meeting.

CME information and select publications here.

]]>Dr Matthew Lunning from the University of Nebraska Medical Center in Omaha, Nebraska, discusses the most important lymphoma studies presented at the 2022 ASH Annual Meeting.

CME information and select publications here.

]]>38b2afc7-aef1-46d6-a94e-1d5184a1dc2dThu, 02 Mar 2023 14:00:00 -040001:28:19falsefull11 <p>Dr Matthew Lunning from the University of Nebraska Medical Center in Omaha, Nebraska, discusses the most important lymphoma studies presented at the 2022 ASH Annual Meeting.</p> <p>CME information and select publications <a href="http://www.researchtopractice.com/OncologyTodayPostASH23/Lymphoma" rel="nofollow">here</a>.</p> Management of Desmoid Tumors with Dr Mrinal GounderManagement of Desmoid Tumors with Dr Mrinal GounderDr Mrinal Gounder from Memorial Sloan Kettering Cancer Center in New York City discusses the management of desmoid tumors.

CME information and select publications here.

]]>Dr Mrinal Gounder from Memorial Sloan Kettering Cancer Center in New York City discusses the management of desmoid tumors.

CME information and select publications here.

]]>dfea81ad-8e4c-46b7-ba98-ab68741d5c58Tue, 28 Feb 2023 12:00:00 -040054:25falsefull11 <p>Dr Mrinal Gounder from Memorial Sloan Kettering Cancer Center in New York City discusses the management of desmoid tumors.</p> <p>CME information and select publications <a href="http://www.researchtopractice.com/OncologyTodayDesmoidTumors22" rel="nofollow">here</a>.</p> Management of HER2-Altered Non-Small Cell Lung CancerManagement of HER2-Altered Non-Small Cell Lung CancerDr Bob Li from Memorial Sloan Kettering Cancer Center in New York City discusses the current and future roles of targeted therapy for HER2-altered non-small cell lung cancer.

CME information and select publications here.

]]>Dr Bob Li from Memorial Sloan Kettering Cancer Center in New York City discusses the current and future roles of targeted therapy for HER2-altered non-small cell lung cancer.

CME information and select publications here.

]]>37103412-1367-4b6b-8d09-91eedaa91b59Tue, 21 Feb 2023 11:00:00 -040001:20:06falsefull11 <p>Dr Bob Li from Memorial Sloan Kettering Cancer Center in New York City discusses the current and future roles of targeted therapy for HER2-altered non-small cell lung cancer.</p> <p>CME information and select publications <a href="http://www.researchtopractice.com/OncologyTodayHER2AlteredNSCLC22" rel="nofollow">here</a>.</p> Management of Metastatic Non-Small Cell Lung Cancer without an Actionable MutationManagement of Metastatic Non-Small Cell Lung Cancer without an Actionable MutationDr Edward Garon from the UCLA Jonsson Comprehensive Cancer Center in Los Angeles, California, discusses the management of NSCLC in patients who do not have actionable activating mutations.

CME information and select publications here.

]]>Dr Edward Garon from the UCLA Jonsson Comprehensive Cancer Center in Los Angeles, California, discusses the management of NSCLC in patients who do not have actionable activating mutations.

CME information and select publications here.

]]>ee4ffdee-6b82-4991-9438-4b6e1f192c14Mon, 13 Feb 2023 10:00:00 -040049:37falsefull11 <p>Dr Edward Garon from the UCLA Jonsson Comprehensive Cancer Center in Los Angeles, California, discusses the management of NSCLC in patients who do not have actionable activating mutations.</p> <p>CME information and select publications <a href="http://www.researchtopractice.com/OncologyTodayNSCLCwithoutActionableMutation22" rel="nofollow">here</a>.</p> Key Presentations on Myeloproliferative Neoplasms from the 2022 ASH Annual Meeting — With Dr Srdan VerstovsekKey Presentations on Myeloproliferative Neoplasms from the 2022 ASH Annual Meeting — With Dr Srdan VerstovsekDr Srdan Verstovsek from the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses new data with myeloproliferative neoplasms presented at the 2022 ASH Annual Meeting.

CME information and select publications here.

]]>Dr Srdan Verstovsek from the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses new data with myeloproliferative neoplasms presented at the 2022 ASH Annual Meeting.

CME information and select publications here.

]]>072fe345-6c0e-4448-b78e-6cc3e70e99cdThu, 09 Feb 2023 09:00:00 -040001:19:13falsefull11 <p>Dr Srdan Verstovsek from the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses new data with myeloproliferative neoplasms presented at the 2022 ASH Annual Meeting.</p> <p>CME information and select publications <a href="http://www.researchtopractice.com/OncologyTodayPostASH23/MPN" rel="nofollow">here</a>.</p> Advances in Diffuse Large B-Cell Lymphoma with Dr Gilles SallesAdvances in Diffuse Large B-Cell Lymphoma with Dr Gilles SallesDr Gilles Salles from Memorial Sloan Kettering Cancer Center in New York City discusses recent data from clinical trials evaluating targeted therapies for diffuse large B-cell lymphoma.

CME information and select publications here.

]]>Dr Gilles Salles from Memorial Sloan Kettering Cancer Center in New York City discusses recent data from clinical trials evaluating targeted therapies for diffuse large B-cell lymphoma.

CME information and select publications here.

]]>f819f034-ab0e-43ef-99ff-2ffc9cdb3967Mon, 06 Feb 2023 14:00:00 -040043:37falsefull11 <p>Dr Gilles Salles from Memorial Sloan Kettering Cancer Center in New York City discusses recent data from clinical trials evaluating targeted therapies for diffuse large B-cell lymphoma.</p> <p>CME information and select publications <a href="http://www.researchtopractice.com/OncologyTodayDLBCL22" rel="nofollow">here</a>.</p> Key Presentations in Acute Myeloid Leukemia and Myelodysplastic Syndromes from the 2022 ASH Annual Meeting with Dr Richard StoneKey Presentations in Acute Myeloid Leukemia and Myelodysplastic Syndromes from the 2022 ASH Annual Meeting with Dr Richard StoneDr Richard Stone from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses new data in acute myeloid leukemia and myelodysplastic syndromes presented at the 2022 ASH Annual Meeting.

CME information and select publications here.

]]>Dr Richard Stone from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses new data in acute myeloid leukemia and myelodysplastic syndromes presented at the 2022 ASH Annual Meeting.

CME information and select publications here.

]]>edcd2640-65b4-4455-9755-ab12b4b3e39cThu, 02 Feb 2023 09:00:00 -040001:10:12falsefull11 <p>Dr Richard Stone from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses new data in acute myeloid leukemia and myelodysplastic syndromes presented at the 2022 ASH Annual Meeting.</p> <p>CME information and select publications <a href="http://www.researchtopractice.com/OncologyTodayPostASH23/AMLMDS" rel="nofollow">here</a>.</p> Special Edition — Management of ER-Positive Breast Cancer with Drs Erica Mayer and Ruth O'ReganSpecial Edition — Management of ER-Positive Breast Cancer with Drs Erica Mayer and Ruth O'ReganDr Erica Mayer from the Dana-Farber Cancer Institute in Boston, Massachusetts and Dr Ruth O'Regan from the University of Rochester in Rochester, New York discuss new developments in ER-positive breast cancer.

CME information and select publications here.

]]>Dr Erica Mayer from the Dana-Farber Cancer Institute in Boston, Massachusetts and Dr Ruth O'Regan from the University of Rochester in Rochester, New York discuss new developments in ER-positive breast cancer.

CME information and select publications here.

]]>73758cf3-5ab1-4faa-beb2-1b0b569d3512Tue, 31 Jan 2023 09:00:00 -040001:40:11falsefull11 <p>Dr Erica Mayer from the Dana-Farber Cancer Institute in Boston, Massachusetts and Dr Ruth O&#39;Regan from the University of Rochester in Rochester, New York discuss new developments in ER-positive breast cancer.</p> <p>CME information and select publications <a href="http://www.researchtopractice.com/OncologyTodayERPositiveBreastCancer23" rel="nofollow">here</a>.</p> HER2-Positive Metastatic Breast Cancer with Professor Giuseppe CuriglianoHER2-Positive Metastatic Breast Cancer with Professor Giuseppe CuriglianoProfessor Giuseppe Curigliano from the European Institute of Oncology in Milan, Italy discusses recent therapeutic advances in HER2-positive metastatic breast cancer.

CME information and select publications here.

]]>Professor Giuseppe Curigliano from the European Institute of Oncology in Milan, Italy discusses recent therapeutic advances in HER2-positive metastatic breast cancer.

CME information and select publications here.

]]>4cab4a70-6176-4dec-8ada-92ad3cf52656Thu, 26 Jan 2023 09:00:00 -040047:04falsefull11 <p>Professor Giuseppe Curigliano from the European Institute of Oncology in Milan, Italy discusses recent therapeutic advances in HER2-positive metastatic breast cancer.</p> <p>CME information and select publications <a href="http://www.researchtopractice.com/OncologyTodayHER2PositivemBC22" rel="nofollow">here</a>.</p> Management of Gastroesophageal Cancers with Dr Manish ShahManagement of Gastroesophageal Cancers with Dr Manish ShahDr Manish Shah from Weill Cornell Medicine in New York City discusses current approaches to the management of upper GI malignancies and the potential future role of novel therapies for patients with these cancers. 

CME information and select publications here.

]]>Dr Manish Shah from Weill Cornell Medicine in New York City discusses current approaches to the management of upper GI malignancies and the potential future role of novel therapies for patients with these cancers. 

CME information and select publications here.

]]>51fcfa3c-ad95-4532-a927-5e59e1b80dd8Thu, 12 Jan 2023 09:00:00 -040043:23falsefull11 <p>Dr Manish Shah from Weill Cornell Medicine in New York City discusses current approaches to the management of upper GI malignancies and the potential future role of novel therapies for patients with these cancers. </p> <p>CME information and select publications <a href="http://www.researchtopractice.com/OncologyTodayGastroesophageal22" rel="nofollow">here</a>.</p> Managing Metastatic Urothelial Bladder Cancer with Dr Scott TagawaManaging Metastatic Urothelial Bladder Cancer with Dr Scott TagawaDr Scott Tagawa from Weill Cornell Medicine Sandra and Edward Meyer Cancer Center in New York, New York discusses current treatments and management strategies for metastatic urothelial bladder cancer.

CME information and select publications here.

]]>Dr Scott Tagawa from Weill Cornell Medicine Sandra and Edward Meyer Cancer Center in New York, New York discusses current treatments and management strategies for metastatic urothelial bladder cancer.

CME information and select publications here.

]]>ab8f989c-35c1-4ff2-bd7a-265271e710b7Thu, 05 Jan 2023 08:00:00 -040056:08falsefull11 <p>Dr Scott Tagawa from Weill Cornell Medicine Sandra and Edward Meyer Cancer Center in New York, New York discusses current treatments and management strategies for metastatic urothelial bladder cancer.</p> <p>CME information and select publications <a href="http://www.researchtopractice.com/OncologyTodayMetastaticBladderCancer22" rel="nofollow">here</a>.</p>